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Abstract 
The ‘burden of disease’ methodology introduced by Murray and Lopez in the early 1990s 
represents a useful platform from which to develop insights into contemporary issues 
confronting health systems. However, it is often regarded as having limited value beyond 
what is generally accepted as the domain of public health. The central argument developed 
here is that while such an impression with respect to the underlying conceptual framework is 
largely unfounded, a substantial reinterpretation of Murray and Lopez’s original contributions 
may be required before this possibility achieves more general acceptance. Underlying this 
thesis is the proposition that with a new model of implementation, a number of practical 
impediments—which in the past have prevented the methods from being employed for other 
than a limited range of applications—can be overcome. 
The setting in which to test this hypothesis presented itself in the form of a project undertaken 
by the University of Queensland in collaboration with the Australian Institute of Health and 
Welfare (AIHW). Commissioned by the Australian Government Department of Health and 
Ageing (DOHA) in early 2003 this project had as one of its objectives facilitating the routine 
use of the framework by government agencies such as AIHW and state and territory health 
departments. As such, simple program logic principles were adopted to assess the 
characteristics of an alternative implementation model with respect to both its range of 
outputs compared to what might be expected and its intended outcomes more broadly with 
respect to using the proposed model on a routine basis. 
The main findings are presented in four parts. Part I comprises a critical evaluation of 
existing tools and methods, or inputs, before proposing alternative tools and workflows that 
make the underlying conceptual framework more internally consistent, efficient and flexible 
in practice. Parts II and III comprise a portfolio of four papers, or outputs, that serve as 
important links between the proposed model and the intended outcome by seeking to address 
several areas of contemporary policy concern. The final part is a commentary on the success 
or otherwise of the case study with respect to government use of the proposed model on a 
routine basis.   
The key conclusion to draw from this thesis is that, with respect to outputs, the proposed 
model allowed for a much greater range of analyses than was attempted in the first ‘burden of 
disease study’ in Australia. The specific areas where these benefits were observed included 
 ii 
the ability disaggregate the primary results to a flexible range of geographic areas, the ability 
to fore- and back-cast these results while preserving internal consistency between parameters, 
the ability to generate a complete set of alternative results for various groupings of 
Australia’s Indigenous populations, and the ability to account for dependent and independent 
comorbidity in disability calculations. In addition, the model extended the range of secondary 
analyses regarded as feasible to areas not previously associated with ‘burden of disease’, such 
as health expenditure projections and causal decomposition analyses of health-adjusted life 
expectancy. 
With respect to outcomes however, the conclusions are more circumspect. Certainly, the 
analysis demonstrated that three state governments successfully implemented the model on at 
least one occasion each to update the original case study outputs with more recent data. A 
delay in the release of critical data was the primary factor preventing more extensive use in 
these settings. Nevertheless, a more coordinated adoption of the model at a national level was 
not achieved in the five years since its development, despite efforts by Australia’s peak 
population health information advisory committee to facilitate this outcome. While there is 
emerging evidence of renewed interest in national forums to make further use of the Murray 
and Lopez framework in Australia, it is too early to predict what role design considerations 
will play in these developments. 
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Chapter 1: Introduction 
Several broad social trends in Australia are likely to be of universal interest. On the one hand, 
there has been unprecedented growth in levels of health over the last century and, 
notwithstanding examples of persistent disadvantage, we are, by most measures, healthier 
than ever. On the other, the economic cost of accommodating this growth has increased much 
faster than would seem sustainable but for the very high value we place on health.1 For 
example, over the last half century alone, the expected life span of the average Australian has 
increased by around 15%, to become amongst the longest in the world at a projected 82 years 
in 2011.2 In contrast, total expenditure on health compared to the rest of the economy has 
grown over the same period by almost one and a half times to an estimated 9.5% of GDP.3 
These seemingly inexorable but related trajectories have occurred in the context of a strong 
public healthcare system that remains committed to the principle of universal access, 
notwithstanding having undergone recent reform. 
It is reassuring, therefore, to learn that our overall return on investment in the health sector is 
still comparatively good value internationally.4 However, satisfying public expectations in a 
landscape that is both epidemiologically and technologically vastly different to the one in 
which free hospital care regardless of means became entrenched public policy is becoming 
increasingly difficult. For example, the Queensland Government currently spends around a 
quarter of its total budget on the health portfolio and this expenditure is growing at close to 
10% per annum in nominal terms just to keep pace with existing expectations. Clarity around 
the underlying drivers of this growth seems fundamental to mature debate about how we 
might place publicly funded healthcare on a more sustainable foundation. 
The ‘burden of disease’ methodology introduced by Professors Christopher Murray and Alan 
Lopez in the early 1990s represents a useful platform from which to develop these and other 
                                                
1  From an economic perspective, total spending on health is sustainable so long as the value it produces 
exceeds the opportunity cost. In a growing economy, health spending can grow at a faster rate than other 
sectors of the economy without necessarily compromising economic sustainability.  
2  Estimate based on data to 2009 from Australian Social Trends, Mar 2011 (Cat. no. 4102.0), Australian Bureau 
of Statistics, Canberra, 2011, viewed 21 August 2011, 
http://www.abs.gov.au/AUSSTATS/abs@.nsf/Lookup/4102.0Main+Features10Mar+2011. 
3  Estimate based on data to 2008-09 from Health expenditure data cubes, Australian Insititute of Health and 
Welfare, Canberra, 2011, viewed 21 August 2011, http://www.aihw.gov.au/expenditure-data/. 
4  Banks, G, Health costs and policy in an ageing Australia, in Health Policy Oration, Menzies Centre for Health 
Policy, John Curtin School of Medical Research, Australian National University, Canberra, 26 June 2008. 
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insights. However, it is often portrayed in terms of its theoretical contributions to the field of 
summary measures of population health,5 or as part of an agenda for setting priorities on 
behalf of others.6 While these characterisations may well have been effective at establishing 
the methods as an internationally recognised set of techniques for quantifying health loss in 
particular ways, arguably they have also created the impression 20 years on that, in general, 
the approach has limited value beyond what is commonly considered the domain of public 
health. 
The central thesis I intend developing here is that such an impression with respect to the 
underlying conceptual framework is unfounded; however, for this possibility to achieve more 
general acceptance, a substantial reinterpretation of Murray and Lopez’s original 
contributions may be required. In this chapter I attempt to lay the groundwork for such a 
proposition by outlining what I believe have been basic impediments to employing the 
methods for other than a limited range of applications.7 In the remaining chapters I seek to 
illustrate how these apparent constraints can, in fact, be overcome. While some of the 
examples I will be presenting may appear inconsistent with the existing literature on ‘burden 
of disease’, each has as its basis the core concepts first proposed by Murray and Lopez. 
Conceptual framework 
Superficially at least, the conceptual framework that provides the foundation for the 
following chapters reflects the underlying structure of the International Classification of 
Diseases (ICD),8 a hierarchical nomenclature for attributing all causes of illness in a 
population on a categorical as opposed to a counterfactual basis. In other words, each cause 
of health loss has a place in a mutually exclusive and exhaustive list of all possible causes. 
Counterfactual attribution, on the other hand, is more complex, at least in terms of 
presentation, in that outcomes are not necessarily mutually exclusive. In epidemiology, 
counterfactual attribution is where the impact of a causal agent (e.g. diabetes) on an outcome 
of interest (e.g. mortality) is assessed by removing its influence from the analysis. This 
                                                
5  Murray, C, Salomon, J, Mathers, C and Lopez, A, eds, Summary measures of population health: concepts, ethics, 
measurement and applications, World Health Organization, Geneva, 2002. 
6  Lopez, AD, Mathers, CD, Ezzati, M, Jamison, DT and Murray, CJL, eds, Global burden of disease and risk 
factors, Oxford University Press and the World Bank, New York, 2006. 
7  I make this observation having worked on a number of ‘burden of disease’ projects, details of which are 
provided in Appendix A. 
8  International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, World 
Health Organization, Geneva, 1990, viewed 16 August 2011, http://www.who.int/classifications/icd/en/. 
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approach plays an important role in several processing aspects of the framework, one of 
which is explored in Chapter 3. For the moment though, the implications of counterfactual 
attribution can be put to one side.  
More central to the general thesis being developed here is the proposition that the main 
elements of the framework are best understood as a series of transformative processes that 
ultimately depends on only a handful of parameters: mortality (as a population rate); 
incidence, case-fatality and remission (all as hazards); and severity (as a composite weight 
ranging from 0 to 1). From these five inputs, all but one of which is epidemiological, every 
other framework parameter that might be of interest can be derived. In this sense, the core of 
the framework is essentially a descriptive epidemiological exercise in the tradition of the 
seventeenth century pioneer of population health statistics, John Graunt.9 The conceptual 
model underpinning this understanding is illustrated in terms of the essential information 
flows and processes depicted in Figure 1.  
Figure 1: Information flows and processes within the Murray and Lopez framework  
  
One process in this figure is labelled a core process due to its fundamental transformative 
function. First introduced in the context of ‘burden of disease’ as the ‘Harvard Incidence-
Prevalence Model’ (hereafter, the IPM),10 this process formalises the mathematical 
relationship between the hazard parameters identified above (the input parameters) and 
prevalence and average duration, parameters that, depending on the purpose of the analysis, 
can be regarded as either inputs for further processes (that is, intermediate parameters) or as 
outputs in their own right. Murray and Lopez’s call for the rigorous application of the IPM to 
                                                
9  I am indebted to Dr Chris Bain for pointing out this link to me.  
10  Murray, CJ and Lopez, AD, “Quantifying disability: data, methods and results”, Bull World Health Organ, 
1994, vol. 72(3), pp. 481-94. 
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expose inconsistencies in epidemiological data is arguably one of their more provocative 
challenges to those with an interest in population health statistics. 
Determining the precise origins of the IPM is difficult because reference to possible 
intellectual antecedents11 is absent from the relevant literature. Nevertheless, a reasonably 
well-developed discussion of its conceptual basis appears in a series of books on the Global 
Burden of Disease 1990 study (GBD 1990) edited by Murray and Lopez for the World Bank 
and the World Health Organization.12 Important to this discussion is the diagrammatic 
representation in Figure 2, which the authors explain as follows:  
Susceptibles in a population are assumed to be at risk of incurring a condition at rate i and can die at a 
general mortality rate m. Prevalent cases of the condition can remit at rate r, die from general causes at 
the same rate as the susceptibles m, or die from cause-specific mortality from the condition at rate f.13 
Figure 2: The Incidence-Prevalence Model (IPM), as introduced by Murray and Lopez in 199614 
 
                                                
11  e.g. Freeman, J and Hutchison, GB, “Prevalence, incidence and duration”, Am J Epidemiol, 1980, vol. 112(5), 
pp. 707-23; Leske, MC, Ederer, F and Podgor, M, “Estimating incidence from age-specific prevalence in 
glaucoma”, Am J Epidemiol, 1981, vol. 113(5), pp. 606-13; O'Neill, T, Tallis, G and Leppard, P, “The 
epidemiology of a disease using hazard functions”, Australian Journal of Statistics, 1985, vol. 27(3), pp. 283-97; 
Preston, SH, “Relations among standard epidemiologic measures in a population”, Am J Epidemiol, 1987, vol. 
126(2), pp. 336-45. 
12  Murray, CJL and Lopez, AD, eds, The Global Burden of Disease: a comprehensive assessment of mortality and 
disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Vol I., Harvard School of Public 
Health on behalf of WHO and the World Bank, Cambridge, 1996. 
13  ibid. 
14  ibid. 
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In practice, the number of numerical values that must be analysed on the basis of this model 
can be large. Typical applications of the framework are stratified at least by cause, age and 
sex, but other dimensions have also been considered, such as time, socioeconomic status, 
geography and ethnicity. While the addition of extra dimensions undoubtedly makes the 
outputs more appealing to policy-makers, it also increases the number of values required as 
inputs and, ultimately, the number of values that must be processed and stored as 
intermediate parameters and outputs. However, since many of the calculations used to derive 
these values are identical across dimensions, the addition of extra dimensions can increase 
processing time or analytical load but should not necessarily imply an increase in underlying 
complexity.  
History 
From a purely practical perspective the history of the framework can usefully be divided into 
several distinct but possibly overlapping phases. The first phase undoubtedly begins with the 
GBD 1990 and is characterised by its focus on those parameters most closely related to the 
outputs of immediate interest. In the case of disability-adjusted life years (DALYs), arguably 
perceived by many as the raison d’être of the framework, these are mortality (absolute 
number of deaths using categorical attribution), incidence (cases), duration (average time 
incident cases spend as prevalent cases) and severity. In the case of health-adjusted life 
expectancy (HALE) when calculated using the Sullivan method,15 they are mortality 
(population rate), prevalence (population proportion) and severity.16 In both cases, the two 
inputs less proximal to the outputs (i.e. case-fatality and remission) are not useful in 
themselves, and tend not to be retained consistently, if at all, in an accessible manner. Other 
parameters not yet discussed (e.g. relative risk and attributable mortality) also tend not to be 
readily accessible. Typical information flows and processes characteristic of this phase are 
depicted in Figure 3. 
                                                
15  Sullivan, DF, “A single index of mortality and morbidity”, HSMHA Health Rep, 1971, vol. 86(4), pp. 347-54. 
16  According to Ass. Prof Jan Barendregt, HALE can also be calculated in a multi-state life table by using 
incidence and mortality as inputs. 
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Figure 3: Information flows and processes characteristic of phase one 
 
A key limitation of this approach is reflected in the difficulties Dr Colin Mathers and others 
(including myself) experienced while attempting to replicate some of calculations underlying 
GBD 1990, despite having access to much of the original material.17 In part, these difficulties 
were due to incomplete documentation, with only three of the planned ten volumes in the 
GBD 1990 series reaching publication.18 However, they were exacerbated by Murray and 
Lopez’s extensive reliance on a software implementation of the IPM called Dismod,19 a 
critical shortcoming of which was the absence of a mechanism for copying or exporting 
values for the input and intermediate variables into other software environments. Instead, the 
only way of preserving these parameters outside of the tool was to transcribe the values from 
the screen or print and store them on paper. 
A further limitation relates to the number of dimensions for which the application of the IPM 
is perceived as being feasible. Again, the GBD 1990 is useful for illustrating this point. For 
each of the eight world regions considered in their analysis, Murray and Lopez used Dismod 
to estimate values for the intermediate variables identified above, which they combined with 
                                                
17  For example, Begg, S and Tomijima, N, Global burden of injury in the year 2000: an overview of methods, World 
Health Organization, Geneva, 2003; Truelsen, T, Begg, S and Mathers, C, The global burden of cerebrovascular 
disease, World Health Organization, Geneva, 2003.  
18  Murray, CJL and Lopez, AD, eds, The Global Burden of Disease: a comprehensive assessment of mortality and 
disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Vol I; Murray, CJL and Lopez, AD, 
eds, Global Health Statistics: a compendium of incidence, prevalence and mortality estimates for over 200 conditions. 
Vol II., Harvard School of Public Health on behalf of WHO and the World Bank, Cambridge, 1996; Murray, 
CJL and Lopez, AD, Health dimensions of sex and reproduction : the global burden of sexually transmitted diseases, 
HIV, maternal conditions, perinatal disorders, and congenital anomalies, Harvard School of Public Health on 
behalf of WHO and the World Bank, Cambridge, 1998. This series provides the most detailed account of the 
framework these authors used to describe global health in 1990 across eight regions of the world for the 
GBD 1990 study. 
19  Murray, CJL and Lopez, AD, eds, The Global Burden of Disease: a comprehensive assessment of mortality and 
disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Vol I. 
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input variables in spreadsheets to calculate various outputs of interest.20 They also estimated 
deaths and DALYs for future years, although in this case not by using Dismod.21 Instead they 
projected trends in mortality, from which they inferred trends in DALYs. Thus they report on 
alternative future scenarios for deaths and DALYs but not on trends in other potentially 
useful framework parameters, such as incidence, prevalence, prevalent disability or HALE. 
Professor Theo Vos and I replicated this approach in one of the first applications of the 
framework in Australia,22 which we undertook in collaboration with Mathers, who at the time 
was employed by the Australian Institute of Health and Welfare (AIHW).23  
Yet another limitation relates to the use of spreadsheets as the primary analytical tool of 
choice. In the absence of careful planning, this can make managing information with more 
than several dimensions unwieldy and inefficient, thus increasing perceived complexity and 
the likelihood of errors due to incorrect or out of date cell references. This point is illustrated 
by an analysis for the state of Victoria in which Vos and Ms Anne Magnus used relativities 
between broad population groupings to disaggregate state-level estimates of incidence, 
prevalence and duration to seventy-eight subpopulations.24 From these disaggregations they 
calculated subpopulation-level estimates of DALYs and HALE in spreadsheets. However, an 
examination of the published results shows that the sum of the subpopulation-level DALYs 
does not add to the previously published estimates of total DALYs for the state.25 At the time 
the project material revealed that this discrepancy was due to systematic spreadsheet errors. 
In this history the first phase has no distinct end. However, a second phase arguably begins 
with the first critical evaluation of how best to apply the underlying concepts of the 
                                                
20  Murray, CJ and Lopez, AD, “Quantifying disability: data, methods and results”; World Bank, World 
Development Report: Investing in Health, Oxford University Press, New York, 1993. 
21  Murray, CJ and Lopez, AD, “Alternative projections of mortality and disability by cause 1990-2020: Global 
Burden of Disease Study”, Lancet, 1997, vol. 349(9064), pp. 1498-504; Murray, CJL and Lopez, AD, eds, The 
Global Burden of Disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk 
factors in 1990 and projected to 2020. Vol I. 
22  See Vos, T and Begg, S, Victorian Burden of Disease Study: Morbidity, Public Health Division, Victorian 
Department of Human Services, Melbourne, 1999; Vos, T and Begg, S, Victorian Burden of Disease Study: 
Mortality, Public Health Division, Victorian Department of Human Services, Melbourne, 1999. 
23  See Mathers, C, Vos, T and Stevenson, C, The burden of disease and injury in Australia, (Cat No. PHE 17), 
Australian Institute of Health and Welfare, Canberra, 1999; Mathers, CD, Vos, ET, Stevenson, CE and Begg, 
SJ, “The Australian Burden of Disease Study: measuring the loss of health from diseases, injuries and risk 
factors”, Med J Aust, 2000, vol. 172(12), pp. 592-6; Mathers, CD, Vos, ET, Stevenson, CE and Begg, SJ, “The 
burden of disease and injury in Australia”, Bull World Health Organ, 2001, vol. 79(11), pp. 1076-84. 
24  Burden of Disease (BoD) - LGAs & regions 1996, Department of Health Victoria, Melbourne, 2011, viewed 7 
August 2011, http://www.health.vic.gov.au/healthstatus/composite/bod/bod96-index.htm. 
25  cf. Vos, T and Begg, S, Victorian Burden of Disease Study: Morbidity. These results received substantial media 
coverage at the time, e.g. Toy, M, “Our sickest suburbs”, The Age, 17 January 2001 2001, p. p1. 
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framework in the context of a large-scale project. Led by Mathers at WHO, the purpose of 
this evaluation was to update estimates from GBD 1990 as part of an ongoing research 
agenda known at the time as GBD 2000.26 To facilitate this update WHO commissioned a 
second implementation of the IPM called Dismod II, which Mathers’ team used extensively 
to derive values for the intermediate variables from sets of inputs relating to seventeen world 
regions. What makes this approach distinct from phase one is that Mathers transferred values 
for selected parameters from spreadsheets to a structured processing environment containing 
country-specific information on mortality. In so doing, Mathers was then able to interpolate 
values for 191 member states of the United Nations and extrapolate these values forward in 
time with more up-to-date mortality information as it became available.27 This approach 
provided the basis for a time-series of country-level HALE estimates, which appear as 
appendix tables in the World Health Report series from 2001 to 2004.28 
Figure 4 attempts to represent the essential elements of this phase in the development of the 
framework. The main advantages were that it allowed for time-series outputs within an 
efficient and flexible environment, and maintained a degree of consistency between the 
intermediate variables and the output variables, at least in the short term. However, because 
not all of the inputs indentified in Figure 1 were transferred from spreadsheets to the 
structured possessing environment, Mathers could not use this series of processes to maintain 
consistency between the inputs and intermediate parameters. This represents a key limitation 
over the medium term.29 
                                                
26  Mathers, C, Salomon, J, Ezzati, M, Begg, S, Vander Hoorn, S and Lopez, A, “Sensitivity and uncertainty 
analyses for burden of disease and risk factor estimates”, in Lopez, A, Mathers, C, Ezzati, M, Jamison, D and 
Murray, C, eds, Global burden of disease and risk factors, The World Bank and Oxford University Press, 
Washington, 2006. 
27  The routines for achieving these calculations were collectively known as the “DALYNATOR”, the code for 
which was written by Mr Niels Tomijima.  
28  WHO, World Health Report 2001- Mental Health: New understanding, New Hope., World Health Organization, 
Geneva, 2001; WHO, World Health Report 2002- Reducing Risks, Promoting Healthy Life, World Health 
Organization, Geneva, 2002; WHO, World Health Report 2003 - Shaping the future, World Health 
Organization, Geneva, 2003; WHO, World Health Report 2004 - Changing history, World Health Organization, 
Geneva, 2004. 
29  It appears these implications had not been anticipated when designing the spreadsheets since the primary 
objective was to disaggregate to individual countries the immediate outputs of interest (in this case DALYs 
and HALE). While the distortions introduced by these methods were probably insignificant over the period 
reported on by WHO, the effects over the medium term would have been non-trivial. 
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Figure 4: Information flows and processes characteristic of phase two 
 
It is worth briefly making a few observations about the version of the IPM Mathers had to 
work with. Within the context of this discussion, the key advantage of Dismod II over its 
predecessor was the ability to store the inputs and calculated intermediate parameters in an 
accessible database format, and the inclusion of a function that allowed this information to be 
exported into various other formats, including spreadsheets. This increased the chance of 
preserving key input parameters over time. It also incorporated a goal-seeking algorithm for 
working with a larger combination of inputs than just incidence, case-fatality and remission 
(i, f and r using the notation in Figure 2 — the only inputs accepted by its predecessor) and 
the ability to transfer inputs to different populations for further processing, both functions that 
increased its efficiency. In addition, the tool included various enhancements not relevant to 
this discussion, including the ability to manipulate inputs prior to processing.  
However, none of Dismod II’s functions, including the core IPM transformation, could be 
accessed via internal scripts, nor could they be initiated externally via batch processing 
techniques. Moreover, calculated values for more than one time period could not be accessed, 
even though temporal trends in the inputs could be specified. In practice, therefore, the 
second version was identical to its predecessor in the sense that both tools operated as a 
stand-alone means for manually applying the IPM model one dimension at a time. Thus 
neither tool was particularly suited to maintaining consistency between inputs and 
intermediate parameters across multiple dimensions, as might occur in large-scale 
implementations of the framework, especially if inputs were to be updated on a regular basis.  
My reason for considering these issues arose after joining Mathers’ team in mid 2002. One 
discussion at the time focussed on whether it would be possible to maintain consistency 
between framework parameters by developing an interface between the inputs identified in 
Figure 1 and an automation of the equations underlying the IPM as described by Barendregt 
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and colleagues.30 Exploring the feasibility of such an approach required access to a set of 
inputs across a reasonably large number of dimensions, which Mathers was attempting to 
collect from the many researchers who had contributed to GBD 2000. Translating the 
equations into a set of workable routines was relatively straightforward. However, we were 
unable to develop the idea beyond the proof-of-concept stage, in part because of difficulties 
obtaining a complete set of inputs, but also because the problem of divergence inherent in the 
existing system was unlikely to be material, at least in the short term. 
Thus the opportunity to explore the practical implications of this approach did not arise until 
late 2003 when Lopez himself offered me the opportunity to coordinate an update of the 
national analysis Mathers had undertaken for Australia. The overall analysis had multiple 
aims, the reasons for which are not relevant to the present discussion. In terms of the history 
being portrayed here, however, one particular challenge was conceptually identical to 
meeting the information needs of the World Health Report series. This presented itself in the 
third of five funding agreements for the project, which required us to, 
Make reasonable efforts to automate the calculation process of small area estimates in order to facilitate 
regular updates of estimates rather than special studies to be conducted every 5 years. As such, it 
should become part of routine surveillance task e.g. State Health Departments and AIHW.31 
Aims and objectives 
To set the scene for the following chapters I have recast the above task in terms of a case 
study, the aim of which was to make comprehensive health outcomes assessment a routine 
function of government by increasing the feasibility of implementing the Murray and Lopez 
framework on a regular basis. Implicit here is the assumption that there exists an appetite (at 
least among the project funders) for up-to-date information on health outcomes to inform 
government activity. Figure 5 is an attempt to encapsulate the essential elements of this 
vision.  
                                                
30  Barendregt, JJ, Van Oortmarssen, GJ, Vos, T and Murray, CJ, “A generic model for the assessment of disease 
epidemiology: the computational basis of DisMod II”, Popul Health Metr, 2003, vol. 1(1), pp. 4. 
31  Vos, ET, Updating the Australian Burden of Disease: small areas estimates component study, funded by Rural 
Health, Palliative Care and Health Strategies Branch, DOHA. 
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Figure 5: Selected aims and objectives of the case study 
 
It is worth noting here that I have formulated Figure 5 on the basis of the terms of the funding 
agreement quoted above. As such, it would be incorrect to interpret it as a normative 
statement about the actual translation of knowledge into policy, which I acknowledge is an 
inherently political or ‘non-linear’ process.32 Rather, my objective here is to characterise the 
case study as an attempt to optimise the potential for health outcomes assessment activities to 
contribute to this process. 
As an analytical framework for the thesis as a whole I have attempted to assess the success or 
otherwise of the case study in facilitating the change implied in Figure 5 by applying simple 
program logic principles. Program logic encourages a focus on the ‘inputs’, ‘processes’ and 
‘outputs’ required to achieve an intended ‘outcome’. Consistent with my opening remarks, 
the desired outcome in this case can be defined in terms of a responsive, informed and 
accountable policy environment (as opposed to policy itself) supported by a routine 
population health monitoring capacity. Returning to Figure 5, the key outputs that might be 
expected to enable this transformation include efficient and flexible workflows, a 
contemporary time-series of framework parameters, and a suite of regular and ad hoc 
information products. Various inputs and processes are necessary for delivering these 
outputs, including a shared vision, the framework itself and sufficient resources to develop 
                                                
32  I am indebted to one of my examiners, Professor Martin McKee CBE, for pointing out the extensive 
literature on these aspects of policy formulation. 
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and apply enhanced workflows to available data. Figure 6 presents a more complete 
articulation of these relationships within a program logic framework. 
Figure 6: Analysis of the case study within a program logic framework 
 
Structure 
The thesis itself is loosely structured around this framework and is divided into four parts. 
Part I comprises these introductory remarks and two additional chapters, the first of which is 
largely a technical discussion in which I critically evaluate existing tools and methods, or 
inputs, before proposing an alternative set of tools and workflows that I believe make the 
underlying conceptual framework more internally consistent, efficient and flexible in 
practice. The development and refinement of these alternatives represents a core activity or 
process of the case study, aspects of which my colleagues and I have already described in a 
report published by the AIHW in 2007.33 That report therefore serves as an important stand-
alone appendix both to the chapter and the thesis more generally. Chapter 3 presents a more 
in-depth examination of the IPM and illustrates some of its limitations in practice. 
Parts II and III are structurally related and comprise a portfolio of information products or 
outputs that serve as links between the underlying processes and the project outcome. The 
particular outputs I have selected represent four papers—three of which have been 
published—that seek to address several areas of current policy concern: the dynamics of the 
chronic disease epidemic; a decomposition of the drivers of growth in health expenditure; and 
the magnitude and distribution of health problems, including the Indigenous health gap. Each 
paper has been allocated on the basis of whether it relied primarily on those methods outlined 
                                                
33  Begg, S, Vos, T, Barker, B, Stevenson, C, Stanley, L and Lopez, A, The burden of disease and injury in Australia, 
2003, (Cat. no.PHE 82), Australian Institute of Health and Welfare, Canberra, 2007. According to AIHW 
documentation, this report was the second most downloaded publication from the AIHW website, after 
Australia’s Health 2006, including 48,000 times in the first few days after its release. By October 2009, the 
entire publication had been downloaded more than 322,000 times. 
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in Chapter 2 relating to projections, in which case it is presented in Part II, or those relating to 
subpopulation disaggregations, in which case it appears in Part III. While the published 
papers were prepared in collaboration with others, I have taken the liberty of adding 
comments pointing to specific processes where these were understated or overlooked 
altogether in the original text. 
The final part is a commentary on the success or otherwise of the case study with respect to 
its intended outcome. In other words, to what extent did an alternative implementation model 
as represented by the set of tools and workflows presented in Chapter 2 facilitate government 
uptake of the Murray and Lopez framework in Australia? I approach this question from two 
angles: first in Chapter 8, from the perspective of various state-based implementations of the 
model, and then in the final chapter, from a national perspective. 
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Chapter 2: Critical evaluation of typical workflows and 
proposed alternatives 
As mentioned in the opening chapter, the most critical limitation of both Dismod II and its 
predecessor in the context of this thesis is the inability to automate the core IPM 
transformation function across multiple dimensions. In the past, the main alternative was to 
adopt methods that either compromise the mathematical integrity or consistency between 
each of the framework parameters, or omit certain parameters altogether. Such outcomes are 
clearly undesirable for certain purposes and, arguably, limit the appeal of the conceptual 
framework proposed by Murray and Lopez for other than a restricted range of applications. 
My objectives in this chapter, therefore, were twofold: first, to show how it is possible to 
incorporate the IPM into a set of workflows that not only maintains consistency across a 
complete set of framework parameters but, more importantly, achieves this across several 
dimensions fundamental to population health statistics (i.e. time, place and person); and 
second, to introduce the secondary problem of comorbidity and to illustrate how this too can 
be resolved within the context of the proposed workflows. The underlying conceptual model 
is illustrated in terms of the information flows and processes depicted in Figure 7, which have 
their origins in discussions with Mathers and colleagues at WHO. The unique and defining 
characteristic is its focus on the processes identified in Figure 1 of the previous chapter as 
core, rather than on possible secondary processes, such as the calculation of DALYs or 
HALE.   
Figure 7: Information flows and processes adopted in the case study 
 
To implement this approach one requires a set of working rules that does not inhibit existing 
work practices (e.g. creating cross-sectional epidemiological models using spreadsheets and 
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• Case,
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Dismod II) where there is no better alternative, but that ensures the information generated 
through such activities is accurately passed to a structured environment for further 
processing.  
In the context of the case study, the following protocol was both workable and not overly 
restrictive:  
1. Model each health problem such that each component sequela can be explicitly identified; 
2. Estimate a complete set of transition hazards (i.e. incidence, remission and case-fatality) 
for each sequela, either in Dismod II or by other means; and 
3. Record transition hazards and a relevant severity weight for each sequela in a 
predetermined format within the relevant spreadsheet.  
These workflows enabled me to construct a database of cross-sectional parameters that served 
as inputs for the methods described in the remainder of the chapter. An important aspect of 
the case study not revisited here are the sources of data and modelling assumptions for each 
of the 180 individual disease and injury models developed as part of the above activities. 
These details are available elsewhere.34 
Cohort-enabled IPM 
Figure 8 provides a conceptual model for an alternative implementation of the IPM that 
overcomes Dismod II’s limitations with respect to the time dimension (i.e. the inability to 
access calculated values for more than one time period and the inability to automate the core 
IPM transformation function across multiple dimensions). In this model, values for those 
parameters that might be of interest for secondary processes are derived by determining 
complete epidemiological representations of causes on a cohort as opposed to a cross-
sectional basis. Using the notation in Figure 2 of Chapter 1, such a model requires for each 
cause and associated sequela the complete specification of the parameters m and i, f and r at 
each preceding age a and time t relevant to the cross-section t of interest. For this reason I 
have called it the Cohort-enabled Incidence-Prevalence Model.  
                                                
34  See ibid. 
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Figure 8: Conceptual model for the cohort-enabled Incidence-Prevalence Model (IPM) 
 
I have implemented the calculations underlying this model in Mata using the equations set 
out by Barendregt and colleagues.35 Mata is a matrix-programming environment built into the 
Stata statistics and data management software package.36 The model consists of the following 
Mata subroutines: mata_cohort-IPM, which executes the underlying calculations for 
each age cohort as it ages over time; mata_IPM_calc, which performs most of the actual 
calculations, except duration; and mata_dur_calc, which performs the duration 
calculations. These routines are called by a Stata ado program cohort-IPM, which, if 
installed correctly, can be accessed from the command line like any other Stata command. 
The last two subroutines are also used elsewhere, as discussed shortly. 
cohort-IPM is fast and ‘byable’, meaning the user can specify, in theory, any number of 
stratifying variables within which the calculations are to be repeated. However, in practice 
the actual number of dimensions is limited by memory considerations, although the minimum 
requirement is a variable that stratifies the data by cause and associated sequela. For 
convenience, hereafter I use the right-hand subscript k to denote a cause within a complete set 
of K causes.  
                                                
35  Barendregt, JJ, Van Oortmarssen, GJ, Vos, T and Murray, CJ, “A generic model for the assessment of disease 
epidemiology: the computational basis of DisMod II”. 
36  StataCorp, Stata Statistical Software: Release 11, StataCorp LP, College Station, TX, 2009. 
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By choosing the by option, cohort-IPM automatically checks whether the variables 
specified in the by statement uniquely identify the data across the following required input 
variables: age (0, 1, 5, 10…100, although other age groupings could be implemented), year 
(1993, 1994…2023, although other calculation periods could be implemented), sex 
(1=males). In addition, cohort-IPM requires i, f and r, all expressed as a hazard per unit of 
population, and a valid filename and path to a data file containing all-cause mortality 
(essentially a hazard, which I denoted as mK) by age, sex and year using the same 
categorisations as the inputs. The code that enables mata_IPM_calc and 
mata_dur_calc is at Appendix B, while the code that enables cohort-IPM is at 
Appendix C.  
In practice, various assumptions can simplify specifying the inputs required by cohort-
IPM. For most chronic diseases, i and f are the primary drivers of changes in observed cause-
specific mortality (which I denoted as mk), while r plays little if any role. This is because the 
‘hazard’ of recovering from a chronic disease is, by definition, small. It follows that a 
complete epidemiological model in this instance can be back-cast from cross-sectional 
estimates of i and f by making plausible assumptions about the relative contribution of these 
hazards to observed changes in mortality. This reasoning applies equally to projections if one 
is willing to make predictions about mortality into the future.  
The above general approach depends on complete sex-specific vectors of mortality for each 
cause and birth cohort over the calculation period. Fortunately for the case study, Australia 
has a high quality vital registration system by international standards and, with several 
notable exceptions, observable trends in mortality provide a reasonably consistent (albeit 
indirect) source of information on changes in the incidence of diseases and injuries over the 
last century, notwithstanding frequent revisions to the ICD over this period. Nevertheless, 
these revisions make it difficult to analyse cause-specific trends in mortality over more than a 
decade or so, except at very broad levels of aggregation. As such, a reasonable compromise 
between specificity and the length of the data series is to focus on the period from 1979, 
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when the ninth version of the ICD was introduced for the coding of mortality data in 
Australia.37 
In the case study, I derived plausible sex-specific vectors of mortality for each cause and birth 
cohort over [t | –24 ≤ t ≤ 20] where t = 0 represents the year 2003 (the most recent year of 
available data at the time) as follows. For each age and sex group, observed mK over [t | –24 ≤ 
t ≤ 0] were extrapolated to [t | 1 ≤ t ≤ 20] in a Poisson regression model that used t as a 
predictor and population as an offset variable. Observed vectors of mk over [t | –24 ≤ t ≤ 0] 
were then aggregated into 51 clinically meaningful groups (denoted by k+), and multinomial 
logistic regression was used to predict changes in each mk+ proportional to mK as a 
consequence of changes in ln(mK). This model was used to extrapolate each mk+ for [t | 1 ≤ t ≤ 
20] using projected ln(mK) as a predictor. Average distributions of mk within each mk+ over [t 
| -2 ≤ t ≤ 0] were then applied to projected mk+ to derive projected vectors of mk over [t | 1 ≤ t 
≤ 20]. In the absence of more detailed historic trends, values of mk over [t | –110 ≤ t ≤ –25] 
were assumed to be equivalent to values for t = –24. 
Among the causes analysed in this manner, cardiovascular disease, cancers, chronic 
obstructive pulmonary disease (COPD), diabetes, alcohol-related conditions, road traffic 
accidents, falls, suicide and homicide showed consistent mortality trends. However, the 
apparent trend in dementia mortality was ignored for a number of reasons: there has been a 
shift in coding practices with more deaths being attributed to dementia; the incidence data 
from international epidemiological studies show no clear change in this condition over time; 
and the case-fatality is unlikely to have changed much over time as there are no effective life-
saving interventions. 
This approach also requires complete vectors of i, f and r for each cause and birth cohort over 
the calculation period. In the case study, I derived these from the time-series vectors of m 
over [t | –110 ≤ t ≤ 20] described above and the cross-sectional vectors for i, f and r from the 
database described above. I combined these using the simplifying set of assumptions set out 
in Table 1, which stem from a number of observations: 
                                                
37  It should be noted that due to changes in coding rules and practices associated with the ICD, even mortality 
trends from 1979 are unreliable indicators of trends in incidence for certain diseases (most notably 
pneumonia and diabetes). 
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1. For a number of causes (e.g. cancers, COPD, alcohol-related conditions, road traffic 
accidents, falls, suicide and homicide), past trends in observed mortality are most likely 
due to changes in incidence. 
2. For cardiovascular diseases (CVD), there is evidence that past trends in observed 
mortality are the result of changes in both incidence and case-fatality.38 
3. For Type 2 diabetes (T2DM), trends in observed mortality are likely to be unreliable due 
to changes in diagnostic criteria and coding practices over time. A feasible alternative in 
this instance is to translate historical trends in measured body mass index (BMI), the main 
risk factor for T2DM, into changes in incidence using established risk attribution 
methods39 and published regression models of the distribution of BMI on age, birth cohort 
and sex.40 In the absence of direct measures of case-fatality, it seems reasonable to 
assume that half the mortality in diabetics is most likely due to vascular causes. The 
methods arising from these assumptions are set out in greater details in Chapter 8. 
4. For other causes, a reasonable default assumption is no trend in any of the input hazards. 
Table 1: Assumptions in the case study for extrapolating baseline input hazards  
Cause %∆ik %∆fk %∆rk 
Cancers, COPD, alcohol-related conditions, 
road traffic accidents, falls, suicide and 
homicide 
%∆mk No trend No trend 
Cardiovascular diseases (CVD) %∆mCVD × 58% %∆mCVD × 42% No trend 
Type 2 diabetes %∆iBMI %∆mCVD × 42% × 50% No trend 
All other causes No trend No trend No trend 
 
From these vectors of mK, i, f and r I estimated vectors of average duration d and prevalence p 
for each cause, sex, and birth cohort over [t | –110 ≤ t ≤ 20] and [a | 0 ≤ a ≤ 100] using 
cohort-IPM. This approach is analogous to dynamic population modelling41 and has 
several advantages over the projection methods mentioned in the previous chapter. First, it 
provides an efficient method for deriving a complete set of framework parameters by age and 
                                                
38  Unal, B, Critchley, JA and Capewell, S, “Explaining the decline in coronary heart disease mortality in 
England and Wales between 1981 and 2000”, Circulation, 2004, vol. 109(9), pp. 1101-7. 
39  Ezzati, M, Lopez, AD, Rodgers, A and Murray, CJL, eds, Comparative quantification of health risks: Global and 
regional burden of disease attributable to selected major risk factors - Volume 1, World Health Organization, 
Geneva, 2004. 
40  Haby, MM, Markwick, A, Peeters, A, Shaw, J and Vos, T, “Future predictions of body mass index and 
overweight prevalence in Australia, 2005-2025”, Health Promot Int, 2011. 
41  Frauenthal, JC, “A dynamic model for human population growth”, Theor Popul Biol, 1975, vol. 8(1), pp. 64-
73. 
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sex for a large number of causes and time periods. Unlike other approaches, however, 
internally consistency between parameters is maintained. Second, it allows for incremental 
revisions of these parameters by updating selected inputs with new data as it becomes 
available. Finally, the underlying principles can be adapted to maintain internal consistency 
for dimensions other than time, an advantage I expand on below.  
Subpopulation-enabled IPM 
In addition to cohort-IPM, I developed an alternative implementation of the IPM to assist 
with maintaining internal consistency when estimating framework parameters for multiple 
subpopulations. The general approach is conceptually more straightforward than the one 
described in the previous section since it is based on a cross-sectional model; the underlying 
calculations are therefore the same as in cohort-IPM when no trends in hazard are 
specified. However, each of the hazards must nevertheless be fully specified for every 
subpopulation of interest.  
A generic version of the model consists of the following Mata subroutines: mata_subpop-
IPM, which executes the underlying calculations for each subpopulation; mata_IPM_calc, 
which performs most of the actual calculations, except duration; and mata_dur_calc, 
which performs the duration calculations. These routines are called by a Stata ado program 
subpop-IPM, which requires the same inputs as the cohort version upon which it is based, 
except that it requires a subpopulation variable as an input (instead of year) and a valid 
filename and path to a Stata data file containing mK by age, sex and subpopulation (using the 
same categorisations as the inputs). 
In the case study I implemented subpop-IPM in two versions: the first was designed to 
estimate framework parameters for a 15-cell matrix of subpopulations comprising three 
remoteness categories (major cities, regional areas and remote areas) by five socioeconomic 
quintiles. The second was designed to estimate framework parameters for two Indigenous 
populations (major cities and regional areas combined, and remote areas). The code that 
enables each version is at Appendix D and E, respectively. 
While these versions are technically similar, their application within the context of the case 
study was conceptually quite different. In the first application a complete set of framework 
parameters for Australia in the year 2003 had already been established by the processes 
described above; the objective of subpop-IPM, therefore, was to maintain internal 
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consistency when disaggregating each of the parameters within the constraints imposed by 
this envelope. 
Table 2: Data used to disaggregate i across jurisdictions, and 15 subpopulations within each jurisdiction 
Cause Jurisdictions Subpopulations  
Tuberculosis, other sexually transmitted diseases, HIV/AIDS, diarrhoeal diseases, 
septicaemia, hepatitis b (including hepatitis b related liver cancer and cirrhosis), 
trachoma, other infectious and parasitic diseases, lower respiratory tract infections, 
upper respiratory tract infections, otitis media, maternal haemorrhage, maternal sepsis, 
hypertensive disorders of pregnancy, obstructed labour, abortion, other maternal 
conditions, birth trauma and asphyxia, low birth weight, neonatal infections, protein-
energy malnutrition, deficiency anaemia, other nutritional deficiencies, uterine myomas, 
benign neoplasms of meninges and brain, other benign neoplasms, type 1 diabetes, type 
2 diabetes, haemolytic anaemia, other non-deficiency anaemia, cystic fibrosis, 
haemophilia, other endocrine and metabolic disorders, alcohol dependence and harmful 
use (including alcoholic cirrhosis), heroin or polydrug dependence and harmful use, 
benzodiazepine dependence and harmful use, cannabis dependence and harmful use, 
other drug dependence and harmful use, schizophrenia, anorexia nervosa, Alzheimer and 
other dementias, epilepsy, Parkinson’s disease, multiple sclerosis, glaucoma-related 
blindness, cataract-related blindness, other nervous system and sense organ disorders, 
rheumatic heart disease, ischaemic heart disease, stroke, inflammatory heart disease, 
non-rheumatic valvular disease, aortic aneurysm, peripheral vascular disease, other 
cardiovascular disease, chronic obstructive pulmonary disease, other chronic respiratory 
diseases, cirrhosis of the liver (excluding alcoholic and hepatic cirrhosis), appendicitis, 
intestinal obstruction, diverticulitis, gallbladder and bile duct disease, pancreatitis, 
inflammatory bowel disease, vascular insufficiency bowel, other digestive system 
diseases, benign prostatic hypertrophy, other genitourinary diseases, ulcers, other skin 
diseases, slipped disc, other musculoskeletal diseases, congenital heart disease, cleft lip 
and/or palate, other digestive system malformations, other urogenital tract 
malformations (including polycystic renal failure), road traffic accidents, other transport 
accidents, poisoning, falls, fires, burns and scalds, drowning, sports injuries, natural and 
environmental factors, machinery accidents, suffocation and foreign bodies, surgical and 
medical misadventure, adverse effects of drugs in therapeutic use, cutting and piercing 
accidents, striking and crushing accidents, other unintentional injuries, suicide and self-
inflicted injuries, homicide and violence, legal intervention and war 
Hospital data 
 
Hospital data 
Syphilis, chlamydia, gonorrhoea, poliomyelitis, meningitis, Ross River virus, dengue, 
other arbovirus infection, hepatitis A, hepatitis C, malaria 
NNDSS data Hospital data 
Anxiety and depression, personality disorders (isolated) None MHS 
Bipolar disorder Hospital data MHS 
Stomach cancer, colorectal cancer, pancreas cancer, lung cancer, melanoma, breast 
cancer, cervix cancer, corpus uteri cancer, ovary cancer, prostate cancer, testicular 
cancer, bladder cancer, kidney cancer, brain cancer, lymphoma, leukaemia 
Cancer 
registry data 
Mortality data 
Other conditions arising in the perinatal period Hospital data Mortality data 
Haemophilus influenzae type b (Hib), NNDSS data Mortality data 
Mouth and oropharynx cancers, oesophagus cancer, liver cancer, gallbladder cancer, 
bone and connective tissue cancer, non-melanoma skin cancers, thyroid cancer, multiple 
myeloma, larynx cancer, eye cancer, other malignant neoplasms, motor-neuron disease, 
Huntington’s chorea, muscular dystrophy, nephritis and nephrosis, renal agenesis 
Mortality data Mortality data 
Autism spectrum disorders, migraine Hospital data NHS 
Hypertensive heart disease, peptic ulcer disease Mortality data NHS 
Attention-deficit hyperactivity disorder, macular degeneration, refractive errors, other 
vision loss, urinary incontinence, rheumatoid arthritis, osteoarthritis 
None NHS 
Adult-onset hearing loss, asthma, back pain SDAC NHS 
Other hepatitis Hospital data None 
Diphtheria, whooping cough, tetanus, measles, rubella, Barmah Forest virus NNDSS data None 
Bulimia nervosa, other eating disorders, other mental disorders, infertility, eczema, acne, 
psoriasis, occupational overuse syndrome, systemic lupus erythematosus, gout, 
anencephaly, spina bifida, anorectal atresia, oesophageal atresia, abdominal wall defect, 
Down syndrome, other chromosomal disorders, other congenital anomalies, dental 
caries, periodontal disease, edentulism, pulpitis, other oral conditions, sudden infant 
death syndrome, chronic fatigue syndrome 
None None 
Notes: NHS denotes the National Health Survey 2001; SDAC denotes the Survey of Disability, Ageing and Carers 2003; MHS denotes the 
National Mental Health Survey 1997; NNDSS data denotes National Notifiable Diseases Surveillance System; Hospital data denotes the national 
hospital morbidity dataset for 2003; Mortality data denotes the national mortality dataset for 2003. 
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Disaggregation was achieved for each cause by first apportioning m and i across states and 
territories, and then across up to 15 subpopulations within each jurisdiction. In the case of m, 
mortality data was used to determine this apportionment. For i, preference was given to the 
data source underpinning the baseline model, as outlined in Table 2.42 These subpopulation-
specific vectors of i were combined with total population vectors of f and r, from which 
complete vectors of d and p for each subpopulation were estimated using subpop-IPM. 
Minor rescaling was performed if any total across subpopulations was not consistent with the 
corresponding estimate for the total population. 
In the second application, the objective was to generate a complete set of framework 
parameters for the two Indigenous populations. Various strategies were used to derive mK, i, f 
and r for each population, although, since there was no overall envelope of disability to work 
within, none involved disaggregation. Instead, the results were subtracted from the 
corresponding total population estimate.  
In the case of mK, an indirect demographic technique known as the Generalised Growth 
Balance (GGB) method determined the amount to be subtracted.43 The GGB corrects for 
under-reporting, which is necessary when using mortality data relating to Indigenous people.  
For the other hazards, in a relatively small number of cases individual models were 
developed to derive Indigenous-specific estimates of i, f and r. For the majority, however, f 
and r were assumed to be the same as the total population, while Indigenous to non-
Indigenous relativities from a variety of datasets were applied to total population estimates of 
i to derive Indigenous-specific vectors of this parameter. Table 3 identifies for each cause the 
data source used to determine i either directly or via relativities, and also those causes for 
which assumptions with respect to additional parameters were also made.  
 
                                                
42  These sources were only used to apportion the total number of incident cases between subpopulations for a 
particular cause, not the number itself (which should capture multiple episodes of illness). 
43  Hill, K, Barker, B and Vos, T, “Excess Indigenous mortality: are Indigenous Australians more severely 
disadvantaged than other Indigenous populations?”, Int J Epidemiol, 2007, vol. 36(3), pp. 580-9. 
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Table 3: Data used to determine i for Indigenous populations 
Cause Sourceb,c 
Chlamydia, gonorrhoea, whooping cough, Haemophilus influenzae type b, dengue, other arbovirus 
infection, hepatitis A, malaria, Ross River virus, Barmah Forest virus, hepatitis B(a), tuberculosis, 
measles  
NNDSS data 
HIV/AIDS(a) HIV/AIDS data 
Nephritis & nephrosis  Transplant Registry 
Malignant neoplasms, nephritis & nephrosis  Mortality data 
Low birth weight Perinatal Data  
Syphilis, other STDs, diarrhoeal diseases, meningitis, septicaemia, maternal haemorrhage, 
maternal sepsis(a), hypertensive disorders of pregnancy, obstructed labour, abortion(a), other 
maternal conditions, deficiency anaemia, cataract-related blindness(a), ischaemic heart disease(a), 
peripheral vascular disease(a), heart failure(a), chronic obstructive pulmonary disease(a), 
pancreatitis, tuberculosis, lower respiratory tract infections, upper respiratory tract infections, birth 
trauma & asphyxia(a), low birth weight(a), neonatal infections(a), uterine myomas, benign 
neoplasms of meninges and brain, type 2 diabetes(a), cannabis, other drug dependence, 
schizophrenia, haemolytic anaemia, other non-deficiency anaemia, cystic fibrosis, haemophilia, 
heroin or polydrug dependence, bipolar disorder, anorexia nervosa, bulimia nervosa, other eating 
disorders, multiple sclerosis, glaucoma-related blindness(a), refractive errors, stroke(a), 
hypertensive heart disease, aortic aneurysm, peptic ulcer disease, cirrhosis of the liver, 
appendicitis, intestinal obstruction, diverticulitis, gallbladder and bile duct disease, vascular 
insufficiency bowel, benign prostatic hypertrophy, other genitourinary diseases, psoriasis, ulcers, 
osteoarthritis, slipped disc, systemic lupus erythematosus, gout, other musculoskeletal diseases, 
anencephaly, spina bifida, congenital heart disease, cleft lip and/or palate, anorectal atresia, 
oesophageal atresia, other digestive system malformations, renal agenesis, other urogenital tract 
malformations, abdominal wall defect, pulpitis, chronic fatigue syndrome, unintentional injuries, 
intentional injuries 
Hospital data 
Otitis media(a) BEACH 
Stroke(a) WA data 
Trachoma(a), otitis media(a) Eye data 
Asthma(a), alcohol dependence(a), anxiety & depression(a), otitis media(a) NHS 
Anxiety & depression(a) NSW survey & WA survey 
Dental caries(a), periodontal disease, edentulism Oral health survey 
Dental caries(a) SA dental survey 
Measles, tetanus, trachoma(a), hepatitis B(a), type 2 diabetes(a), intellectual disability, epilepsy(a), 
autism and Asperger’s 
Epidemiological studies 
Notes: (a) Denotes the model also included alternative assumptions for case-fatality, remission or severity. (b) Some causes incorporated data 
from multiple sources. (c) NNDSS data denotes the National Notifiable Diseases Surveillance System; HIV/AIDS data denotes the National HIV 
Database and National AIDS Registry; Transplant Registry denotes the Australia and New Zealand Dialysis and Transplant Registry; Mortality 
data denotes the national mortality dataset; Perinatal Data denotes the National Perinatal Data Collection; Hospital data denotes the national 
hospital morbidity dataset; BEACH denotes the Bettering the Evaluation And Care of Health collection; WA data denotes the Western Australian 
Data Linkage System; Eye data denotes the National Trachoma Eye Health Program 1976–78; NHS denotes the National Health Survey 2001 & 
2004–05; NSW survey denotes the NSW Health Survey 1997–98; WA survey denotes the Western Australian Aboriginal Child Health Survey 
2001–02; Oral health survey denote the 2004–06 National Oral Health Survey; SA dental survey denotes the South Australian Child and Adult 
Dental Health Survey 1999–01. 
Table 4 identifies those causes for which i, f and r were assumed to be the same as the total 
population. In both cases, complete vectors of d and p for each subpopulation were estimated 
using subpop-IPM. A number of causes were assumed to be absent in the Indigenous 
population such as trachoma (for the non-remote population only), diphtheria, poliomyelitis, 
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rubella, other conditions arising in the perinatal period, and occupational overuse syndrome. 
Further details regarding these methods are provided in a separate report.44 
Table 4: Causes for which i, f and r were assumed to be the same as the total population 
Cause Source 
Other hepatitis, type 1 diabetes, benzodiazepine dependence, personality disorders (isolated), 
attention-deficit hyperactivity disorder, Alzheimer and other dementias, Parkinson’s disease, 
motor-neuron disease, Huntington’s chorea, muscular dystrophy, macular degeneration, adult-
onset hearing loss, other vision loss, migraine, inflammatory bowel disease, urinary incontinence, 
infertility, eczema, acne, rheumatoid arthritis, back pain (acute and chronic) 
As per the total 
Australian population 
Comorbidity 
My second objective in this chapter was to introduce the problems created by comorbidity 
and to illustrate how these can be resolved as a secondary process within the context of the 
workflows depicted in Figure 7. Comorbidity is when two or more health problems occur in a 
person simultaneously, either by chance or because the conditions are related to each other in 
some way. Independent comorbidity is where the probability of having multiple conditions at 
the same time equals the product of the probabilities for each condition. Dependent 
comorbidity, on the other hand, is where the probability of having multiple conditions is 
greater than the product of the probabilities for each condition, and occurs because of 
common causal pathways (for example common risk factors causing both diabetes and heart 
disease) or because one health problem may increase the risk of another.  
Both types of comorbidity can be problematic for the conceptual framework proposed by 
Murray and Lopez,45 particularly when the set of available severity weights is comprised of 
evaluations for each health state as it occurs independently from others. In the case study, the 
severity weights were mostly derived from two sources,46 with extrapolations based on 
alternative methods in some cases. Nearly all of these weights were based on independent 
evaluations. 
                                                
44  Vos, T, Barker, B, Stanley, L and Lopez, A, The Burden of Disease and Injury in Aboriginal and Torres Strait 
Islander Peoples 2003, School of Population Health, The University of Queensland, Brisbane, 2007. 
45  van Baal, PH, Hoeymans, N, Hoogenveen, RT, de Wit, GA and Westert, GP, “Disability weights for 
comorbidity and their influence on health-adjusted life expectancy”, Popul Health Metr, 2006, vol. 4, pp. 1. 
46  Murray, CJL and Lopez, AD, eds, The Global Burden of Disease: a comprehensive assessment of mortality and 
disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Vol I; Stouthard, ME, Essink-Bot, 
M, Bonsel, GJ, Barendregt, JJ, Kramers, PGN, van de Water, HPA, Gunning-Schepers, LJ and van der Maas, 
PJ, Disability weights for diseases in The Netherlands, Department of Health, Erasmus University Rotterdam, 
Rotterdam, 1997. 
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The severity of a health state associated with two or more conditions in combination may not 
necessarily be the sum of the severity weights for each condition. In most cases, it is likely to 
be less than the sum. In others, there may be exacerbating effects on overall health of having 
the combination of conditions. For example, the experience of symptomatic grade 2 
osteoarthritis of the hip and severe vision loss together is probably not as disabling as the 
addition of the two weights for these health states (0.14 and 0.43, respectively). However, the 
experience of the latter with profound deafness may be equal to or even more disabling than 
the summation approach indicates.  
In an early response to this problem, Mathers proposed an adjustment that assumed health 
state valuations (that is, 1 minus the severity weight) are multiplicative, so that a combined 
weight for two conditions is more severe than the weight for either condition on its own but 
less than if the weights were simply added together. In this approach, the combined severity 
weight for causes k = 1 and k = 2 is given by, 
€ 
comDW[1,2] =1− (1−DW1) × (1−DW2). 
Equation 1 
This can be generalised to n conditions thus, 
€ 
comDW[1,n ] =1− (1−DW j ),
j=1
n
∏  
Equation 2 
where ∏ denotes the product operator. Equation 2 has been extensively used to derive 
combined weights for comorbid conditions in a number of applications of the framework. 
Subsequent work indicates that, in the absence of anything else, the multiplicative approach 
to deriving composite weights is reasonably robust.47 
Mathers’ initial implementation derived individual weights consistent with these composite 
weights by leaving the weight for the most severe condition unchanged but adjusting the 
weight for the milder condition such that it equalled the composite weight minus the weight 
                                                
47  Flanagan, W, McIntosh, CN, Le Petit, C and Berthelot, JM, “Deriving utility scores for co-morbid conditions: 
a test of the multiplicative model for combining individual condition scores”, Popul Health Metr, 2006, vol. 4, 
pp. 13. 
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for the more severe condition. For example, for a person with symptomatic grade 2 
osteoarthritis of the hip or knee (DW1 = 0.14) and severe vision loss (DW2 = 0.43), the 
combined weight for both conditions (comDW[1,2]) is 0.51 and the adjusted weight for the 
osteoarthritis (adjDW2 ) is 0.08. However, the ‘adjusted’ weight for severe vision loss 
remains unchanged (i.e. adjDW1 = DW1). These adjustments were calculated in a spreadsheet 
and manually fed back into multiple spreadsheets relating to individual disease and injury 
models. 
Implicit in this approach is an assumption that the prevalence of a set of comorbid conditions 
is equal to the product of the individual prevalences of these conditions; in other words, that 
health problems occur independently of each other. Subsequent work by Mathers, Iburg and 
me demonstrated that correcting for dependence between groups of conditions has a non-
trivial impact on comorbidity-adjusted severity weights and ultimately summary measures 
such as HALE and DALYs.48  
In the context of the case study, the research team decided in consultation the project’s 
steering committee that severity weights based on independent evaluations should be 
combined multiplicatively and in a way that corrected for dependency. The following 
discussion sets out an approach that is consistent with both principles.  
Using basic set theory, I define the universe of every cause k of interest as the set A. The 
power set of A, denoted here as ℘(A), is the set of all possible subsets of A, including the 
empty set and A itself; because A is finite with |A| = n elements, ℘(A) contains 2n elements. 
In addition, I define B as a set in which each element corresponds to the largest element of A 
for which estimates of prevalence can be derived by age and sex from an element of set C. To 
construct B, I define C to be the set of available empirical data sources in which each 
corresponding element of B intersects with at least one other element from that set. The 
intersection between elements of B is important for capturing information on dependency 
between causes across empirical data sources. 
From these definitions I construct, for each age and sex, a set based on the union of power 
sets for each element of B (which, for convenience, I denote as D) such that each element in 
the new set represents an estimate of prevalence from C expressed as a population probability 
                                                
48  Mathers, CD, Iburg, KM and Begg, S, “Adjusting for dependent comorbidity in the calculation of healthy 
life expectancy”, Popul Health Metr, 2006, vol. 4(1), pp. 4. 
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(i.e. 0 to 1). It follows that the super set that contains these sets represents the subset of ℘(A) 
for which empirical probabilities are available by age and sex. This super set can be used in a 
series of Monte Carlo simulations to expose an artificial cohort reflecting the age and sex 
profile of the population of interest to conditional probabilities across the relevant subset of 
℘(A). Such a cohort can then be aggregated so as to derive a set of simulated age- and sex-
specific estimates of prevalence pʹ′ for every element of D. 
Estimating comorbidity-adjusted severity weights on the basis of these principles involves 
several steps. First, a partially adjusted severity weight for a particular cause, age and sex for 
any given element of D can be derived from Equation 2 using, 
€ 
part _ adjDWk =
DWk
DW j
j
|d |
∑
× 1− 1−DW j( )
j
|d |
∏
⎛ 
⎝ 
⎜ ⎜ 
⎞ 
⎠ 
⎟ ⎟  
Equation 3 
where d is an element of D. This approach differs somewhat from the one proposed by 
Mathers in that the attenuating effect of the adjustment is applied to each cause in proportion 
to its contribution to an additively derived composite weight, rather than to all but the most 
severe cause. While neither approach is empirically based, this algorithm is arguably less 
arbitrary.  
To correctly combine the differential attenuations that exist across every combination of 
causes in which k occurs, part_adjDWk is summed across elements of D in proportion to the 
corresponding pʹ′ for each element using, 
€ 
adjDWk =
part _ adjDWk, j × ʹ′ p j
j
|D |
∑
ʹ′ p j
j
|D |
∑
. 
Equation 4 
With these methods, each adjDWk accounts for dependent and independent comorbidity to 
the extent that this is reflected in the simulated cohort. Simulated estimates of prevalence 
could obviously be substituted with empirical estimates subjected to availability.  
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Table 5: Attenuating effect (%) on severity weights of comorbidity adjustments applied in the case study 
 Comorbidity attenuation (%) 
Cause 0–14 15–29 30–44 45–59 60–69 70–79 80+ 
All 
ages 
Infectious and parasitic diseases -2.5 -3.9 -5.5 -7.9 -10.7 -13.5 -16.6 -7.3 
Acute respiratory infections -2.2 -1.9 -2.6 -3.5 -3.8 -3.1 -5.2 -2.6 
Maternal conditions 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Neonatal causes -9.1 -10.4 -11.4 -12.6 -13.7 -15.0 -16.7 -11.4 
Nutritional deficiencies 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Malignant neoplasms -6.5 -7.6 -8.8 -11.1 -13.3 -14.9 -16.5 -13.1 
Other neoplasms -3.9 -6.8 -10.3 -13.7 -18.6 -23.2 -29.3 -14.4 
Diabetes mellitus -3.4 -4.6 -6.5 -8.4 -10.4 -12.4 -15.3 -10.8 
Endocrine and metabolic disorders -3.6 -4.9 -6.8 -9.4 -12.1 -14.8 -18.0 -8.3 
Mental disorders -4.8 -6.8 -8.4 -10.8 -12.7 -14.1 -15.5 -9.3 
Nervous system & sense organ disorders -7.9 -5.8 -6.3 -8.6 -11.9 -16.1 -20.6 -15.1 
Cardiovascular disease -1.4 -2.3 -4.7 -8.5 -10.7 -13.1 -15.7 -11.9 
Chronic respiratory disease -2.4 -3.4 -6.2 -9.8 -12.9 -15.1 -17.6 -9.9 
Diseases of the digestive system -5.5 -6.8 -8.5 -11.0 -14.0 -17.0 -20.5 -12.6 
Genitourinary diseases -7.5 -7.7 -8.8 -11.3 -13.5 -15.6 -18.7 -11.0 
Skin diseases -2.6 -4.1 -5.7 -8.2 -12.2 -15.8 -20.9 -8.9 
Musculoskeletal diseases -6.3 -6.1 -7.1 -9.7 -12.3 -14.6 -17.0 -12.0 
Congenital anomalies -11.9 -12.9 -13.8 -14.7 -15.5 -16.3 -17.5 -13.7 
Oral conditions 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Ill-defined conditions n.a -6.6 -9.4 -12.4 -15.9 -19.5 -23.8 -11.6 
Unintentional injuries 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Intentional injuries 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
All causes -5.1 -6.1 -7.3 -9.3 -11.4 -14.1 -17.7 -10.6 
Notes: Based on simulations of comorbidity as measured by Ausdiab 1999, the National Health Survey 2001, the Survey of Disability, Ageing and 
Carers 2003, and the National Mental Health Survey 1997. Attenuation calculated as ((prevalence multiplied by adjusted severity weight) divided 
by (prevalence multiplied by unadjusted severity weight) minus one) multiplied by 100. n.a denotes not applicable. 
 
For the case study I implemented the above approach in Stata to derive a set of adjusted 
severity weights for each age and sex across the group of 180 disease and injuries, and their 
individual sequela. The attenuating effect of these adjustments is summarised at an 
aggregated level in Table 5, while the adjusted weights themselves are summarised at the 
same level of detail in Table 6. The routines that performed the underlying calculations are at 
Appendix F. Time constraints prevented the estimation of separate sets of adjustments factors 
severity weights for different subpopulations and time periods. 
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Table 6: Comorbidity-adjusted severity weights applied in the case study 
 Severity weight 
Cause 0–14 15–29 30–44 45–59 60–69 70–79 80+ 
All 
ages 
Infectious and parasitic diseases 0.045 0.049 0.087 0.091 0.089 0.083 0.090 0.077 
Acute respiratory infections 0.060 0.054 0.055 0.066 0.075 0.086 0.105 0.061 
Maternal conditions 0.112 0.113 0.140 0.294 0.388 0.388 0.388 0.135 
Neonatal causes 0.216 0.200 0.198 0.194 0.189 0.183 0.173 0.199 
Nutritional deficiencies 0.006 0.006 0.006 0.007 0.006 0.006 0.006 0.006 
Malignant neoplasms 0.391 0.165 0.087 0.072 0.083 0.081 0.075 0.080 
Other neoplasms 0.238 0.186 0.146 0.139 0.156 0.168 0.185 0.148 
Diabetes mellitus 0.068 0.069 0.069 0.069 0.070 0.068 0.066 0.069 
Endocrine and metabolic disorders 0.198 0.170 0.149 0.152 0.183 0.206 0.207 0.174 
Mental disorders 0.114 0.082 0.089 0.135 0.132 0.103 0.077 0.102 
Nervous system & sense organ disorders 0.065 0.036 0.033 0.037 0.045 0.070 0.117 0.060 
Cardiovascular disease 0.240 0.232 0.188 0.163 0.159 0.156 0.149 0.159 
Chronic respiratory disease 0.053 0.053 0.060 0.074 0.093 0.104 0.104 0.072 
Diseases of the digestive system 0.247 0.132 0.090 0.077 0.093 0.114 0.131 0.094 
Genitourinary diseases 0.010 0.017 0.036 0.036 0.060 0.070 0.069 0.032 
Skin diseases 0.026 0.034 0.029 0.030 0.042 0.063 0.080 0.036 
Musculoskeletal diseases 0.057 0.043 0.042 0.044 0.047 0.051 0.055 0.047 
Congenital anomalies 0.203 0.188 0.177 0.166 0.155 0.142 0.118 0.176 
Oral conditions 0.023 0.016 0.011 0.007 0.005 0.005 0.005 0.008 
Ill-defined conditions 0.000 0.316 0.308 0.298 0.286 0.274 0.260 0.300 
Unintentional injuries 0.064 0.095 0.115 0.116 0.117 0.117 0.137 0.111 
Intentional injuries 0.166 0.198 0.187 0.175 0.175 0.145 0.099 0.174 
All causes 0.066 0.055 0.062 0.067 0.063 0.068 0.083 0.065 
Notes: Severity weights measured on a scale from 0 (equivalent to perfect health) to 1 (equivalent to death). 
A practical consideration arises when deriving DALYs using adjusted severity weights such 
as the ones implied by Table 6.49 In their original discussion, Murray and Lopez introduce the 
general equation for the non-fatal component of the DALY as,  
€ 
YLD = D KCe
ra
r + β( )2
e − r+β( ) L+a( ) − r + β( ) L + a( ) −1( ) − e− r+β( )a − r + β( )a −1( ) + 1_Kr 1− e
−rL( )
⎛ 
⎝ 
⎜ 
⎞ 
⎠ 
⎟ 
⎛ 
⎝ 
⎜ ⎜ 
⎞ 
⎠ 
⎟ ⎟ , 
Equation 5 
where YLD is years lived with disability, a is the age of onset of the disability, L is the 
duration of disability, r is the discount rate, β is the age-weighting parameter, K is the age-
                                                
49  I am indebted to Professor Theo Vos for drawing my attention to this detail. 
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weighting modulation factor, C is the adjustment constant necessary because of unequal age-
weights and D is the severity weight.50 
Obscured in Equation 5 by the discounting and age-weighting functions—the latter being a 
normative assumption ignored in many applications of the framework—is the assumption 
that weighting for severity is constant across duration and therefore, by implication, across 
age. Thus a simplified expression that is consistent with the notation already established in 
this chapter, is given by, 
€ 
unadjYLDka = DWka × f a,d,β,δ( ), 
Equation 6 
where a is the age of onset of cause k, d is the duration of k, δ is the discount rate, β is the 
age-weighting parameter, and DW is the severity weight. In this equation, I have added the 
right-hand superscript a to both the severity weight and the result to make explicit the age-
constancy assumption. I have also added the unadj prefix to indicate that YLD calculated in 
this way are unadjusted for age effects arising from factors such as comorbidity.  
A modified version of Equation 6 that accommodates age-varying severity weights is given 
by, 
€ 
adjYLDka =
adjDWka × f a,d,β,δ( ),
adjDWka × f a,d,β,δ( ) +
adjDWka+ j × f a + j, j +1,β,δ( ) − adjDWka+ j × f a + j, j,β,δ( )( ) +
j=1
d⎣ ⎦−1
∑
adjDWka+ d⎣ ⎦ × f a + d⎣ ⎦,d,β,δ( ) − adjDWka+ d⎣ ⎦ × f a + d⎣ ⎦, d⎣ ⎦,β,δ( )( ),
⎧ 
⎨ 
⎪ 
⎪ 
⎪ 
⎪ 
⎪ 
⎩ 
⎪ 
⎪ 
⎪ 
⎪ 
⎪ 
if d ≤1
elsewhere
Equation 7 
where ⎣x⎦ indicates the floor function. 
For the case study I implemented Equation 7 as a discrete process using Stata as set out at 
Appendix F. The code is run as a secondary process using as inputs i and d from the set of 
                                                
50  Murray, CJL and Lopez, AD, eds, The Global Burden of Disease: a comprehensive assessment of mortality and 
disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Vol I. 
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workflows depicted in Figure 7, and the corresponding adjDWs implied by Table 6. Table 7 
summarises the percentage difference between Equation 5 and Equation 7 when using 
severity weights that varying by age. 
Table 7: Difference (%) between Equation 5 and Equation 7 to calculate YLD using age-varying severity 
weights as applied in the case study 
 Difference (%) 
Cause 0–14 15–29 30–44 45–59 60–69 70–79 80+ 
All 
ages 
Infectious and parasitic diseases 1.3 1.6 1.8 1.2 0.9 0.3 -0.1 1.4 
Acute respiratory infections 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.1 
Maternal conditions 0.0 0.0 0.0 0.0 n.a n.a n.a 0.0 
Neonatal causes 1.6 n.a n.a n.a n.a n.a n.a 1.6 
Nutritional deficiencies 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Malignant neoplasms 0.3 0.9 2.1 3.0 2.1 0.6 -0.9 1.7 
Other neoplasms 0.0 0.5 0.2 0.0 0.0 0.0 0.0 0.1 
Diabetes mellitus 2.3 2.6 2.5 2.1 1.6 1.2 0.7 1.9 
Endocrine and metabolic disorders 1.6 1.1 1.1 1.0 0.5 0.3 0.1 1.2 
Mental disorders 0.6 -1.2 -8.1 3.0 17.5 21.1 0.1 -1.6 
Nervous system & sense organ disorders 0.7 1.2 1.8 2.3 1.9 -1.8 0.6 0.5 
Cardiovascular disease 0.2 0.3 0.5 -1.2 -1.2 0.3 0.3 -0.3 
Chronic respiratory disease 0.6 1.6 2.3 1.9 1.5 1.0 0.6 1.3 
Diseases of the digestive system 2.6 2.7 2.6 1.9 1.4 0.9 0.3 2.1 
Genitourinary diseases -3.1 0.7 0.3 1.3 -4.4 1.2 0.7 0.0 
Skin diseases 0.2 0.2 0.2 0.2 0.1 0.0 0.0 0.1 
Musculoskeletal diseases 0.9 0.9 0.9 0.9 0.9 0.8 0.6 0.9 
Congenital anomalies 0.6 2.2 1.7 1.2 1.0 0.6 0.3 0.6 
Oral conditions 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Ill-defined conditions n.a 0.5 0.7 0.9 1.2 n.a n.a 0.8 
Unintentional injuries -0.2 -0.3 -0.4 -0.9 0.0 0.0 0.0 -0.3 
Intentional injuries -0.3 -0.6 -1.3 -2.5 0.0 0.0 0.0 -1.0 
All causes 0.6 -0.4 -2.4 1.7 1.7 -0.1 0.4 0.2 
Notes: Difference calculated as ((YLD using Equation 5 divided by YLD using Equation 7) minus one) multiplied by 100. Age-varying severity 
weights were used in both cases. n.a denotes not applicable.  
The overall effect of this correction is marginal (not greater than ±2.4% across all age and 
cause groups). However, it is relatively large for mental disorders between the ages of 30 and 
79 years due to the combined influence of long duration and declining severity with age, at 
least from 45 years.
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Chapter 3: Cause-specific mortality and the IPM 
Introduction 
By their own account, Murray and Lopez can be credited with having the IPM implemented 
as the software package Dismod, in which a hypothetical cohort is exposed to a set of user-
specified values with respect to i, f and r (using the notation in Chapter 1 Figure 2) and 
‘general mortality’ to derive values for those parameters that might be of interest for 
secondary processes.51 As an alternative to f, users could enter a ‘relative risk minus one 
coefficient’ as a mortality input, although the correct use of this particular function is not 
elaborated on in their initial explanations of the model. As a result, I will denote the relative 
risk component of this parameter as RR´ to indicate that it is for moment undefined. 
A key requirement of Dismod was that i, r, and f (or RR´-1) must be entered as inputs. 
However, some or all of these parameters are often not known, in which case users of the tool 
had to guess the correct values using an iterative process such that the modelled outputs were 
consistent with observed data or assumptions. As noted already in Chapter 1, to overcome 
this and other limitations WHO commissioned a second implementation of the IPM in the 
late 1990s to facilitate work on the GBD 2000. Most noticeably from the user’s perspective, 
Dismod II incorporated a goal-seeking algorithm to find values for the hazards such that a 
consistent model could be developed from most combinations of at least three of the model’s 
parameters.52 This implementation of the IPM was used extensively in the GBD 2000 study53 
and other work that followed.54 
In their introduction to Dismod II, Associate Professor Jan Barendregt and others, including 
Murray and Vos, refer to a conceptual model that is identical to the one depicted in Chapter 1 
                                                
51  ibid. 
52  Less noticeably, an exact solution to the underlying differential equations was implemented rather than the 
finite difference method used in the original software. 
53  Mathers, C, Salomon, J, Ezzati, M, Begg, S, Vander Hoorn, S and Lopez, A, “Sensitivity and uncertainty 
analyses for burden of disease and risk factor estimates”. 
54  e.g. Begg, S, Vos, T, Barker, B, Stevenson, C, Stanley, L and Lopez, A, The burden of disease and injury in 
Australia, 2003; Begg, S, Vos, T, Goss, J and Mann, N, “An alternative approach to projecting health 
expenditure in Australia”, Aust Health Rev, 2008, vol. 32(1), pp. 148-55; Bundhamcharoen, K, 
Teerawatananon, Y, Vos, T and Begg, S, The Burden of Disease and Injuries in Thailand, Bureau of Health 
Policy and Planning, Ministry of Public Health, Bangkok, 2002; Vos, T, Barker, B, Begg, S, Stanley, L and 
Lopez, AD, “Burden of disease and injury in Aboriginal and Torres Strait Islander Peoples: the Indigenous 
health gap”, Int J Epidemiol, 2009, vol. 38(2), pp. 470-7; Yusoff, A, Mustafa, A, Kaur, G, Omar, M, Vos, T, Rao, 
V and Begg, S, Malaysian Burden of Disease and Injury Study, Division of Burden of Disease, Institute of Public 
Health, Ministry of Health, Kuala Lumpur, 2004. 
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except that m is used to denote mortality from ‘all other causes’55 rather than the more 
inclusive meaning provided in the original explanation. Whereas Murray and Lopez do not 
discuss the relationship of this parameter to others in the model, Barendregt and colleagues 
refer specifically to m by arguing that because it does not influence i, r, and f when it is truly 
independent of a cause (i.e. it is experienced by healthy and diseased people equally) it can be 
omitted from the equations without affecting all but one of the calculated parameters. The 
exception is average duration (d using the notation in Chapter 2), which can only be 
calculated once m is determined.  
Barendregt and colleagues define another parameter b to represent ‘all excess mortality 
caused by the disease’, a definition which, in their view, is consistent with a broader but 
otherwise undefined aim of the framework. In explaining this parameter, they note that b is 
not necessarily consistent with cause-specific mortality reported by national statistics 
agencies (or mk using the notation in Chapter 2). In other words, the actual deaths coded to a 
cause may not reflect all mortality that might be attributable to that particular cause. My 
objectives in this chapter therefore are twofold: to position this distinction within a more 
developed conceptual framework than provided for in the literature; and to explore its 
implications for the IPM, particularly with respect to the relative risk function in two 
implementations of the model.56 
Cause-specific mortality 
In Chapter 1, I noted two separate traditions for attributing causes to health outcomes: 
categorical and counterfactual attribution. This distinction has its origins in a discussion by 
Mathers, Murray, Lopez and others with respect to comparative risk assessment.57 The initial 
treatment of mortality within the Murray and Lopez framework largely reflects categorical 
attribution. However, Barendregt and colleagues point to situations in which this approach is 
an inadequate basis for determining cause-specific mortality in the IPM.  
                                                
55  Barendregt, JJ, Van Oortmarssen, GJ, Vos, T and Murray, CJ, “A generic model for the assessment of disease 
epidemiology: the computational basis of DisMod II”. 
56  I am indebted to Dr Colin Mathers for inspiring me to undertake this investigation. 
57  Mathers, CD, Ezzati, M, Lopez, AD, Murray, CJL and Rodgers, AD, “Causal decomposition of summary 
measures of population health”, in Murray, CJL, Salomon, J, Mathers, CD and Lopez, AD, eds, Summary 
measures of population health: concepts, ethics, measurement and applications, World Health Organization, 
Geneva, 2002. 
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A useful example is perhaps diabetes, which confers an underlying vascular risk that 
predisposes diabetics to die from other related causes in addition to diabetes, such as 
cardiovascular disease and stroke; thus the actual mortality coded to diabetes does not reflect 
the true mortality associated with this disease.58 This phenomenon can be illustrated using 
basic set theory. In Figure 9, I denote A as the set of deaths not coded to diabetes and B the 
set of deaths attributable to diabetes. It follows that the union between these sets is the 
universe of all deaths (panel a) and the intersection is the subset of deaths attributable to 
diabetes but not coded to this disease (panel b). Similarly, the relative complement of A in B 
(or B \ A) is the subset of deaths coded to diabetes (panel c).  
Figure 9: Understanding m in the IPM using basic set theory 
 
With respect to the equations underlying Dismod II, the logic proposed by Barendregt and 
colleagues depends on b being independent of m to derive externally valid results from the 
IPM. In theory, this condition is met when m is understood as the subset of A that excludes B 
(panel d); in practice, as Kruijshaar, Barendregt and others note in an earlier discussion, 
satisfying this condition is difficult, making it a problematic aspect of IPMs more generally.59 
While Barendregt and colleagues suggest in their introduction to Dismod II that the problem 
relates to the unobservable nature of b, the intersection between A and B is at the centre of 
                                                
58  A proportion of diabetics will also be obese, which confers additional mortality risk from non-vascular 
diseases such as certain cancers. To the extent that the proportion of obesity is greater in diabetics than in 
non-diabetics, this would confer additional mortality risk over and above the risk associated with simply 
having diabetes.   
59  Kruijshaar, ME, Barendregt, JJ and Hoeymans, N, “The use of models in the estimation of disease 
epidemiology”, Bull World Health Organ, 2002, vol. 80(8), pp. 622-8. 
!"! #!
Panel a: A ! B  
!"! #!
Panel d: A \ B 
!"! #!
Panel b: A " B 
!!#!"!
Panel c: B \ A 
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these difficulties, not the subset of B that excludes A, which is, by definition, observable. In 
any case, the RR´ function in both versions of Dismod provides what appears to be a solution 
by allowing b to be specified via counterfactual analysis principles instead of as a categorical 
parameter.  
Relative risk of mortality 
Relative risk is an established concept in the epidemiological literature and typically 
expresses the ratio of total mortality or other health outcome in a group exposed to a 
particular risk over that experienced by a group in which the risk is absent. This ratio can be 
used to estimate the proportion of a health outcome due to exposure to a particular risk.60 In 
its simplest form, the formula for this calculation is, 
€ 
AF = p RR −1( )p RR −1( ) +1 
Equation 8 
where AF is the attributable fraction of the health outcome in a population that is due to 
exposure to the risk, p is the prevalence of exposure in the population, and RR is the relative 
risk as defined above. 
While Murray and Lopez first introduce relative risk in the context of Dismod as a means for 
determining the ‘number of deaths associated with a disease’,61 arguably this application has 
only limited value given they largely adopt categorical attribution for the mortality 
component of their framework.62 Nevertheless, as a description of the intended relationship 
between RR´ and b it is possibly a more useful explanation than the one provided by 
Barendregt and colleagues. In the Dismod II documentation, Barendregt and colleagues 
                                                
60  Ezzati, M, Hoorn, SV, Rodgers, A, Lopez, AD, Mathers, CD and Murray, CJ, “Estimates of global and 
regional potential health gains from reducing multiple major risk factors”, Lancet, 2003, vol. 362(9380), pp. 
271-80; Ezzati, M, Lopez, AD, Rodgers, A and Murray, CJL, eds, Comparative quantification of health risks: 
Global and regional burden of disease attributable to selected major risk factors - Volume 1; Ezzati, M, Lopez, AD, 
Rodgers, A and Murray, CJL, eds, Comparative quantification of health risks: Global and regional burden of disease 
attributable to selected major risk factors - Volume 2, World Health Organization, Geneva, 2004; Mathers, CD, 
Ezzati, M, Lopez, AD, Murray, CJL and Rodgers, AD, “Causal decomposition of summary measures of population 
health”; Murray, CJL and Lopez, AD, eds, The Global Burden of Disease: a comprehensive assessment of mortality 
and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Vol I. 
61  Murray, CJL and Lopez, AD, eds, The Global Burden of Disease: a comprehensive assessment of mortality and 
disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Vol I. 
62  Murray and Lopez do present an alternative set of results for a group of 10 diseases based on counterfactual 
attribution. However, is not clear whether the relative risk function in Dismod was used in these 
calculations. 
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define RR´ as the mortality hazard in prevalent cases over the mortality hazard in prevalent 
and non-prevalent cases combined. I will denote these hazards as mp and mt, respectively, and 
use RRd to denote the documented definition of RR´. In comparison, a conventionally defined 
relative risk, which I denote as RRc, has the mortality hazard in non-prevalent cases as the 
denominator. I will use mn to denote this hazard.  
It is worth briefly noting the relationships between RRc and previously defined measures of 
mortality. For example, an alternative expression of the hazard f is the difference between mp 
and mn, which is consistent with a measure referred to elsewhere as excess risk.63 It can also 
be expressed as b over p, where these parameters are as defined above. Similarly, f can be 
derived from RRc and mn using, 
€ 
f = mn RRc −1( ), 
Equation 9 
a relationship that presumably underpins Barendregt and colleagues’ observation, ‘case 
fatality and relative risk for total mortality contain the same information, given total 
mortality’.64 
Given these relationships, it seems reasonable to assume that Murray and Lopez conceived of 
the RR´ function as a means of deriving f from relative risk in situations where the former 
could not be observed directly and where an estimate of the latter was available. Certainly, in 
Barendregt and colleagues’ implementation the derivation of the former from the latter must 
occur before proceeding with the main calculations because f is one of the three inputs to the 
underlying set of formulae, not relative risk. However, the formula implemented by 
Barendregt and colleagues to derive f, which can be determined from a comparison of inputs 
and outputs, is given by,  
€ 
ʹ′ f = mt R ʹ′ R −1( ). 
Equation 10 
                                                
63  Gail, MH and Bénichou, J, Encyclopedia of epidemiologic methods, Wiley, Chichester, 2000. 
64  Barendregt, JJ, Van Oortmarssen, GJ, Vos, T and Murray, CJ, “A generic model for the assessment of disease 
epidemiology: the computational basis of DisMod II”. 
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In this formula I use the prime to denote it represents an approximate rather than an exact 
derivation because of the use of mt in place of mn.65  
Thus it is possible to identify two potential issues with the RR´ function as implemented in 
Dismod II. First, the relative risk measure referred to in the documentation relating to how to 
input RR´ appears at odds with convention.66 Second, mt is used to derive an approximation 
of f when an exact derivation might be possible. Common to both issues is the use of mt as a 
proxy for mn; the latter, by definition, does not intersect with b and is therefore experienced 
by prevalent and non-prevalent cases equally. The former, on the other hand, represents a 
superset of b and is therefore not independent of the disease. The greater b is in proportion to 
the total number of deaths, the greater the independence assumption would appear to be 
compromised by the RR´ function. This observation seems true whichever relative measure of 
mortality is used as an input. 
Implications 
It is possible to compare RRd and RRc as separate inputs to RR´ and assess whether the 
substitution of one for the other has material implications for the derivation of f and 
ultimately b. In the case of RRd, my expectation was that Dismod II would underestimate f 
because, by definition, the relative measure of mortality used in this instance does not 
represent the full excess mortality risk between prevalent and non-prevalent cases. 
Nevertheless, it is understandable that users might input RRd since it is the documented 
definition of RR´.67 
In the case of RRc, users might reasonably expect this relative measure of mortality to result 
in an exact derivation of f since RRc expresses the full excess mortality risk between prevalent 
                                                
65  Associate Professor Jan Barendregt confirms that the derivation occurs in this way. He also acknowledges 
that this leads to an acceptable approximation when disease prevalence is low (personal communication, 20 
August 2009 and 18 August 2011), although such a caveat is not mentioned in the formal literature or in 
Dismod II’s documentation.  
66  Professor Theo Vos counters by noting that Dismod II’s definition follows that of the Standardised Mortality 
Ratio (SMR) and is therefore not without precedent in the epidemiological literature. The SMR is typically 
used to compare the mortality risk between two populations with dissimilar age distributions—particularly 
when the size of one population is too small to use other standardisation techniques—and is interpreted as 
the number of deaths in one population (usually the smaller one) over the number of deaths in that 
population had it experienced the age-specific death rates of the other. This seems conceptually distinct 
from the way in which relative risk might be entered into Dismod II. 
67  It is also consistent with a view promoted by Professor Theo Vos that Dismod II somehow transforms RRd 
as an input into RRc as an output (personal communication, 7 August 2009). 
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and non-prevalent cases. However, the internal derivation still uses mt rather than mi, thus f is 
in fact overestimated by a factor equivalent to, 
€ 
ec = p RRc −1( ), 
Equation 11 
where ec denotes the RRc derivation error and p denotes prevalence. These predictions can be 
explored using data from an existing Dismod II model for diabetes in Australian males68, 
which I have reproduced in columns a through d of Table 8. The remaining columns 
represent four expressions of mortality derived from these parameters without using Dismod 
II. 
Table 8: Selected epidemiological parameters for diabetes in Australian males 
  Population    Mortality    
 structure(a) p(b)   per 1,000   f(h) 
Age group (%) (%) RRc(c) mt(d) mn(e) mp(f) RRd(g) (%) 
<1 1.3 0.0 2.43 5.3 5.3 13.0 2.43 0.8 
1-4 5.3 0.0 2.43 0.3 0.3 0.7 2.43 0.0 
5-9 7.0 0.0 2.43 0.1 0.1 0.3 2.43 0.0 
10-14 7.2 0.0 2.43 0.1 0.1 0.3 2.43 0.0 
15-19 7.1 0.0 2.43 0.6 0.6 1.5 2.43 0.1 
20-24 7.1 0.0 2.43 0.9 0.9 2.2 2.43 0.1 
25-29 6.9 0.1 2.43 1.0 1.0 2.4 2.43 0.1 
30-34 7.6 0.5 2.43 1.1 1.1 2.6 2.42 0.2 
35-39 7.3 1.6 2.43 1.3 1.3 3.2 2.38 0.2 
40-44 7.7 3.5 2.43 1.8 1.7 4.1 2.32 0.2 
45-49 7.0 6.9 2.37 2.5 2.3 5.5 2.16 0.3 
50-54 6.6 9.7 2.27 3.5 3.1 7.1 2.03 0.4 
55-59 5.9 12.6 2.16 5.9 5.1 11.0 1.88 0.6 
60-64 4.4 16.1 2.02 9.7 8.3 16.9 1.73 0.9 
65-69 3.6 19.6 1.87 16.2 13.8 25.8 1.60 1.2 
70-74 3.1 23.4 1.71 27.6 23.7 40.6 1.47 1.7 
75-79 2.4 26.4 1.57 46.1 40.1 62.8 1.36 2.3 
80-84 1.5 30.5 1.44 78.0 68.8 98.9 1.27 3.0 
85-89 0.7 34.8 1.34 135.6 121.2 162.7 1.20 4.1 
90-94 0.2 39.5 1.28 206.6 186.0 238.1 1.15 5.2 
95-99 0.0 43.1 1.22 293.2 267.8 326.7 1.11 5.9 
100+ 0.0 45.1 1.18 359.7 332.7 392.5 1.09 6.0 
All ages 100.0 5.9 1.93 7.0 6.2 10.6 1.71 1.4 
Notes: (a) Estimated resident population for 2000 (n=9,871,642; Source: ABS); (b) Prevalence of diabetes in per cent (Source: AusDIAB); (c) 
Relative Risk defined as total mortality rate in diabetics over total mortality rate in non-diabetics (Source: Asia Pacific Cohort Studies 
Collaboration); (d) Total mortality rate in general population per 1,000 (Source: ABS); (e) Total mortality rate in non-diabetics per 1,000, 
calculated as mt/(p(RRc-1)+1); (f) Total mortality rate in diabetics per 1,000, calculated as mn*RRc; (g) Relative Risk defined as total mortality rate 
in diabetics over total mortality rate in general population, calculated as mp/mt; (h) Case-fatality hazard calculated as mn(RRc-1). 
                                                
68  Begg, S, Vos, T, Barker, B, Stevenson, C, Stanley, L and Lopez, A, The burden of disease and injury in Australia, 
2003; Begg, SJ, Vos, T, Barker, B, Stanley, L and Lopez, AD, “Burden of disease and injury in Australia in the 
new millennium: measuring health loss from diseases, injuries and risk factors”, Med J Aust, 2008, vol. 
188(1), pp. 36-40. 
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In Table 9, I present the ‘case-fatality’ output (f´) from Dismod II for two models: Model 1, 
in which I used RRc as the mortality input, and Model 2, in which I substituted RRc for RRd. 
Both models were calculated with the default settings using p as the prevalence input and 
zero for the remission input. Population structure and total mortality were the same in both 
instances. As predicted, f´ is greater than or equal to the true case-fatality (f in Table 9) at 
each age in the first model. Conversely, f´ is less than or equal to the true case-fatality in 
second model.  
Table 9: ‘Case-fatality’ output from Dismod II 
 Actual f´(%) 
Age group f (%) Model 1 Model 2 
25-29 0.1 0.1 0.1 
30-34 0.2 0.2 0.2 
35-39 0.2 0.2 0.2 
40-44 0.2 0.3 0.2 
45-49 0.3 0.3 0.3 
50-54 0.4 0.5 0.4 
55-59 0.6 0.7 0.5 
60-64 0.9 0.9 0.7 
65-69 1.2 1.3 0.9 
70-74 1.7 1.9 1.2 
75-79 2.3 2.5 1.6 
80-84 3.0 3.4 2.1 
85-89 4.1 4.5 2.6 
90-94 5.2 5.5 3.0 
95-99 5.9 6.4 3.3 
100+ 6.0 6.8 3.4 
All ages 1.4 1.50 0.98 
 
In Figure 10, I present the percentage difference from the true values, or bias, under both 
models for three Dismod II outputs: f, incidence (i) and average duration (d). I also present 
the product of i and d with a 3% discounting function (denoted as i*d[0,3]), which represents 
the epidemiological component of the YLD calculation, as specified in Equation 7 of the 
previous chapter.  
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Figure 10: Percentage difference from the true values under models 1 and 2 for f, i, d, and i*d[0,3] 
 
These results indicate that under typical usage, the relative risk approach to estimating cause-
specific mortality in Dismod II results in epidemiological models that are systematically 
inconsistent with intended assumptions or what can be implied from observational data. Such 
inconsistencies appear to be material in some cases and are likely to be greater with a relative 
risk defined as total mortality in diseased people over total mortality in the population as a 
whole—as the limited literature on this aspect of the tool implies should be used—than with a 
conventional relative risk. 
The results also indicate that incorrectly specifying cause-specific mortality in the IPM can 
have a non-trivial effect, especially in the elderly. As will be discussed in the following 
chapter, for countries entering a possible new phase in human development, accurate 
information on the old and very old is becoming increasingly important as greater proportions 
of the population survive to these ages.69 In the case study, for example, at least 25% of total 
                                                
69  Caldwell, JC, What we know about health transition : the cultural, social and behavioural determinants of health : the 
proceedings of an international workshop, Canberra, May 1989, Health Transition Centre, Australian National 
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DALYs was experienced by Australians aged 75 years and above, and approximately 30% of 
total DALYs for all ages was based on epidemiological models that relied on relative risk as 
an input.70 As such, it seems likely that the results reported in the remaining chapters are not 
entirely consistent with the intended mortality assumptions. Further work would be required 
to determine whether the same is true for Murray and Lopez’s original GBD 1990 study and 
subsequent analyses that make extensive use of the IPM.71  
Options 
Based on the above, I propose several options for accommodating the biases inherent within 
Dismod II if prevalence is known. First, they can be corrected using, 
€ 
RRe =
RRc −1
p(RRc −1)
+1,
 
Equation 12 
where RRe is an error-corrected relative risk, which can be used as an input instead of its 
conventional equivalent. Alternatively, they can be avoided altogether by deriving f outside 
Dismod II using, 
€ 
f = mt RRc −1( )p RRc −1( ) +1
. 
Equation 13 
One advantage of Equation 13 is that Dismod II has the ability to output values for f that 
correspond exactly to the input values, whereby allowing users to develop epidemiological 
models that are entirely consistent with observational data or assumptions. The equivalent 
functionality is not available in Dismod II if choosing to use Equation 12.  
These considerations notwithstanding, it seems advisable to balance judgements about the 
plausibility of models estimated by Dismod II—including the effect of any potential biases, 
corrected or otherwise—against the extent to which the available observational data can be 
                                                                                                                                                  
University, Canberra, 1990; Frenk, J, Bobadilla, JL, Stern, C, Frejka, T and Lozano, R, “Elements for a theory 
of the health transition”, Health Transit Rev, 1991, vol. 1(1), pp. 21-38. 
70  Begg, S, Vos, T, Barker, B, Stevenson, C, Stanley, L and Lopez, A, The burden of disease and injury in Australia, 
2003. 
71  Such considerations may also apply to a third version of Dismod being used for the most recent Global 
Burden of Disease Study, although this was not assessed in the present analysis. 
 43 
considered an accurate reflection of the true epidemiology of the cause being modelled. For 
example, information on relative risk is often only available for very coarse age groupings, or 
for all ages combined. In these situations, the systematic biases identified above might be a 
secondary consideration to deriving a plausible age pattern for RR´. Similarly, it is not 
uncommon for information on case-fatality or relative risk to be reported by age of incidence 
rather than age of death. Dr Judy Katzenellenbogen and colleagues show how this further 
complicates the way in which such information can be used to derive total attributable 
mortality in the IPM.72 
This concludes Part I of this thesis. In the following two parts I present a portfolio of papers 
or outputs that seek to address several areas of contemporary policy concern. Those in Part II, 
‘Policy applications of proposed projection methods’, rely predominantly on an alternative 
set of projection methods, as proposed in Chapter 2, while those in Part III, ‘Policy 
applications of proposed subpopulation methods’, depend on the subpopulation 
disaggregation methods also outlined in that chapter. 
    
                                                
72  Katzenellenbogen, JM, Vos, T, Somerford, P, Begg, S, Semmens, JB and Codde, JP, “Excess mortality rates 
for estimating the non-fatal burden of stroke in Western Australia: a data linkage study”, Cerebrovasc Dis, 
2010, vol. 30(1), pp. 57-64. 
 Part II: Policy applications of proposed 
projection methods 
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Chapter 4: Health in a post-transition population – 
adding years to life or life to years? 
Introduction 
The emerging field of population health dynamics is informed by a number of 
overlapping theories about change. From demography comes the theory of the 
demographic transition. Characterised as the central preoccupation of modern 
demography,73 this is a generalisation from observed trends that development leads to 
low birth and death rates where once both were high. The transition is the period 
separating the two situations and is typically characterised by rapid population growth 
and more gradual population ageing.74 The discipline of epidemiology provides the 
complimentary theory of the epidemiologic transition,75 a generalisation, again from 
observed trends, that a decreasing proportion of deaths caused by infectious diseases 
accompanies declining mortality. Figure 11 provides a graphic illustration of these 
trends in Australia over the twentieth century. 
Figure 11: A century of health improvement in Australia76 
 
                                                
73  Caldwell, JC, “Demography and social science”, Popul Stud (Camb), 1996, vol. 50(3), pp. 305-33. 
74  As the survival curve becomes increasingly ‘rectangular’; see Rowland, D, Demongraphic methods 
and concepts, Oxford University Press, New york, 2003.  
75  Omran, AR, “The epidemiologic transition. A theory of the epidemiology of population change”, 
Milbank Mem Fund Q, 1971, vol. 49(4), pp. 509-38. 
76  Adapted from AIHW, Mortality over the twentieth century in Australia: Trends and patterns in major 
causes of death. Mortality Surveillance Series no. 4, Australian Institute of Health and Welfare, 
Canberra, 2005. 
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More recently, researchers have become interested in describing what happens to 
levels of morbidity as mortality declines. Termed the health transition,77 this dynamic 
has proven more difficult to characterise due to differing interpretations of the term 
morbidity and the paucity of reliable and consistently recorded time-series 
information on non-fatal health outcomes at a population level. Nevertheless, several 
competing theories have emerged. The compression of morbidity hypothesis, first 
proposed by Fries,78 posits an increase in both the absolute expectation of life towards 
a biological limit and the proportion of the life span free of illness. A variation of this 
idea, termed the relative compression of morbidity scenario, is that only the latter 
increases. The expansion of morbidity hypothesis, on the other hand, predicts an 
increase in the proportion of the life span with disability79 because of improvements 
in the survival of those with disabling conditions and a shift in the distribution of 
causes of disability from fatal to non-fatal diseases of ageing.80 
The theory of dynamic equilibrium, first described by Manton,81 combines elements 
of both the compression and expansion hypotheses by proposing that mortality 
reductions are associated with a redistribution of disease and disability from more to 
less severe states. Under this scenario, the proportion of the life span with serious 
illness stabilises or decreases with decreasing mortality, whereas the proportion with 
less severe illness increases. 
As mentioned in Chapter 1, understanding the impact of future trajectories of 
morbidity and mortality has important practical and strategic implications, particularly 
in developed countries where increasingly attention is turning to the future 
sustainability of public finances as life expectancies increase to unprecedented levels 
                                                
77  Caldwell, JC, What we know about health transition : the cultural, social and behavioural determinants of 
health : the proceedings of an international workshop, Canberra, May 1989; Frenk, J, Bobadilla, JL, Stern, 
C, Frejka, T and Lozano, R, “Elements for a theory of the health transition”. 
78  Fries, JF, “Aging, natural death, and the compression of morbidity”, N Engl J Med, 1980, vol. 303(3), 
pp. 130-5. 
79  Gruenberg, EM, “The failures of success”, Milbank Mem Fund Q Health Soc, 1977, vol. 55(1), pp. 3-24. 
80  Olshansky, SJ, Rudberg, MA, Carnes, BA, Cassel, CK and Brody, JA, “Trading Off Longer Life for 
Worsening Health: The Expansion of Morbidity Hypothesis”, J Aging Health, 1991, vol. 3(2), pp. 
194-216. 
81  Manton, KG, “Changing concepts of morbidity and mortality in the elderly population”, Milbank 
Mem Fund Q Health Soc, 1982, vol. 60(2), pp. 183-244. 
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and populations grow older. A useful class of analytic tools for exploring this 
dynamic is health expectancy.82 First developed in a practical sense by Sullivan,83 
health expectancy extends the concept of life expectancy by reducing the estimated 
duration a person can expect to live at various ages given current risks of mortality by 
the amount of time spent at each age in states of less than perfect health.  
Like life expectancy, measures of health expectancy are expressed in years and are 
independent of the age structure of the population being measured. Unlike life 
expectancy, however, health expectancy takes account of both mortality and health in 
the surviving population thereby providing information on both the length and 
healthfulness of life.  
Measures of health expectancy have been used to show that the health transition in 
different contexts can add both years to life and ‘life to years’.84 Until quite recently, 
however, no decomposition or partitioning method was available for assessing the 
respective contribution of particular causes of death and disability to these findings. 
Instead, researchers looked at what happened when a specific disease was fully 
eliminated compared to the status quo.85 Although useful for identifying major causes 
of health loss, the disease elimination approach is less appropriate for assessing the 
contribution of specific causes to differences in health expectancies over time.  
Thus it is timely for Nusselder and Looman to have developed a method for 
partitioning differences in health expectancy into the additive contributions of death 
and disability from individual causes.86 Using a modification of Arriaga’s method for 
decomposing differences in life expectancy,87 they illustrate the utility of their 
approach by decomposing male-female differences in disability-free life expectancy 
(DFLE) for the Netherlands. DFLE uses age-specific proportions of the population 
that meet a threshold criterion for disability (available in many countries from 
                                                
82  Robine, J-M, Determining health expectancies, J. Wiley, Chichester, 2003. 
83  Sullivan, DF, “A single index of mortality and morbidity”. 
84  Robine, J-M, Determining health expectancies. 
85  Mathers, CD, “Gains in health expectancy from the elimination of diseases among older people”, 
Disabil Rehabil, 1999, vol. 21(5-6), pp. 211-21. 
86  Nusselder, WJ and Looman, CW, “Decomposition of differences in health expectancy by cause”, 
Demography, 2004, vol. 41(2), pp. 315-34. 
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surveys) to dichotomise the number of years lived at each age into those with and 
without disability.  
DFLE has the advantage of being relatively straightforward to calculate. However, it 
ignores variations in severity below and above what is essentially an arbitrary 
threshold and is therefore a fairly crude measure for assessing theories about the 
health transition such as the one proposed by Manton.88 Health-adjusted life 
expectancy (HALE), on the other hand, is more suited to this purpose because it 
involves summing across all major causes of health loss the product of the prevalence 
proportion for each cause and a corresponding numerical weight for severity ranging 
from 0 (equivalent to full health) to 1 (equivalent to death). Although HALE has 
greater information requirements than DFLE, it can still be calculated using the 
Sullivan method and can therefore be decomposed using the method proposed by 
Nusselder and Looman. 
In this chapter I use HALE to explore the dynamics of the health transition as they are 
manifest at the beginning of the twenty-first century in Australia, a country that 
experienced changes over the preceding century characteristic of the demographic and 
epidemiologic transitions and which, as a consequence, now experiences very low 
levels of mortality. My aim is to determine whether existing theories about the health 
transition adequately describe the likely impact of future trajectories of morbidity and 
mortality in a population as it moves into a post epidemiologic transition phase of 
development. Australia is a convenient setting within which to pursue this 
investigation due to our recent comprehensive assessment of the health status of its 
population.89  
Methods 
My primary outcome of interest is the difference between life expectancy (LE) and 
health-adjusted life expectancy, which I will refer to as absolute lost health 
expectancy (ALHE) and define as, 
                                                
88  Manton, KG, “Changing concepts of morbidity and mortality in the elderly population”. 
89  Begg, S, Vos, T, Barker, B, Stevenson, C, Stanley, L and Lopez, A, The burden of disease and injury in 
Australia, 2003; Begg, SJ, Vos, T, Barker, B, Stanley, L and Lopez, AD, “Burden of disease and injury 
in Australia in the new millennium: measuring health loss from diseases, injuries and risk factors”. 
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€ 
ALHEat = LEat −HALEat , 
Equation 14 
using the standard demographic right-hand superscript and subscript to denote a point 
in time t and an exact age a, respectively. I estimate LE and HALE using the Sullivan 
method for abridged life tables90 from the estimates of mortality and prevalent 
disability described below and presented in Table 10. I measure absolute change in 
morbidity from t to t+n in years using, 
€ 
ΔALHEat,t+n( ) = ALHEat − ALHEat+n, 
Equation 15 
where absolute compression over time is indicated by a negative value and absolute 
expansion by a positive value. A related outcome of interest is lost health expectancy 
expressed as a proportion of life expectancy, which I call here relative lost health 
expectancy (RLHE) and define as, 
€ 
RLHEat =
ALHEat
LEat
. 
Equation 16 
I assess change in RLHE from t to t+n using, 
€ 
ΔRLHEat,t+n( ) = RLHEat − RLHEat+n, 
Equation 17 
where relative compression in morbidity over time is indicated by a negative value 
and relative expansion by a positive value. The other outcome of interest is evidence 
of a shift towards less severe causes of health loss with decreasing mortality, which I 
explore by partitioning changes in ALHE over time into additive contributions from 
changes in levels of cause-specific mortality and disability.  
The decomposition analysis followed the equations described by Nusselder and 
Looman91, which I implemented in the Mata matrix programming environment.92 The 
                                                
90  Sullivan, DF, “A single index of mortality and morbidity”. 
91  Nusselder, WJ and Looman, CW, “Decomposition of differences in health expectancy by cause”.
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model consists of the following Mata subroutines: mata_cause_decomp, 
mata_decomp and mata_lt_rate. These routines are ‘wrapped’ in the Stata ado 
program hale_decomp, which, if installed correctly, can be accessed from the 
command line like any other Stata command.  
hale_decomp operates on a uniformly structured dataset and requires the following 
variables as inputs: age (0, 1, 5, 10…100, although other age groupings could be 
implemented), ax (the average midpoint for each age category in the population), 
deaths (the number of cause-specific deaths in each age category in the population), 
pyld (the number of cause-specific prevalent YLD in each age category in the 
population). It also requires the following variables (numeric or string) as inputs: 
cause (a variable that stratifies the data by cause), strata (a variable that stratifies the 
data by another dimension such as time or subpopulation group) and base (the value 
in strata that identifies the baseline stratum against which other strata are to be 
compared). The code for enabling hale_decomp is at Appendix G. 
Mortality inputs were obtained from the previously mentioned analysis of actual and 
projected mortality by age and sex for a complete set of 180 diseases and injuries of 
public health importance in Australia over the period 1993 to 2023.93 The same 
analysis was used for estimates of prevalent disability, which I refer to here as 
prevalent years lived with disability (PYLD) to be consistent with Murray and 
Lopez’s original terminology.  A prevalent year lived with disability is defined as, 
€ 
k PYLD=kP×kDW , 
Equation 18 
where P denotes the prevalence proportion of cause k in the population and DW 
denotes the corresponding comorbidity-adjusted severity weight (range: 0 for full 
health to 1 for complete loss of health). Table 10 summarises the basic characteristics 
of the dataset used in this analysis.94 
                                                                                                                                       
92  StataCorp. 
93  Begg, S, Vos, T, Barker, B, Stevenson, C, Stanley, L and Lopez, A, The burden of disease and injury in 
Australia, 2003; Begg, SJ, Vos, T, Barker, B, Stanley, L and Lopez, AD, “Burden of disease and injury 
in Australia in the new millennium: measuring health loss from diseases, injuries and risk factors”. 
94  See Chapter 2 for full details. 
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Table 10: Mortality and prevalent disability by selected stratifications, Australia, 1993 and  2023 
 Mortality(a)  PYLD(a) 
 1993  2023  1993  2023 
  n (%) Rate  n (%) Rate  n (%) Rate  n (%) Rate 
Total(b) 
122 
(100.0) 68.8  
187 
(100.0) 37.9  
1,311 
(100.0) 742.2  
2,185 
(100.0) 698.6 
Age group            
0 to <50 13 (10.7) 9.8  9 (4.9) 6.1  619 (47.2) 467.7  706 (32.3) 473.6 
50 to <60 8 (6.9) 50.9  6 (3.3) 19.2  163 (12.4) 986.5  289 (13.2) 909.3 
60 to <70 20 (16.4) 142.6  17 (9.0) 58.2  199 (15.2) 1421.4  354 (16.2) 1225.1 
70 to <80 34 (28.3) 363.5  39 (21.0) 181.1  196 (14.9) 2068.2  406 (18.6) 1872.8 
80 to <90 35 (28.4) 931.3  63 (33.5) 627.4  114 (8.7) 3056.1  305 (14.0) 3050.9 
90 to <100 11 (8.8) 2,077.3  48 (25.8) 1,698.7  20 (1.5) 3883.3  114 (5.2) 3995.7 
100+ 1 (0.4) 4,759.3  5 (2.7) 1,866.4  0 (0.0) 4365.9  11 (0.5) 4019.8 
Cause group(b,c)            
Infectious 2 (1.4) 1.0  4 (2.0) 0.9  18 (1.4) 10.4  28 (1.3) 10.5 
Acute respiratory 1 (0.8) 0.6  9 (4.8) 1.4  11 (0.8) 6.3  14 (0.6) 6.3 
Maternal 0 (0.0) 0.0  0 (0.0) 0.0  2 (0.2) 1.1  2 (0.1) 1.1 
Neonatal 1 (0.7) 0.5  0 (0.1) 0.2  34 (2.6) 19.5  46 (2.1) 19.5 
Nutritional 0 (0.1) 0.1  0 (0.1) 0.0  5 (0.4) 2.8  7 (0.3) 2.8 
Cancer 33 (26.8) 18.5  54 (29.0) 12.6  79 (6.0) 44.8  103 (4.7) 27.9 
Other neoplasms 1 (0.5) 0.3  1 (0.8) 0.3  3 (0.2) 1.4  4 (0.2) 1.3 
Diabetes 3 (2.3) 1.6  6 (3.1) 1.2  64 (4.9) 36.2  204 (9.3) 55.5 
Endocrine 1 (1.0) 0.7  2 (1.3) 0.5  16 (1.2) 9.1  31 (1.4) 10.0 
Mental 1 (1.1) 0.7  2 (0.8) 0.5  345 (26.3) 195.2  485 (22.2) 194.9 
Neurological 5 (3.9) 2.7  15 (7.9) 2.6  199 (15.2) 112.9  458 (21.0) 115.4 
Cardiovascular 53 (43.6) 30.0  56 (29.6) 9.3  111 (8.4) 62.6  146 (6.7) 36.3 
Chronic respiratory 7 (6.1) 4.2  15 (7.9) 3.0  129 (9.8) 73.0  188 (8.6) 60.5 
Digestive 3 (2.2) 1.5  4 (2.3) 0.8  28 (2.1) 15.7  51 (2.3) 15.4 
Genitourinary 2 (1.8) 1.3  8 (4.0) 1.3  38 (2.9) 21.8  60 (2.7) 22.1 
Skin 0 (0.2) 0.1  1 (0.4) 0.1  16 (1.2) 9.2  25 (1.1) 9.1 
Musculoskeletal 1 (0.5) 0.4  1 (0.7) 0.3  75 (5.7) 42.4  150 (6.8) 42.7 
Congenital 1 (0.7) 0.5  1 (0.3) 0.2  35 (2.6) 19.6  44 (2.0) 19.0 
Oral 0 (0.0) 0.0  0 (0.0) 0.0  20 (1.5) 11.2  32 (1.5) 11.2 
Other syndromes 0 (0.2) 0.2  0 (0.1) 0.0  7 (0.5) 4.1  11 (0.5) 4.1 
Injuries 7 (6.0) 4.1  9 (4.8) 2.8  76 (5.8) 42.8  97 (4.4) 32.5 
Severity group(b,d)            
0 to <0.1 13 (10.6) 7.3  28 (14.9) 6.0  430 (32.8) 243.7  828 (37.9) 264.6 
0.1 to <0.2 59 (48.5) 33.4  81 (43.2) 15.4  430 (32.8) 243.4  647 (29.6) 211.0 
0.2 to <0.3 27 (22.6) 15.6  44 (23.3) 9.6  206 (15.7) 116.3  307 (14.1) 103.9 
0.3 to <0.4 17 (13.7) 9.4  23 (12.2) 4.5  139 (10.6) 78.6  205 (9.4) 62.8 
0.4 to 1 6 (4.6) 3.2  12 (6.4) 2.5  106 (8.1) 60.2  196 (9.0) 55.9 
Notes: (a) numbers expressed in units of 1,000, rates expressed per 10,000 population; (b) rates standardised to the age structure of 
Australian population in 1993; (c) approximately equivalent to chapter headings of the International Classification of Diseases version 
10; (d) determined by classifying each cause-, age and sex-specific PYLD estimate to its corresponding severity weight; totals may 
not add due to rounding; PYLD = prevalent years lived with disability. 
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Results 
The total area under the survival curve for all survivors (including those with and 
without disability) and survivors without disability represents 
€ 
LE0t  and 
€ 
HALE0t  , 
respectively (Figure 12). The projected trajectories for cause-, age- and sex-specific 
mortality and prevalent disability presented in Table 10 differentially shift these 
survival curves to the right over time, as demonstrated by a 0.28% per annum increase 
in 
€ 
LE0t to 84.6 years in 2023 compared with a 0.26% increase per annum in 
€ 
HALE0t  to 
76.2 years in the same year.  
Figure 12: Cumulative survival with and without disability, Australia, 1993 and 2023  
 
 
Cumulative survival with disability (the dark and light grey areas in Figure 12) is 
presented on its own axis in Figure 13. The area under the lines represents 
€ 
AHLE0t , 
which is projected to increase from 7.3 years in 1993 to 8.5 years in 2023. The 
difference between the areas under the lines for 2023 and 1993 is the absolute change 
in life with disability between the two periods (represented by the total area in grey in 
Figure 2). A net value of greater than 0 across the life span represents absolute 
expansion of morbidity over time; a net value less than 0 represents absolute 
compression. Between 1993 and 2023 absolute morbidity is projected to expand by 
1.22 years. 
€ 
RLHE0t  is projected to increase from 9.3% in 1993 to 10.0% in 2023, 
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indicating a relative expansion of morbidity of 0.7% of the total life span over this 
period.  
Decomposition of the projected absolute expansion in morbidity between 1993 and 
2023 (the grey area in Figure 13) by age, cause and severity is presented in Table 11. 
Overall, declining trends in mortality across all ages, but particularly between ages 75 
and 94, contributed to an expansion in morbidity of 1.70 years over the study period. 
This was offset by declining trends in disability below the age of 85, which 
contributed to morbidity compression of 0.49 years. Increasing trends in morbidity 
between ages 85 and 99 contributed to a slight expansion in morbidity of about 0.01 
year. The combined effect of trends in both mortality and disability below age 70 was 
a compression of morbidity of 0.14 years. From age 70, the effect was a net expansion 
of morbidity of 1.36 years. 
Figure 13: Cumulative survival with disability, Australia, 1993 and 2023 
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Table 11: Decomposition of projected absolute expansion of morbidity by age, cause and severity, 
Australia, 1993 to 2023 
   Mortality    Disability  Net 
 Rate  ΔALHE0  Rate  ΔALHE0  ΔALHE0 
 %Δ pa  Years (%)  %Δ pa  Years (%)  Years (%) 
All causes -2.0  1.70 (100.0)  -0.2  -0.48 (100.0)  1.22 (100.0) 
Decomposition by age group          
0 to <50 -1.6  0.02 (1.4)  0.0  -0.06 (12.6)  -0.04 (-2.9) 
50 to <60 -3.2  0.03 (1.9)  -0.3  -0.08 (16.2)  -0.05 (-3.7) 
60 to <70 -2.9  0.11 (6.4)  -0.5  -0.17 (35.8)  -0.06 (-5.2) 
70 to <80 -2.3  0.33 (19.5)  -0.3  -0.16 (33.2)  0.17 (14.1) 
80 to <90 -1.3  0.67 (39.7)  0.0  -0.02 (3.5)  0.66 (53.8) 
90 to <100 -0.7  0.42 (24.7)  0.1  0.01 (-2.5)  0.43 (35.4) 
100+ -3.1  0.11 (6.4)  -0.3  -0.01 (1.1)  0.10 (8.5) 
Decomposition by cause group          
Infectious -0.1  0.00 (0.2)  0.0  0.00 (0.2)  0.00 (0.2) 
Acute respiratory 3.1  -0.05 (-2.7)  0.0  0.00 (-0.1)  -0.05 (-3.8) 
Maternal -1.5  0.00 (0.0)  0.0  0.00 (0.0)  0.00 (0.0) 
Neonatal -3.8  0.02 (1.1)  0.0  0.00 (-0.1)  0.02 (1.6) 
Nutritional -2.9  0.00 (0.1)  0.0  0.00 (0.0)  0.00 (0.2) 
Cancer -1.3  0.32 (19.1)  -1.6  -0.19 (39.4)  0.14 (11.2) 
Other neoplasms -0.7  0.00 (0.2)  -0.3  0.00 (0.3)  0.00 (0.2) 
Diabetes -0.8  0.02 (1.1)  1.4  0.23 (-48.7)  0.25 (20.6) 
Endocrine -1.2  0.01 (0.6)  0.3  0.03 (-6.0)  0.04 (3.2) 
Mental -1.3  0.01 (0.8)  0.0  0.00 (0.1)  0.01 (1.1) 
Neurological -0.1  0.00 (0.1)  0.1  0.03 (-6.5)  0.03 (2.8) 
Cardiovascular -3.8  1.13 (66.6)  -1.8  -0.37 (78.1)  0.76 (62.1) 
Chronic respiratory -1.2  0.07 (4.1)  -0.6  -0.12 (25.1)  -0.05 (-4.1) 
Digestive -2.3  0.04 (2.5)  -0.1  0.00 (-0.1)  0.04 (3.5) 
Genitourinary 0.0  0.00 (0.0)  0.0  0.01 (-1.6)  0.01 (0.7) 
Skin -0.1  0.00 (0.0)  0.0  0.00 (0.4)  0.00 (-0.1) 
Musculoskeletal -1.2  0.01 (0.3)  0.0  0.00 (-0.3)  0.01 (0.6) 
Congenital -2.6  0.02 (0.9)  -0.1  0.00 (0.8)  0.01 (1.0) 
Oral 0.0  0.00 (0.0)  0.0  0.00 (0.1)  0.00 (0.0) 
Ill defined -7.2  0.01 (0.5)  0.0  0.00 (0.0)  0.01 (0.7) 
Injuries -1.3  0.07 (4.3)  -0.9  -0.09 (18.8)  -0.02 (-1.4) 
Decomposition by severity group          
0 to <0.1 -0.7  0.07 (4.4)  0.3  0.28 (-58.8)  0.35 (29.1) 
0.1 to <0.2 -2.6  0.99 (58.2)  -0.5  -0.42 (88.3)  0.57 (46.4) 
0.2 to <0.3 -1.6  0.33 (19.3)  -0.4  -0.12 (24.7)  0.21 (17.2) 
0.3 to <0.4 -2.4  0.27 (16.0)  -0.7  -0.18 (38.6)  0.09 (7.2) 
0.4 to 1 -0.8  0.04 (2.2)  -0.2  -0.03 (7.2)  0.00 (0.2) 
Note: column totals may not add due to rounding; ΔALHE0 = change in absolute lost health expectancy at birth between 1993 and 
2023. 
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Cardiovascular disease, diabetes and cancer together contributed 1.14 years (93.8%) 
to the projected 1.22-year expansion of morbidity between 1993 and 2023. A decline 
in cardiovascular disease mortality accounted for 1.13 years of this expansion but was 
offset by more modest declines in cardiovascular disease disability, resulting in a net 
contribution from this cause of 0.76 years (62.1%). The 0.25-year (20.6%) net 
contribution from diabetes, on the other hand, was almost entirely due to increasing 
disability from this cause, with modest declines in diabetes mortality expected to 
make only a 0.02-year contribution to total morbidity expansion. Cancer is expected 
to make a net contribution of 0.14 years (11.2%), with the 0.32-year contribution from 
declines in cancer mortality being partially offset by declines in disability from this 
cause. 
Discussion 
This analysis indicates that the most likely consequence of a continuation of recent 
trajectories in levels of mortality and morbidity in Australia will be a modest 
expansion of morbidity over the life course. This expansion will be manifest in both 
an absolute and a relative sense; in other words, time spent with disability will most 
likely increase both in terms of numbers of years lived and as a proportion of the 
average life span. Underlying this dynamic is the expectation that overall levels of 
mortality will continue decreasing at a faster rate than overall levels of disability  
(-2.0% and -0.2% per annum, respectively), resulting in gains in total life expectancy 
that exceed gains in health-adjusted life expectancy (0.28% and 0.26% per annum, 
respectively).  
The analysis also indicates that the vast majority of projected changes to levels of 
morbidity over the life course will most likely hinge on a small group of chronic 
diseases: cardiovascular disease, diabetes and cancer (particularly lung cancer). In two 
out of three of these diseases, the prevailing trends in both mortality and disability are 
favourable; these can rightly be regarded as twentieth century public health success 
stories. In fact, the only unfavourable trend of any note is the increase in disability 
from diabetes, which is based on the expectation that recent failures to curb rising 
levels of obesity will continue. Mortality from diabetes, on the other hand, is expected 
to decline in line with declining cardiovascular disease mortality since most mortality 
from diabetes has vascular origins.  
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The strength of this analysis is that it quantifies for a comprehensive range of diseases 
and injuries of public health importance the impact of trends in both fatal and non-
fatal health outcomes using a standardise analytical framework and uniform methods. 
In addition, it represents one of the first attempts to analyse temporal dynamics in 
HALE in terms of age, cause and impact (fatal and non-fatal) within an additive 
decomposition framework, as opposed to the single cause deletion approach. The 
availability of a structured database in which each of these dimensions was 
represented greatly facilitated the analytical processes.  
The limitation of the analysis, of course, is that the underlying data set relied on a 
range of simplifying assumptions that cannot possibly reflect the full range of 
population health dynamics over the projection period. Notwithstanding this 
important caveat, however, the analysis is illustrative in several respects. 
First, the results undermine support for a popular interpretation of Fries’ hypothesis 
that populations, even in advanced stages of the epidemiologic transition, experience 
a compression of morbidity. This refutation is, of course, qualified since the 
underlying data set did not include assumptions about changes in levels of severity for 
a particular cause arising from, for example, technological innovations; rather, these 
assumptions were limited to expected changes in the underlying epidemiological 
parameters. Nevertheless, given expected declines in mortality outpaced expected 
declines in morbidity by a factor of 10, the impact of technology would have to very 
large for gains in health-adjusted life expectancy to catch up with life expectancy. 
Varying the severity weights within plausible bounds would shed further light on this 
dimension of the results. 
Second, the results provide qualified support for Manton’s theory that the proportion 
of the life span with serious illness stabilises or decreases with decreasing mortality, 
whereas the proportion with less severe illness increases. This is evident in the results 
from the decomposition analysis by severity group, which indicated that over three-
quarters of the absolute expansion in morbidity over the projection period was 
accounted for by low severity causes (i.e. those causes with severity weight of less 
than 0.2). By far the greatest contributor was the 0.1 to <0.2 severity group, which 
together accounted for 46.4% of morbidity expansion and was driven by much faster 
declines in rates of mortality than disability over this period (-2.6% and -0.5% per 
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annum, respectively). The second largest was the zero to <0.1 severity group (29.1%), 
although the dominant driver in this case was a modest increase in rates of morbidity 
of 0.3% per annum, with the -0.7% per annum decline in mortality having only a 
minor effect. Again, a sensitivity analysis of the severity weight assumptions would 
shed further light on these dynamics. 
The results also have implications for how epidemiology should be used to explain 
health system demand pressures. Correctly understood, the role of cardiovascular 
disease and cancer—both diseases typically portrayed as central to these pressures95—
has been to increase demand, but not because the underlying risks associated with 
these causes is increasing. In fact, the risk of disability and mortality from both is 
decreasing. Rather it is because these declines have already had such a profound 
impact on life expectancy that people are now living to ages where they experience 
the effects of degenerative diseases of old age (such as sensory and musculoskeletal 
disorders, dementias and Parkinson's disease) for which risk has remained relatively 
stable but for which prevalence is growing as a result of the increasingly greater 
proportion of the population living at older ages. These are, in broad terms, the 
dominant epidemiological drivers of health system demand in a post transition 
population. 
Of course there are other non-epidemiological drivers as well, such as trends in 
fertility, technological innovation and increasing wealth. As such, the tendency in 
policy discourse to portray prevention as having untapped potential to curb demand 
pressures arising from the chronic disease epidemic that is engulfing the health 
system, while rhetorically appealing, is nevertheless inconsistent with the evidence 
and thus not very helpful. In fact, such efforts will, if the past is any guide, most likely 
result in a further expansion of morbidity hence demand simply by continuing the 
tendency for the health system as a whole to generate faster declines in mortality than 
in disability. The dynamic at play here is that past successes have for the most part 
been confined to causes with a predominantly fatal impact (e.g. cardiovascular 
disease, cancer) whereas health service demand is driven by the prevalence of 
disability more broadly.  
                                                
95  National Health Priority Action Council, National Chronic Disease Strategy, Australian Government 
Department of Health and Ageing, Canberra, 2006. 
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The most notable exception to these general trends is diabetes, which is expected to 
account for around one-fifth of the total expansion in morbidity over the projection 
period. This is driven almost entirely by the expected 1.8% per annum increase in risk 
of disability, with the -0.7% per annum decline in risk of mortality having a much 
smaller but nevertheless still expansionary impact. Thus diabetes is a key area where 
prevention as a demand mitigation strategy might have potential. However, efforts to 
prevent further growth in levels of obesity, the key risk factor for diabetes, have 
largely been unsuccessful and it seems likely that the overall expansionary impact of 
this disease will continue in the absence of a much greater commitment to developing 
the evidence base on how to implement effective obesity control.  
This analysis also has more fundamental philosophical implications. It should be of 
general concern, for example, that one of the returns on our increasing investments in 
health relative to both total government expenditure and the rest of the economy 
appears to be a modest expansion of morbidity over the life course. This observation 
is only partially tempered by the related finding that we are, on average, getting 
healthier in absolute terms (i.e. the length of the life course is increasing). Perhaps the 
greatest policy challenge over the coming decades, therefore, will be to articulate the 
benefits of an increasingly costly health system adept at adding years to life but not 
necessarily life to years, particularly amongst those with degenerative diseases of old 
age. 
 Chapter 5: An alternative approach to projecting health 
expenditure in Australia96 
Introduction 
Improvements in health, particularly among the elderly, have been an important consequence 
of economic development. Better health, in turn, has led to greater economic development 
and more people surviving to old age. Together with decreasing fertility, this has contributed 
to population ageing. Interest is increasing across the developed world in the long-term 
sustainability of public finances in the context of these widespread demographic trends. 
In most countries with time series data, expenditure on health has increased substantially 
across all components of the health system beyond what can be explained by changing age 
structure and size of the population alone. The main non-demographic factors influencing 
these trends are: new technologies, such as diagnostics, drugs or procedures; changing 
medical practice and policy; the organisation and financing of the health care system; the 
intensity or coverage of health services; the greater rate of increase in health prices compared 
with general prices (excess health inflation); and changes in population health status. 
The influence of non-demographic factors is unlikely to be uniform across the health care 
system. Furthermore, the impact of these factors is likely to vary over time depending on the 
type of health service and the particular health problem it addresses. Taking into account such 
detail when projecting health expenditure would be impractical. Instead, analysts have tended 
to extrapolate from observed trends in expenditure growth for aggregate categories of 
expenditure. 
A common approach has been to apply growth factors for the combined effect of the non-
demographic growth in health expenditure over time without necessarily making explicit the 
identified non-demographic growth factors.97 A few of these studies have considered overall 
                                                
96 This chapter was first published as Begg, S, Vos, T, Goss, J and Mann, N, “An alternative approach to 
projecting health expenditure in Australia”. See Declarations and Statements for the respective contributions 
of each author. 
97  ABS, Population Projections Australia 2002 to 2101, (Cat. No. 3222.0), Australian Bureau of Statistics, Canberra, 
2003; de Hollander, AEM, Hoeymans, N, Melse, JM, J.A.M., vO and Polder, JJ, Zorg voor gezondheid: 
Volksgezondheid Toekomst Verkenning 2006, Rijksinstituut voor Volksgezondheid en Milieu, Bilthoven, the 
Netherlands, 2006; Economic Policy Committee and the European Commission (DG ECFIN), The impact of 
ageing on public expenditure: projections for the EU-25 Member States on pensions, healthcare, long-term care, 
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changes in population health status by making assumptions about the increase in healthy 
years lived as life expectancy increases.98 Some have also included an adjustment to account 
for the fact that many health resources are used in the last year of life99; improvements in life 
expectancy shift period to older ages.100 
Two health expenditure projection models have explicitly accounted for changes in 
population health status in greater detail.101 The first model projected public health 
expenditure in The Netherlands based on historical expenditure by disease, age and sex, and 
epidemiological projections of incidence and prevalence for 52 disease groups. This study did 
not quantify the contribution of disease trends to expected changes in health expenditure. The 
second model projected health expenditure in Australia for nine disease groups in a pilot 
study covering less than half of all health expenditure. This study did not quantify the 
contribution of changes in population health status to expected changes in total health 
expenditure. 
The aim of this chapter is to introduce a body of work undertaken by researchers at the 
University of Queensland’s School of Population Health and the Australian Institute of 
Health and Welfare that applied the methods developed for the pilot study to all components 
of health expenditure.102 This work provides an alternative analysis of future health 
expenditure in Australia by incorporating likely changes in both the epidemiology of disease 
and injury, and the volume of health service delivery for a comprehensive set of health 
outcomes over the period 2003–2033. 
                                                                                                                                                  
education and unemployment transfers (2004–50). 2006; OECD, Projecting OECD health and long-term care 
expenditures: What are the main drivers?, Organisation for Economic Co-operation and Development, Paris, 
2006, viewed 16 August 2011, http://www.oecd.org/dataoecd/57/7/36085940.pdf; United Nations, World 
Population Ageing 1950-2050, 2002; Vos, T, Goss, J, Begg, S and Mann, N, Australian Burden of Disease and 
Injury Study: Projected health care costs report, University of Queensland, Brisbane, Australia, 2005. 
98  Economic Policy Committee and the European Commission (DG ECFIN), The impact of ageing on public 
expenditure: projections for the EU-25 Member States on pensions, healthcare, long-term care, education and 
unemployment transfers (2004–50); OECD, Projecting OECD health and long-term care expenditures: What are the 
main drivers? 
99  Begg, S, Vos, T, Barker, B, Stevenson, C, Stanley, L and Lopez, A, The burden of disease and injury in Australia, 
2003; Economic Policy Committee and the European Commission (DG ECFIN), The impact of ageing on public 
expenditure: projections for the EU-25 Member States on pensions, healthcare, long-term care, education and 
unemployment transfers (2004–50); United Nations, World Population Ageing 1950-2050. 
100  AIHW, Health system expenditure on disease and injury in Australia, 2000-01, (Cat. No. HWE 28), Australian 
Institute of Health and Welfare, Canberra, 2005; Mathers, C, Penm, D, Carter, C and Stevenson, C, Health 
system costs of diseases and injury in Australia 1993-94, (Health and Welfare Expenditure Series No. 2), 
Australian Institute of Health and Welfare, Canberra, 1998. 
101  de Hollander, AEM, Hoeymans, N, Melse, JM, J.A.M., vO and Polder, JJ, Zorg voor gezondheid: 
Volksgezondheid Toekomst Verkenning 2006; Vos, T, Goss, J, Begg, S and Mann, N, Australian Burden of Disease 
and Injury Study: Projected health care costs report. 
102  United Nations, World Population Ageing 1950-2050. 
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Methods 
Separate projections were calculated for each health condition (or group of conditions in 
some cases) and type of expenditure (hospital care, medical services, pharmaceuticals, aged 
care homes and other health services). Analyses accounted for expected changes in the 
number of affected cases (epidemiology), the proportion of cases treated (treatment 
proportion), the volume of health services per treated case (treatment volume), and excess 
health price inflation (price). Numbers of cases were calculated to be a function of changes in 
population size and age structure, as well as trends in epidemiology. A brief overview of the 
data sources and methods used to derive each of these components follows. A more detailed 
account is available as a background paper for the United Nations World Economic and 
Social Survey 2007.103 
Population	  size	  and	  age	  structure	  
Population projections were obtained from the Australian Bureau of Statistics (ABS) Series 8 
population projections.104 This series is based on the 2001 census and assumes high net 
overseas migration (125,000 annually), constant improvements in life expectancy (low 
mortality assumption), and total fertility declining to a rate of 1.6 by 2011 and then remaining 
constant. 
Incidence	  and	  prevalence105	  
Estimates of incidence and prevalence were obtained from the Australian Burden of Disease 
and Injury 2003 study. Methods and assumptions for these estimates are described in detail 
elsewhere.106 The key analytical steps were: 
1. Baseline models specifying the complete epidemiology for over 180 diseases and injuries 
in Australia for the year 2003 were developed using a large range of data sources, 
methods and assumptions. 
2. Trends in observed cause-specific mortality over the period 1979–2003 were analysed 
and projected into the future using a combination of regression techniques. 
                                                
103  ibid. 
104  ABS, Population Projections Australia 2002 to 2101. 
105  See Chapter 2 for further details. 
106  Begg, S, Vos, T, Barker, B, Stevenson, C, Stanley, L and Lopez, A, The burden of disease and injury in Australia, 
2003. 
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3. Hazards for fatal conditions were extrapolated backwards and forwards from baseline 
using assumptions about the relative contribution of incidence and case-fatality to 
changes in cause-specific mortality (both observed and projected). For non-fatal 
conditions, incidence was the only hazard for which extrapolations were made. 
4. The epidemiology of each condition was estimated in a temporal model that accounted 
for changes in all-cause mortality as well as changes in incidence and case-fatality (where 
appropriate) at all points throughout the projection period. 
5. Absolute numbers of incident and prevalent cases were derived by applying the 
population rates from the above analyses to projected population estimates. 
Treatment	  proportion	  and	  treatment	  volume	  
Comparable per-unit health care costs by health condition and type of expenditure (hospital 
care, medical services, pharmaceuticals, aged care homes and other health services) were 
available for two time periods (1993–94 and 2000–01) from previous work.107 These 
estimates were divided by epidemiological estimates for the same years to derive estimates of 
treatment proportion and treatment volume for each health condition, type of expenditure and 
time period. Expected future changes in these parameters were extrapolated from the 
observed changes between 1993–94 and 2000–01. 
For most conditions, prevalent cases were used to derive these parameters because total 
expenditure for a condition was assumed to be primarily influenced by the number of people 
with the condition at a point in time. For cancer, incident cases were used because most 
expenditure for cancer occurs in the first year after diagnosis. For ischaemic heart disease and 
stroke, expenditure on admitted patients was derived from incident cases, while medical and 
pharmaceutical expenditure was derived from prevalent cases. For some conditions the data 
for the period 1993–94 to 2000–01 were deficient so that valid trends in treatment proportion 
and volume could not be estimated. In this case a standard growth in treatment volume of 
2.5% per 5 years was assumed. 
Judgement was used to adjust observed trends in treatment proportion and treatment volume 
that appeared unusual and could not be explained, or were considered unsustainable into the 
                                                
107  AIHW, Health system expenditure on disease and injury in Australia, 2000-01; Mathers, C, Penm, D, Carter, C 
and Stevenson, C, Health system costs of diseases and injury in Australia 1993-94. 
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future.108 Lipid lowering drugs for the prevention of cardiovascular disease, for example, 
experienced a large increase in expenditure over the period 1993–94 and 2000–01. When 
these drugs go off patent it is likely that per unit pharmaceutical costs for this disease will 
decrease.  
Price	  
The price factor is the amount by which health prices are expected to exceed general inflation 
in the economy. This is often called excess health price inflation. In the period 1993–94 to 
2000–01 excess health price inflation averaged 0.73% per year, with small variations across 
areas of expenditure. In this model, excess health price inflation was assumed to increase into 
the future at the average rate of 0.73% across all areas of expenditure except dental services 
where a higher rate of 2.0% per was assumed. It would be desirable in future models to vary 
this assumption for more areas of expenditure. For example, an important source of 
uncertainty in this analysis is the impact on pharmaceutical prices of patent expiry and the 
growing use of cost control measures. 
Decomposition	  of	  factors	  
Decomposition of the respective contribution of each of the factors in the projection model to 
changes in total health expenditure should account for expected interaction between factors. 
A simplified model was adopted in which interaction effects were allocated to each of the six 
factors in the analysis in proportion to the ratio of the sixth root of a particular factor to the 
sixth root of all factors combined. 
Comparisons	  with	  other	  studies	  
Comparisons with other studies that use different projection periods was achieved by 
annualising projected growth in health expenditure and expressing this as percentage points 
above projected growth in gross domestic product (GDP). 
Results 
Total health expenditure in Australia is expected to increase from $71.4 billion in 2002–03 to 
$162.3 billion in 2032–33, an increase of 127.4% or $90.9 billion (Table 12). On the basis of 
                                                
108  The term judgement in this context refers to the process whereby commonsense was applied when 
determining model parameters. 
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Australian Treasury estimates, GDP will increase by 96.9% over the same period, meaning 
that health expenditure is expected to increase from 9.4% of GDP in 2002–03 to 10.8% of 
GDP in 2032–33. This represents an increase of 14.9% in the health to GDP proportion, or an 
annual growth of 0.5% greater than growth in the economy more generally. 
Table 12: Projected total health expenditure (2002–03 dollars), Australia, 2002–03 to 2032–33 
 Year Change 
  2002–03 2012–13 2022–23 2032–33 
2003–2033 
(%) 
Total health expenditure ($ billion) 71.4 91.7 122.2 162.3 127.4 
Gross domestic producta (GDP; $ billion) 762.0 995.0 1,230.0 1,500.0 96.9 
Total health expenditure as a proportion of GDP (%) 9.4 9.2 9.9 10.8 14.9 
Notes: (a) Sourced from the Australian Treasury. 
 
Neurological and sense disorders—mostly dementia and Parkinson’s disease—are expected 
to experience the greatest absolute growth in expenditure over the projection period, followed 
by cardiovascular disease and dental services (Table 13). The expected growth for 
cardiovascular disease is due to a $5.0 billion increase in expenditure on treatment services 
and a $3.3 billion increase in expenditure on prevention efforts (mainly blood pressure 
lowering drugs and lipid lowering drugs). Diabetes is expected to experience the greatest 
proportional increase in expenditure over the projection period, followed by neurological 
disorders, musculoskeletal conditions and dental services. 
 65 
Table 13: Projected total health expenditure (2002–03 dollars) by cause, Australia, 2002–03 to 2032–33 
 Expenditure by year ($ billion) Change 2003 to 2033 
Cause 2002–03 2032–33 $ billion % 
Cardiovascular 7.9 16.2 8.3 104.7 
Treatment 4.5 9.4 5.0 111.1 
Prevention 3.4 6.8 3.3 96.2 
Respiratory 5.9 12.6 6.7 113.0 
Chronic obstructive pulmonary disease 0.6 0.8 0.2 35.3 
Other respiratory  5.3 11.8 6.5 121.8 
Injuries 5.6 9.4 3.8 67.4 
Dental 5.1 12.4 7.3 144.0 
Mental 4.3 8.5 4.2 97.1 
Digestive 4.0 9.7 5.6 139.0 
Neurological 4.0 15.1 11.1 279.9 
Dementia and Parkinson’s 3.5 13.9 10.4 294.3 
Other neurological 0.5 1.2 0.8 167.8 
Musculoskeletal 3.7 9.9 6.1 163.5 
Genitourinary 3.1 6.8 3.7 122.2 
Cancer 2.8 5.2 2.4 84.0 
Sense disorders 2.3 5.1 2.8 124.4 
Endocrine, nutritional and metabolic 2.2 4.1 2.0 91.2 
Skin 2.0 4.5 2.5 127.4 
Maternal 1.8 2.5 0.7 40.9 
Infectious 1.5 2.7 1.2 74.6 
Diabetes 1.4 7.0 5.6 400.8 
Neonatal 0.5 0.7 0.2 41.7 
Congenital 0.3 0.4 0.1 55.3 
Other 13.0 29.6 16.6 127.4 
Total health expenditure 71.4 162.3 90.9 127.4 
 
Admitted patient services are expected to experience the greatest absolute growth in 
expenditure over the projection period, followed by other health services and pharmaceutical 
scripts (Table 14). Residential aged care expenditure is likely to show the greatest 
proportional increase in expenditure, followed by pharmaceutical expenditure. Expenditure 
on admitted patients in hospitals is expected to show a similar growth to health expenditure 
as a whole, while medical services expenditure will experience a somewhat lower growth. 
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Table 14: Projected total health expenditure (2002–03 dollars) by area of expenditure, Australia, 2002–03 
to 2032–33 
 Expenditure by year ($ billion) Change 2003 to 2033 
Expenditure area 2002–03 2032–33 $ billion % 
Admitted patient services 23.4 51.7 28.3 121.0 
Medical services 14.6 28.7 14.1 96.5 
Pharmaceutical prescriptions 10.0 24.5 14.5 145.2 
Residential aged care (high care) 4.9 16.8 11.9 241.9 
Other health services 18.5 40.6 22.1 120.0 
Total health expenditure 71.4 162.3 90.9 127.4 
 
Decomposition analysis shows that population ageing and increases in population size are 
likely to account for two-thirds of the expected $90.9 billion increase in total health 
expenditure over the projection period ($29.4 billion and $28.4 billion, respectively) (Figure 
14). Excess health price inflation ($19.1 billion), changes in treatment volume (number of 
health services provided) per case ($14.0 billion) and, to a lesser extent, treatment proportion 
($1.3 billion) also contribute to this increase.  
Figure 14: Decomposition of factors leading to projected change in total health expenditure, Australia, 
2002–03 to 2032–33 
 
Favourable trends in the epidemiology of cardiovascular disease, chronic obstructive 
pulmonary disease (COPD), cancers and injuries are expected to decrease overall expenditure 
by $5.0 billion. This reduction will be offset by large increases in diabetes and other diseases, 
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which are expected to result in a $3.7 billion increase in treatment expenditure. The net effect 
of epidemiological trends is expected to be a $1.3 billion reduction in total health expenditure 
over the projection period. 
Annualised projected growth in health expenditure in this study is comparable to reported 
estimates for the European Union and New Zealand. Higher estimates are reported for Hong 
Kong, the United States and Australia in previous studies, with those for OECD 
(Organisation for Economic Co-operation and Development) countries lying in the middle of 
this range (Table 15). 
Table 15: Health expenditure growth as percentage points above projected gross domestic product (GDP) 
growth for selected countries 
Country 
Annual growth in health expenditure  
(% above growth in GDP) 
Australia  
 Intergenerational Report 1.7 
 Productivity Commission 1.6 
 OECD  
  Cost pressure scenario 0.9 
  Cost containment scenario 1.2 
 This study 0.5 
Other countries  
 USA 2.3 
 Hong Kong 1.9 
 OECD average  
  Cost pressure scenario 1.4 
  Cost containment scenario 0.9 
 New Zealand 0.5 
 European Union countries  
  Average 0.5 
  High (Spain) 0.6 
  Low (Portugal) 0.2 
OECD = Organisation for Economic co-operation and Development 
Discussion 
This analysis suggests that total health expenditure in Australia will grow by 0.5% greater 
than growth in the economy, to 10.8% of GDP in 2032–33. Population ageing will account 
for 32.3% of this growth; and non-demographic factors (excess price inflation, treatment 
proportion and volume per case) a further 36.5%. The remaining 31.2% will be due to 
 68 
increases in population size, a particular feature of a high immigration country such as 
Australia. 
An annual growth of 0.5% greater than growth in GDP is comparable to estimates for the 
European Union and New Zealand but is lower than estimates for Hong Kong and US. Other 
estimates for Australia are not directly comparable as they relate to different projection 
periods or do not quantify expected changes in total health expenditure. The Australian 
Treasury, for example, estimated that federal government spending on health (including aged 
care) would grow by 1.7% greater than growth in the economy to 7.9% of GDP in 2032–
33.109 The Australian Government’s Productivity Commission estimated that all government 
spending (federal, state and territory) would grow by 1.6% greater than growth in the 
economy to 9.4% of GDP in 2034–35.11 The OECD estimated that all government health 
expenditure in Australia would grow by 0.9% greater than growth in the economy to 8.5% of 
GDP in 2050 in a cost-containment scenario.110 In a cost-pressure scenario, this growth was 
estimated to be 1.2%. 
Few studies have explicitly commented on the relative contribution of demographic and non-
demographic factors to growth in health expenditure. The OECD study estimated that the 
effect of population ageing would be about half the estimated effect of non-ageing residual 
factors in a cost-pressure scenario, but that these factors would contribute in equal 
proportions in a cost-containment scenario.111 Similarly, the New Zealand study estimated 
that for the period 2020–2040—which is when the post-WWII generation will move into the 
very old ages—ageing would have a similar impact as non-demographic growth.112 With the 
exception of the OECD cost-pressure scenario, these estimates are largely consistent with the 
findings reported here. 
Variation in estimates of growth in health expenditure between different models is likely to 
reflect differences in underlying assumptions. Certain assumptions have only a small impact 
on projection estimates. The OECD and Productivity Commission models allowed for 
                                                
109  Australian Treasury, Intergenerational Report 2002-03, Australian Government, Canberra, 2002. 
110  OECD, Projecting OECD health and long-term care expenditures: What are the main drivers? 
111  ibid. 
112  Johnston, G and Teasdale, A, Population ageing and health spending: 50-year projections, Ministry of Health, 
Wellington, 1999. 
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proximity to death costs but this had only a minor downward impact on projections.113 The 
OECD model also assumed that years gained from improvements in life expectancy were 
equivalent to years in full health, an assumption that lowered estimates of growth by a small 
amount. Likewise, epidemiological trends, as this paper has shown, have only a marginal 
downward effect when the net impact across all conditions is considered. 
Assumptions regarding non-demographic growth factors have a much greater impact. The 
OECD, Treasury and Productivity Commission all used estimates of non-demographic 
expenditure growth of around 2.6% per year compared with an average of around 1.2% per 
year in our study. The latter was calculated separately for each condition to explicitly account 
for condition-specific assumptions regarding excess health price inflation, volume per case 
and treatment proportion. Since excess health price inflation was set to be constant across 
conditions, much of the variability in expenditure estimates is due to differences in volume 
per case assumptions. 
Changes in volume per case over time are largely influenced by the introduction of new 
technologies and changes in treatment practices. Volume per case assumptions in this paper 
were based on information from two time points 7 years apart. By quantifying changes in 
volume per case for each condition over this period, it was possible to ensure that trends in 
volume per case remained within plausible limits. There is uncertainty about whether trends 
observed over such a short period are likely to continue to influence expenditure in future 
years. There is likely to be greater uncertainty, however, around a single non-demographic 
growth estimate for all conditions, as has been assumed, either explicitly or implicitly, in 
other expenditure projection models. 
An important by-product of this work is the quantification, for the first time, of a 
comprehensive description of likely future health expenditure in Australia by area of 
expenditure, health condition, age and sex. Researchers wanting to model the cost-
effectiveness of treating health conditions under various intervention scenarios will find this a 
useful resource. Health planners concerned with the changing health service needs of 
Australia’s ageing population may also find it of interest. The findings presented here, for 
example, show that there is likely be twice the growth in demand for residential age care 
                                                
113  OECD, Projecting OECD health and long-term care expenditures: What are the main drivers; Productivity 
Commission, Economic implications of an Ageing Australia, Productivity Commission, Canberra, 2005. 
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services than there will be for admitted patient services over the next 30 years. Similarly, 
growth in demand for services from particular specialty areas such as diabetes, neurology and 
geriatrics is expected to outstrip growth in demand for other specialty areas such as 
paediatrics and gynaecology. 
Australian’s preparedness for the economic and social consequences of population ageing 
will be greatly enhanced by forward planning around the infrastructure and workforce needs 
that are likely to emerge over the coming decades. The analyses introduced here have the 
potential to make a valuable contribution to such debate. 
Afterword 
Following the publication of this paper by the Australian Health Review, one of my co-
authors, Mr John Goss, revisited some of the parameter assumptions in the underlying 
expenditure model to derive an updated set of projections. This reanalysis was commissioned 
by the National Health and Hospitals Reform Commission (NHHRC) and was subsequently 
published by the AIHW as two separate reports,114 both of which were used to inform the 
Commission’s final recommendations.115  
The key difference between the revised analysis and its predecessor is the higher rate of 
growth in total expenditure over the projection period (3.6% per annum compared to 2.8%), 
resulting in a 52.9% increase in projected change in expenditure from $105.3 billion to 
$161.0 billion. This was largely driven by a change in assumptions relating to volume per 
case treated, which resulted in a 444.1% increase in projected change in expenditure from 
$14.9 billion to $81.3 billion. However, offsetting some of this increase was a change in 
assumptions relating to per unit price, which resulted in a 30.3% decrease in projected change 
in expenditure from $21.0 billion to $8.8 billion. 
                                                
114  AIHW, Estimating the impact of selected National Health and Hospitals Reform Commission (NHHRC) reforms on 
health care expenditure, 2003 to 2033, (Cat. no. HWE 45), Australian Institute of Health and Welfare, Canberra, 
2009; Goss, J, Projection of Australian health care expenditure by disease, 2003 to 2033, (Cat no. HWE 43), 
Australian Institute of Health and Welfare, Canberra, 2008. 
115  NHHRC, A healthier future for all Australians : final report : June 2009, National Health and Hospitals Reform 
Commission, Canberra, 2009. 
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Table 16: Comparison between results published by the Australian Health Review and those published by 
AIHW 
 Original Revised Difference 
 ($ billion) ($ billion) (%) 
Total expenditure (2006-07 dollars)    
2002-03 82.7 85.1 2.9 
2032-33 188.0 246.1 30.9 
Expenditure change 105.3 161.0 52.9 
Decomposition of change    
Ageing 33.7 37.8 12.2 
Population 32.7 34.4 5.1 
Disease rate -1.8 -2.3 25.3 
Volume per case 14.9 81.3 444.1 
Treatment 1.5 1.0 -30.3 
Price 21.0 8.8 -58.0 
 
This concludes Part II of this thesis. In Part III, I present two additional papers, this time to 
illustrate the potential policy relevance of the subpopulation disaggregation methods 
proposed in Chapter 2.
 Part III: Policy applications of proposed 
subpopulation methods 
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Chapter 6: Burden of disease and injury in Australia in the 
new millennium: measuring health loss from diseases, 
injuries and risk factors116 
Introduction 
Information on the magnitude and distribution of health problems in a population is important 
for health policy decision-making. Popular epidemiological measures such as mortality, 
incidence and prevalence are available for many health problems, but cannot be compared 
across causes as comprehensive indicators of population-level health. Summary measures of 
population health, on the other hand, extend the utility of descriptive epidemiology by 
combining information on mortality and non-fatal health problems into a common measure 
that can be used to provide a comprehensive picture of the health status of a population.117 
We present here a reanalysis of a large body of work that used summary measures to describe 
the health of Australians in the new millennium.118 The research on which it is based follows 
a comparable study for the year 1996 reported in the Medical Journal of Australia in 2000.119 
Both studies use a particular summary measure—the disability-adjusted life year (DALY)—
to quantify health loss from a comprehensive set of diseases, injuries and health risks of 
public health importance in Australia. The DALY, in turn, has its origins in an assessment of 
global health for the World Bank.120 One undiscounted DALY is equivalent to one lost year 
of healthy life and represents the gap between current health status and an ideal situation of 
                                                
116  This chapter was first published as Begg, SJ, Vos, T, Barker, B, Stanley, L and Lopez, AD, “Burden of disease 
and injury in Australia in the new millennium: measuring health loss from diseases, injuries and risk 
factors”. See Declarations and Statements for the respective contributions of each author. 
117  Murray, C, Salomon, J, Mathers, C and Lopez, A, eds, Summary measures of population health: concepts, ethics, 
measurement and applications. 
118  Begg, S, Vos, T, Barker, B, Stevenson, C, Stanley, L and Lopez, A, The burden of disease and injury in Australia, 
2003. 
119  Mathers, CD, Vos, ET, Stevenson, CE and Begg, SJ, “The Australian Burden of Disease Study: measuring the 
loss of health from diseases, injuries and risk factors”. 
120  Murray, CJL and Lopez, AD, eds, The Global Burden of Disease: a comprehensive assessment of mortality and 
disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Vol I; Murray, CJL and Lopez, AD, 
eds, Global Health Statistics: a compendium of incidence, prevalence and mortality estimates for over 200 conditions. 
Vol II. 
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the whole population living into old age in full health.121 This gap is referred to here as health 
loss, rather than the less accurate but more commonly used term ‘burden of disease’. 
The DALY combines the descriptive epidemiology of each health condition of interest with a 
multidimensional numerical weighting for the severity of that condition. As the weighting 
given to each dimension implies a judgement about its relative importance to the total 
measure, the DALY has obvious normative characteristics that make it not necessarily 
compatible with other classifications of health (e.g., WHO’s International classification of 
functioning, disability and health122). For this reason, others have highlighted the importance 
of limiting interpretation of the DALY to the specific purposes for which it is being used123—
which, in this case, is as a comparative measure of health loss. 
Our article provides an assessment of the magnitude and distribution of health problems in 
Australia in order to identify key opportunities for health gain. Our specific objectives were 
to calculate: 
1. DALYs by cause, age and sex for the year 2003; 
2. DALYs attributable to past and current exposure to major modifiable health risks; 
3. Differentials in DALY rates between subpopulations (e.g. between state and territory 
jurisdictions, socioeconomic groups, and remoteness categories124); and 
4. DALYs projected 10 and 20 years beyond 2003. 
Methods 
Health loss was estimated for a comprehensive set of diseases and injuries of public health 
importance in Australia, using DALYs as the outcome measure. Diseases and injuries were 
the smallest reported unit of disaggregation, and are referred to here as specific causes or 
conditions. Each is mutually exclusive and belongs to one of 22 broad cause groups, most of 
                                                
121  The published version of this sentence used the more common explanation, “one DALY is equivalent to one 
lost year of healthy life ”. This explanation is misleading when used in reference to discounted DALYs. 
122  International Classification of Functioning, Disability and Health (ICF), World Health Organization, 
Geneva, 2011, viewed 16 August 2011, http://www.who.int/classifications/icf/en/. 
123  AIHW, Disability and its relationship to health conditions and other factors, (AIHW Cat. No. DIS 37), Australian 
Institute of Health and Welfare, Canberra, 2004. 
124  Indigeneity was another key subpopulation grouping, although the relevant analyses were not complete at 
the time of publication.  
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which correspond to chapter-level headings of the International classification of diseases.125 
Each broad cause group, in turn, belongs to one of three broad clusters: communicable, 
maternal, neonatal and nutritional conditions; non-communicable diseases; and injuries. A 
brief overview of methods and assumptions is provided below. 
Baseline	  models	  
Baseline models describing the epidemiology of each specific cause for Australia in 2003 
were developed using a range of data sources, methods and assumptions.126 Typical inputs 
included prevalence (from surveys), incidence (from disease registers), case fatality (from 
cohort studies), remission (from cohort and intervention studies), clinical judgement, and 
information about changes over time in any of these variables. Complete and internally 
consistent cross-sectional epidemiological models were derived from three of these inputs 
using modelling software.  
Epidemiological	  trends127	  
Trends in observed cause-specific mortality over the period 1979–2003 were analysed and 
projected to 2023 using a combination of regression techniques. Transition hazards for 
conditions that cause mortality were extrapolated from baseline using assumptions about the 
relative contribution of incidence and case fatality to changes in cause-specific mortality. For 
non-fatal conditions, incidence was the only transition hazard for which extrapolations were 
made. Estimates for each specific cause through time were calculated in a model that 
accounted for changes in all-cause mortality as well as changes in incidence and case fatality 
(where appropriate) at all points throughout the study period. Absolute numbers of incident 
and prevalent cases were derived by applying the population rates from these analyses to 
Australia Bureau of Statistics population projections.128 
DALY	  estimates	  
DALYs were calculated by applying severity weights (range, 0–1) to the estimated number of 
incident cases and average duration for each condition. Weights were derived from two 
                                                
125  International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, World 
Health Organization. 
126  See Begg, S, Vos, T, Barker, B, Stevenson, C, Stanley, L and Lopez, A, The burden of disease and injury in 
Australia, 2003. 
127  See Chapter 2 for further details. 
128  ABS, Population Projections Australia 2002 to 2101. 
 76 
sources129, with extrapolations based on alternative methods in some cases. Adjustments were 
made to account for the possibility of two or more conditions occurring simultaneously in the 
same person, either by chance or because the conditions are related. These corrections were 
achieved by determining numbers of people for every combination of causes of ill health as 
measured by various surveys and hospital admission data.130 
Health	  risk	  assessment131	  
Past and current exposure to 14 selected risk factors (listed in Table 19) were analysed for 
their contribution to health loss in 2003. Analyses were based on the theoretical framework 
developed for the WHO-initiated Comparative Risk Assessment project.132 This approach 
incorporates a ‘hypothetical minimum’ as the alternative exposure distribution against which 
health loss is calculated, and uses continuous rather than categorical measures of exposure 
where appropriate. Results were also calculated for the combined effect of health risks.  
Health	  differentials	  
Health differentials were assessed by comparing subpopulation-specific age-standardised 
DALY rates derived from disaggregated national DALY estimates. Disaggregation was 
achieved in two stages, whereby condition-specific estimates of incidence and mortality were 
first apportioned to states and territories and then to a 15-cell matrix of subpopulations. The 
matrix was composed of three remoteness categories (major cities, regional areas and remote 
areas) by five socioeconomic quintiles within each jurisdiction. 
To disaggregate conditions with a predominantly fatal impact, preference was given to 
mortality data. For the remaining conditions, preference was given to the data source on 
which the baseline model was based (e.g., hospital data, health survey data). Condition-
                                                
129  Murray, CJL and Lopez, AD, eds, The Global Burden of Disease: a comprehensive assessment of mortality and 
disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Vol I; Stouthard, ME, Essink-Bot, 
M, Bonsel, GJ, Barendregt, JJ, Kramers, PGN, van de Water, HPA, Gunning-Schepers, LJ and van der Maas, 
PJ, Disability weights for diseases in The Netherlands. 
130  See Chapter 2 for further details. 
131  For the purposes of this thesis, comparative risk assessment is regarded as a secondary analysis for applying 
established models to a complete set of framework outputs. While the comparative risk assessment in the 
case study was facilitated by the workflows outlined in Chapter 2, the underlying analytical modelling was 
largely derivative of other work. For further details, see Appendix 2 of Begg, S, Vos, T, Barker, B, Stevenson, 
C, Stanley, L and Lopez, A, The burden of disease and injury in Australia, 2003.  
132  Ezzati, M, Lopez, AD, Rodgers, A and Murray, CJL, eds, Comparative quantification of health risks: Global and 
regional burden of disease attributable to selected major risk factors - Volume 1; Ezzati, M, Lopez, AD, Rodgers, A 
and Murray, CJL, eds, Comparative quantification of health risks: Global and regional burden of disease attributable 
to selected major risk factors - Volume 2. 
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specific estimates of prevalence and duration for each subpopulation were derived from 
subpopulation-specific incidence and all-cause mortality rates, as well as national 
assumptions regarding remission and case fatality. Subpopulation-specific DALYs were 
calculated using comorbidity-corrected national severity weights.  
Results 
Key findings are presented here at two levels of aggregation: broad cause groups and specific 
conditions. Both levels are referred to as causes and are ranked in terms of leading causes 
compared with others at the same level of aggregation. 
Leading	  broad	  cause	  groups	  
Total health loss in Australia in 2003 was 2.63 million DALYs or 132 DALYs lost per 1000 
people. Fifty-one per cent of the loss was from non-fatal causes. Over 75% was accounted for 
by the six leading broad cause groups: cancer, cardiovascular disease, mental disorders, 
neurological and sense organ disorders, chronic respiratory diseases, and injuries (Table 17). 
Table 17: Health loss, by broad cause group, Australia, 2003 
 Rate/1000 people (%) 
Broad cause group Non-fatal health loss(a) Fatal health loss(b) Total health loss(c) 
Cancers 4.4 (6.5) 20.7 (32.2) 25.1 (19.0) 
Cardiovascular disease 5.3 (7.7) 18.6 (28.9) 23.8 (18.0) 
Mental disorders 16.5 (24.2) 1.2 (1.8) 17.6 (13.3) 
Neurological and sense organ disorders  13.0 (19.1) 2.7 (4.2) 15.7 (11.9) 
Chronic respiratory diseases 5.8 (8.5) 3.6 (5.6) 9.4 (7.1) 
Injuries 2.2 (3.2) 7.1 (11.0) 9.3 (7.0) 
Diabetes mellitus 5.6 (8.2) 1.6 (2.5) 7.2 (5.5) 
Musculoskeletal diseases 5.0 (7.3) 0.4 (0.5) 5.3 (4.0) 
Genitourinary diseases 2.1 (3.0) 1.2 (1.9) 3.3 (2.5) 
Other 8.3 (12.3) 7.3 (11.4) 15.6 (11.7) 
Total 68.1 (100.0) 64.3 (100.0) 132.4 (100.0) 
Notes: (a) Calculated as incidence × severity weight (range, 0–1) × average duration in years (discounted at 3%) and referred to as years lost due 
to disability (YLD); (b) Calculated as deaths × global standard expectation of life at age of death in years (discounted at 3%) and referred to as 
years of life lost (YLL); (c) Calculated as YLD + YLL and referred to as disability-adjusted life years (DALYs). 
Broad	  cause	  groups,	  by	  age	  
DALY rates increased steeply with age, apart from small but significant peaks in infancy and 
early adulthood. Injuries (particularly in males) and mental disorders accounted for the 
majority of DALYs in early adulthood, after which cancer, cardiovascular disease, and 
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neurological and sense organ disorders were more prominent. The contribution from cancer 
peaked at age 70 years then declined, leaving cardiovascular disease as the major cause of 
DALYs in the very old. 
Leading	  specific	  conditions,	  by	  sex	  
Ischaemic heart disease was the leading specific cause of health loss in males, followed by 
type 2 diabetes, anxiety and depression, lung cancer and stroke. For females, anxiety and 
depression was the leading specific cause of health loss, followed by ischaemic heart disease, 
stroke, type 2 diabetes and dementia (Table 18). 
Table 18: Ten leading specific causes of health loss(a), by sex, Australia, 2003 
 Males Females 
Rank Specific cause 
Rate/1000  
people (%)  Specific cause 
Rate/1000  
people (%) 
1 Ischaemic heart disease 1.5 (11.1) Anxiety and depression 1.3 (10.0) 
2 Type 2 diabetes 0.7 (5.2) Ischaemic heart disease 1.1 (8.9) 
3 Anxiety and depression 0.7 (4.8) Stroke 0.7 (5.1) 
4 Lung cancer 0.6 (4.0) Type 2 diabetes 0.6 (4.9) 
5 Stroke 0.5 (3.9) Dementia 0.6 (4.8) 
6 Chronic obstructive pulmonary 
disease 
0.5 (3.6) Breast cancer 0.6 (4.8) 
7 Adult-onset hearing loss 0.4 (3.1) Chronic obstructive pulmonary disease 0.4 (3.0) 
8 Suicide and self-inflicted injuries 0.4 (2.8) Lung cancer 0.3 (2.7) 
9 Prostate cancer 0.4 (2.7) Asthma 0.3 (2.7) 
10 Colorectal cancer 0.4 (2.5) Colorectal cancer 0.3 (2.3) 
Notes: (a) Expressed as disability-adjusted life years lost per 1000 people. 
Risks	  to	  health,	  by	  broad	  cause	  group	  
The 14 selected risk factors together explained almost a third of health loss (expressed as 
total DALYs). Ten risk factors explained 32.9% of cancer-related health loss, tobacco use 
being the most important. Twelve risk factors explained 69.3% of health loss from 
cardiovascular disease, with high blood pressure and high blood cholesterol levels being the 
largest contributors. Four risk factors explained 26.9% of health loss from mental disorders, 
with alcohol and illicit drug use contributing in roughly equal proportions. Seven risk factors 
explained 31.7% of injury-related health loss, alcohol consumption being the dominant risk. 
Two risk factors explained 60.1% of health loss from type 2 diabetes, high body mass being 
the largest contributor (Table 19). 
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Table 19: Health loss(a) attributable(b) to 14 selected risk factors, by selected broad cause groups, 
Australia, 2003  
 Broad cause group  
 Cancers CVD 
Mental 
disorders Injuries 
Diabetes 
 mellitus All causes 
Total health loss (DALYs lost/1000 people) 25.1 23.8 17.6 9.3 7.2 132.4 
Attributable(b) health loss—individual (%)(c)       
Tobacco use 20.1 9.7 na 0.5 na 7.8 
High blood pressure na 42.1 na na na 7.6 
High body mass 3.9 19.5 na na 54.7 7.5 
Physical inactivity 5.6 23.7 na na 23.7 6.6 
High blood cholesterol levels na 34.5 na na na 6.2 
Alcohol consumption 3.1 - 4.7 9.7 18.1 na 2.3 
Low consumption of fruit and vegetables 2.0 9.6 na na na 2.1 
Illicit drug use na < 0.1 8.0 3.6 na 2.0 
Occupational exposures and hazards 3.1 0.4 na 4.7 na 2.0 
Intimate partner violence 0.5 0.3 5.5 2.5 na 1.1 
Child sexual abuse < 0.1 < 0.1 5.8 1.4 na 0.9 
Urban air pollution 0.8 2.7 na na na 0.7 
Unsafe sex 1.0 na na na na 0.6 
Osteoporosis na na na 2.4 na 0.2 
Attributable(b) health loss—combined 
(%)(d) 32.9 69.3 26.9 31.7 60.1 32.2 
Notes: CVD = cardiovascular disease; DALY = disability-adjusted life year; (a) Expressed as DALYs lost per 1000 people; (b) Attributable health 
loss is health loss that is explained by past exposure and that might be averted through future changes in exposure to a health risk; (c) 
Attributable health loss within each column is expressed as a percentage of total DALY rates for that column; (d) Figures for combined effects are 
not necessarily column totals because risk factors can share common causal pathways. 
Health	  differentials	  
Age-standardised DALY rates were 31.7% higher in the lowest socioeconomic quintile than 
in the highest, and 26.5% higher in remote areas than in major cities. Age-standardised 
DALY rates in the Northern Territory were 88.7% higher than in the Australian Capital 
Territory, these jurisdictions having the highest and lowest rates, respectively (Figure 15). 
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Figure 15: Age-standardised133 DALY rates per 1000 people, by jurisdiction, socioeconomic quintile and 
remoteness category, for selected broad cause groups, Australia, 2003 
 
Past,	  present	  and	  future	  health	  loss	  
Age-standardised DALY rates declined from 151.0/1000 people to 132.4/1000 people over 
the period 1993–2003, and are projected to decline by 0.8% per year to 111.4/1000 people by 
the year 2023. Over the period 2003–2023, age-standardised DALY rates associated with 
cardiovascular disease are expected to experience the greatest annual rate of decline (−2.5%), 
followed by cancer (−1.4%), injuries (−1.1%) and chronic respiratory conditions (−0.9%). On 
the other hand, age-standardised DALY rates associated with diabetes are projected to grow 
by 1.8% a year over the period 2003–2023. Age-standardised DALY rates for other broad 
cause groups are likely to experience much smaller changes over this period (Table 20). 
                                                
133  Standardised to the age structure of the Australian population (males and females combined). 
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Table 20: Past and projected future changes in health loss(a), by selected broad cause groups and sex, 
Australia, 1993–2023 
 Proportion of total (%) Standardised rate/1000 people(b) 
Broad cause group 1993 2003 2013 2023 1993 2003 2013 2023 
Cancers 18.8 19.0 18.9 18.2 29.5 25.1 21.8 18.2 
Cardiovascular disease 22.3 18.0 15.4 13.1 36.5 23.8 17.1 12.0 
Mental disorders 13.2 13.3 12.9 11.9 17.8 17.6 17.8 17.7 
Neurological and sense disorders 9.6 11.9 13.9 16.4 15.1 15.7 16.1 16.3 
Chronic respiratory diseases 7.1 7.1 6.8 6.9 10.6 9.4 8.4 7.7 
Injuries 7.7 7.0 6.3 5.4 10.6 9.3 8.4 7.3 
Diabetes mellitus 4.1 5.5 7.0 8.7 6.3 7.2 8.4 9.8 
Musculoskeletal diseases 3.4 4.0 4.5 4.9 5.2 5.3 5.4 5.5 
Other 13.8 14.2 14.1 14.4 19.5 18.9 17.7 16.8 
Total 100.0 100.0 100.0 100.0 151.0 132.4 121.1 111.4 
Notes: (a) Expressed as disability-adjusted life years; (b) Standardised to the age structure of the Australian population (males and females 
combined).  
Discussion 
Our findings emphasise that despite steady improvements in Australia’s health over the past 
decade, significant opportunities for further progress remain at the beginning of the twenty-
first century. 
The strength of our analysis is that it is based on an internally consistent assessment of the 
incidence, prevalence, duration and mortality for a mutually exclusive and comprehensive set 
of diseases and injuries of importance in Australia. Health loss from these causes was 
quantified for different periods, subpopulations and risks to health using methods that 
incorporate fatal and non-fatal health outcomes and include adjustments to account for 
individuals who simultaneously experience multiple conditions. Health loss is likely to be 
over-estimated without such corrections, as the severity weights used to derive DALYs were 
originally determined for health states in isolation, without reference to coexisting 
conditions.134 
A potential limitation is that the severity weights used in our analysis were derived from 
international sources135 and applied without evidence of their validity in Australia. However, 
                                                
134  Mathers, CD, Iburg, KM and Begg, S, “Adjusting for dependent comorbidity in the calculation of healthy 
life expectancy”. 
135  Murray, CJL and Lopez, AD, eds, The Global Burden of Disease: a comprehensive assessment of mortality and 
disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Vol I; Stouthard, ME, Essink-Bot, 
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studies conducted elsewhere suggest that there are only minor variations across populations 
in the values people ascribe to different health states.136 
We have not quantified uncertainty in our analysis, although a qualitative assessment 
suggests it is unlikely to be excessive.137 Overall, about half of the total estimated health loss 
is due to mortality, for which estimates are fairly robust. Of the remainder, half is due to non-
fatal outcomes from conditions for which reasonably good data are available (including 
cardiovascular disease, cancers, diabetes, common mental disorders and injuries), leaving a 
quarter with varying and probably higher levels of uncertainty. Precision varies between 
causes, with estimates for hearing loss, neurological conditions, osteoarthritis and cirrhosis 
being the most inaccurate. 
Our results are not directly comparable with previous DALY estimates for Australia138, 
owing to the different methods used. First, a number of the epidemiological models in our 
analysis benefit from more accurate inputs, particularly the cardiovascular disease models, 
which incorporated linked data from Western Australia. Second, unlike in the previous 
analysis, the comorbidity adjustments here capture the dependent nature of certain health 
states (e.g., diabetes increases the risk of heart disease). Third, the current risk attribution 
methods incorporate a number of methodological advances absent from previous health risk 
analyses.139 Because of this lack of comparability, we back-calculated estimates for 1993 
based on methods that were consistent with estimates for 2003.140 
Several implications for policy are worth emphasising. For example, all of the health risks 
examined here are amenable to modification through intervention, and together explain a 
large proportion of health loss in Australia. In addition, the large health differentials between 
                                                                                                                                                  
M, Bonsel, GJ, Barendregt, JJ, Kramers, PGN, van de Water, HPA, Gunning-Schepers, LJ and van der Maas, 
PJ, Disability weights for diseases in The Netherlands. 
136  Murray, CJL and Lopez, AD, eds, The Global Burden of Disease: a comprehensive assessment of mortality and 
disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Vol I. 
137  Professor Theo Vos now considers this assessment optimistic on the basis that our selection of 
epidemiological data was largely arbitrary and we did not consider uncertainty around key parameters 
such as mortality risk, remission or causal attribution in mortality data. 
138  Mathers, CD, Vos, ET, Stevenson, CE and Begg, SJ, “The Australian Burden of Disease Study: measuring the 
loss of health from diseases, injuries and risk factors”. 
139  English, DR, Holman, CDJ, Milne, E, Winter, MG, Hulse, GK, Codde, JP, Bower, CI, Corti, B, de Klerk, N, 
Knuiman, MW, Kurinczuk, JJ, Lewin, GF and Ryan, GA, The quantification of drug caused morbidity and 
mortality in Australia, Commonwealth Department of Human Services and Health, Canberra, 1995; Mathers, 
CD, Vos, ET, Stevenson, CE and Begg, SJ, “The Australian Burden of Disease Study: measuring the loss of 
health from diseases, injuries and risk factors”; Ridolfo, B and Stevenson, C, The quantification of drug-caused 
mortality and morbidity in Australia, 1998, (7), Australian Institute of Health and Welfare, Canberra, 2001. 
140  See Chapter 2 for details. 
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subpopulations are due, in part, to differential exposure to these risks. Significant health gains 
are likely to be achieved through realistic changes to future levels of exposure to health risks, 
given that even small changes in distribution of exposures can lead to substantial reductions 
in population-level risk.141 
The predicted strong growth in DALY rates associated with diabetes is notable in that it is 
mostly due to increasing body mass. Given that current strategies have failed to mitigate this 
risk, new approaches are critical. The impact of increasing diabetes incidence will be 
magnified by reductions in case fatality from cardiovascular disease through successful 
strategies to reduce smoking and lower cholesterol levels and blood pressure.142 Increased 
survival will result in a greater number of people with diabetes developing other health 
conditions such as renal failure, retinopathy, neuropathy and peripheral vascular disease. 
Notwithstanding the apparent intractability of diabetes, further reductions in cardiovascular 
disease could be achieved given that most of the health loss from this condition continues to 
be explained by exposure to known health risks.  
The much higher DALY rates in the NT compared with other jurisdictions is largely 
explained by a higher concentration of Indigenous people in the NT. Health loss in this 
particular population is considered elsewhere.143 
Several areas for further research flow from this work. First, health loss and expenditure 
under a business as usual approach to health risk management have been projected into the 
future144 and could usefully be extended to include various ‘what if?’ risk-reduction 
scenarios.145 Second, simulation methods have been used elsewhere to quantify uncertainty in 
DALY estimates146, and would enhance interpretability if applied to these findings. Third, 
                                                
141  Rodgers, A, Ezzati, M, Vander Hoorn, S, Lopez, AD, Lin, RB and Murray, CJ, “Distribution of major health 
risks: findings from the Global Burden of Disease study”, PLoS Med, 2004, vol. 1(1), pp. e27. 
142  Begg, S, Vos, T, Barker, B, Stevenson, C, Stanley, L and Lopez, A, The burden of disease and injury in Australia, 
2003; Taylor, R, Dobson, A and Mirzaei, M, “Contribution of changes in risk factors to the decline of 
coronary heart disease mortality in Australia over three decades”, Eur J Cardiovasc Prev Rehabil, 2006, vol. 
13(5), pp. 760-8. 
143  See Chapter 7 for further details. 
144  Begg, S, Vos, T, Barker, B, Stevenson, C, Stanley, L and Lopez, A, The burden of disease and injury in Australia, 
2003; Begg, S, Vos, T, Goss, J and Mann, N, “An alternative approach to projecting health expenditure in 
Australia”. 
145  See Chapter 8 for an example. 
146  Mathers, C, Salomon, J, Ezzati, M, Begg, S, Vander Hoorn, S and Lopez, A, “Sensitivity and uncertainty 
analyses for burden of disease and risk factor estimates”. 
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developments in health state valuation methods could, if applied in Australia, increase 
confidence in the use of the DALY as a valid comparative measure of health loss. 
Finally, our analysis is undermined, to some degree, by significant gaps in Australia’s health 
information infrastructure. In particular, there is limited information on mental disorders, 
neurological conditions, hearing loss, chronic respiratory diseases and musculoskeletal 
disorders. Even more importantly, Australia, unlike other countries, has no mechanism for 
regularly collecting measurement data on biomedical indicators such as body mass, blood 
pressure, and blood glucose and cholesterol levels. Better and more frequent monitoring in 
each of these areas would strengthen future comparative assessments of health in Australia, 
thus enhancing their value for policy and program development. 
 Chapter 7: Burden of disease and injury in Aboriginal and 
Torres Strait Islander Peoples—the Indigenous health 
gap147 
Introduction 
The colonisation of Australia involved a litany of unjust and misguided policies against 
Aboriginal and Torres Strait Islander peoples148 that manifested in the ‘dispossession, 
physical ill-treatment, social disruption, population decline, economic exploitation, codified 
discrimination, and cultural devastation’ of the first inhabitants of this land.149 The fact that 
Indigenous Australians continue to experience substantially worse health, social and 
economic outcomes compared with other Australians is undisputed.150 
Despite the plethora of reports documenting the health disadvantage of Indigenous 
Australians, to date it has been difficult to set priorities for Indigenous health development. In 
part, this is because many of the traditional population health indicators (life expectancy at 
birth, disease specific mortality and hospital rates, health survey findings, small 
epidemiological study results and notifiable disease registry data)151 are based on fragmentary 
data, and do not capture the complete spectrum of diseases, injuries and risk factors. Further, 
routine data collection systems systematically underestimate true disease occurrence due to 
inadequate identification of Indigenous status. Thus, for health policy decision-making, these 
disparate measures inadequately indicate where the opportunities for health improvement lie.  
More than a decade ago, a summary measure of population health, the Disability-Adjusted 
Life Year, or DALY, was developed and has been widely applied since to measure disease 
                                                
147  This chapter was first published as Vos, T, Barker, B, Begg, S, Stanley, L and Lopez, AD, “Burden of disease 
and injury in Aboriginal and Torres Strait Islander Peoples: the Indigenous health gap”. See Declarations 
and Statements for the respective contributions of each author. 
148  Steering Committee for the Review of Government Service Provision, Overcoming Indigenous Disadvantage: 
Key Indicators 2005, Productivity Commission, Canberra, 2005. 
149  Gardiner-Garden, J, From dispossession to reconciliation. Research Paper 27, Commonwealth of Australia, 
Canberra, 1998-99, viewed 14 August 2011, http://www.aph.gov.au/library/pubs/rp/1998-
99/99rp27.htm. 
150  ABS and AIHW, The Health and Welfare of Australia’s Aboriginal and Torres Strait Islander Peoples 2005, 
Australian Bureau of Statistics and Australian Institute of Health and Welfare, Canberra, 2005. 
151  ABS and AIHW, The Health and Welfare of Australia’s Aboriginal and Torres Strait Islander Peoples 2003, (ABS 
cat. no. 4704.0, AIHW cat. no. IHW11), Australian Bureau of Statistics and Australian Institute of Health and 
Welfare, Canberra, 2003; ABS and AIHW, The Health and Welfare of Australia’s Aboriginal and Torres Strait 
Islander Peoples 2005. 
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burden in numerous populations across the globe, including Australia.152 Apart from a study 
in the Northern Territory,153 the burden of disease framework has not been applied to 
measure disease burden in Indigenous populations, although the need for such evidence to 
guide policies and programs is clear.  
This chapter reports on the first burden of disease and injury study for the Aboriginal and 
Torres Strait Islander population of Australia. The study assessed the comparative importance 
of over 170 diseases and injuries for the health of Indigenous Australians in 2003, including 
the contribution of 11 risk factors.154 Similar estimates for the total Australian population 
have been reported elsewhere.155 This paper focuses on those diseases and risk factors that 
are most responsible for the gap in health status between Indigenous Australians and the 
overall Australian population. 
Methods 
For this analysis, we have used the same methods as were applied in the Burden of Disease 
and Injury in Australia 2003 study.156 The main features of this method are the use of the 
DALY as a common integrating metric for fatal and non-fatal health loss; the use of existing 
demographic and epidemiological data sources; critical examination and correction of bias in 
these data sources; the intention to measure loss of health comprehensively even if scarce or 
poor quality data are available; and full transparency of all assumptions and data. Applying 
these common methods to the Indigenous population of Australia posed methodological 
challenges due to the under-identification of Indigenous people in routine health statistics 
                                                
152  Begg, S, Vos, T, Barker, B, Stevenson, C, Stanley, L and Lopez, A, The burden of disease and injury in Australia, 
2003; Begg, SJ, Vos, T, Barker, B, Stanley, L and Lopez, AD, “Burden of disease and injury in Australia in the 
new millennium: measuring health loss from diseases, injuries and risk factors”; Murray, CJL and Lopez, 
AD, eds, The Global Burden of Disease: a comprehensive assessment of mortality and disability from diseases, injuries, 
and risk factors in 1990 and projected to 2020. Vol I; Victorian Department of Human Services, The Victorian 
Burden of Disease Study: Mortality and Morbidity in 2001, Victorian Department of Human Services, 
Melbourne, 2005. 
153  Zhao, Y, Guthridge, S, Magnus, A and Vos, T, “Burden of disease and injury in Aboriginal and non-
Aboriginal populations in the Northern Territory”, Med J Aust, 2004, vol. 180(10), pp. 498-502. This work is 
misleading referred to as a pilot study in the original text. 
154  Vos, T, Barker, B, Stanley, L and Lopez, A, The Burden of Disease and Injury in Aboriginal and Torres Strait 
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155  Begg, S, Vos, T, Barker, B, Stevenson, C, Stanley, L and Lopez, A, The burden of disease and injury in Australia, 
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and Lopez, A, The Burden of Disease and Injury in Aboriginal and Torres Strait Islander Peoples 2003. 
156  Begg, S, Vos, T, Barker, B, Stevenson, C, Stanley, L and Lopez, A, The burden of disease and injury in Australia, 
2003; Begg, SJ, Vos, T, Barker, B, Stanley, L and Lopez, AD, “Burden of disease and injury in Australia in the 
new millennium: measuring health loss from diseases, injuries and risk factors”; Vos, T, Barker, B, Stanley, L 
and Lopez, A, The Burden of Disease and Injury in Aboriginal and Torres Strait Islander Peoples 2003. 
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collections. Under-identification affects numerator data (i.e. counts of health events) and 
denominator data (i.e. population estimates) but not to the same extent as the former relies on 
health staff, funeral directors or relatives to identify while the latter is determined by the 
likelihood of being enumerated and, if so, self-identification. A further complication is that 
Indigenous population counts have increased from census to census by a greater proportion 
than expected from births, deaths and migration. We chose to anchor our results to the 
Indigenous population as identified in the 2001 census. 
Population data were accessed publicly and via customized data requests from the Australian 
Bureau of Statistics (ABS). Australian mortality data were provided by the Australian 
Institute of Health and Welfare. Although almost all deaths in Australia are considered to be 
registered, not all deaths have an identified Indigenous status and there are doubts about the 
validity of Indigenous identification if stated. As a result the number of deaths registered as 
Indigenous is an underestimate. We applied the generalized growth balance (GGB) method, 
an indirect demographic technique to correct for under-registration of deaths. The basic 
premise of indirect demographic methods is to compare population counts from two 
successive censuses and relate these to the number and age distribution of deaths recorded in 
the intercensal period. In a population unaffected by migration the number of people 
enumerated in a particular 5-year age group should equal the number of people enumerated in 
the previous age group minus the deaths that occurred during the 5-year intercensal period. 
The difference between recorded and expected deaths in the intercensal period is a measure 
of under-registration of deaths.157 We applied the GGB method separately to population and 
mortality data for remote and non-remote areas using the ARIA+ classification, a geographic 
approach to remoteness based on road distance to service centres and the population size of 
those centres as a surrogate for availability of services.158 We corrected for migration from 
remote to non-remote areas with data supplied by ABS on change in reported usual area of 
residence between the 1996 and 2001 censuses. Migration of Indigenous Australians in and 
out of the country is considered negligible. 
Indirect demographic methods cannot estimate correction factors for childhood mortality 
rates in an intercensal period as they were not yet born at time of the first census. We 
                                                
157  Hill, K, Barker, B and Vos, T, “Excess Indigenous mortality: are Indigenous Australians more severely 
disadvantaged than other Indigenous populations?”. 
158  AIHW, Rural, Regional and Remote Health: A Guide to Remoteness Classifications, (AIHW cat. no. PHE 53), 
Australian Institute of Health and Welfare, Canberra, 2004. 
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observed that infant mortality estimates in Western Australia (WA) using linked birth and 
death data159 were similar to recorded Indigenous mortality rates. We therefore assumed the 
WA infant mortality rates by remoteness applied across the whole country. We adjusted the 
observed mortality in 1- to 4-year-old Indigenous children in WA for the increased likelihood 
of mortality by remoteness.160 
This gave us a set of corrected age- and sex-specific mortality rates reflecting the average 
mortality experience over the period 1996–2001 for those identified in the 2001 census as 
Indigenous Australians. We then assumed that these mortality rates had remained unchanged 
to 2003, the baseline year of study. We applied the cause of death structure by age and sex 
from recorded Indigenous deaths between 2001 and 2003 onto these corrected mortality 
estimates to derive counts of death by age, sex and cause in 2003.  
We undertook a comprehensive search to identify data sources for calculating Years Lived 
with Disability (YLD) for Indigenous Australians including routine data collections (such as 
Australian perinatal collection data, notification data, mortality data and hospital data; 
accounting for 53% of YLD estimates); self-report and measured population health surveys 
(28% of YLD) and epidemiological studies that identified Indigenous Australians (3% of 
YLD). For a number of conditions, we assumed the same disease occurrence as the national 
study because of the lack of data to suggest otherwise (10% of YLD). In keeping with the 
national study, we applied a ratio of Years of Life Lost to YLD to estimate disability for rest 
categories such as ‘other cancers’ (6% of YLD). We used the same disease case definitions 
(stages and sequelae) and disability weights as the national study.161 
Eleven common health risk factors were analysed for their contribution to disease burden for 
Indigenous Australians in 2003. Analyses were undertaken using standard methods.162 
Briefly, for each risk factor we define a theoretical minimum population distribution of risk 
                                                
159  Freemantle, CJ, Read, AW, de Klerk, NH, McAullay, D, Anderson, IP and Stanley, FJ, “Patterns, trends, and 
increasing disparities in mortality for Aboriginal and non-Aboriginal infants born in Western Australia, 
1980-2001: population database study”, Lancet, 2006, vol. 367(9524), pp. 1758-66. 
160  Freemantle, C, Indicators of Infant and Childhood Mortality for Indigenous and Non-Indigenous Infants and 
Children Born in Western Australia from 1980 to 1997 Inclusive, University of Western Australia, Perth, 2003. 
161  Chapter 2 presents a more complete discussion of these methods. 
162  Begg, S, Vos, T, Barker, B, Stevenson, C, Stanley, L and Lopez, A, The burden of disease and injury in Australia, 
2003; Ezzati, M, Lopez, AD, Rodgers, A and Murray, CJL, eds, Comparative quantification of health risks: Global 
and regional burden of disease attributable to selected major risk factors - Volume 1; Ezzati, M, Lopez, AD, Rodgers, 
A and Murray, CJL, eds, Comparative quantification of health risks: Global and regional burden of disease 
attributable to selected major risk factors - Volume 2.  
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and estimate population attributable fractions from the prevalence of exposure in the 
population of interest and relative risks of disease outcomes causally related to the exposure 
from systematic reviews of the international literature. Data on the prevalence of exposure to 
these risk factors were largely derived from national survey data163 and a few epidemiological 
studies with measurement data.164 
Results 
If Indigenous Australians in 2003 had experienced the same rate of disease burden as the total 
Australian population, a total of 56,455 DALYs would have been avoided, equivalent to 59% 
of the total burden of disease (95,976 DALYs) estimated for Indigenous Australians (Table 
21). Non-communicable diseases explained 70% of this health gap, with cardiovascular 
disease the leading cause group followed by diabetes, mental disorders and chronic 
respiratory disease (Figure 16). 
Ischaemic heart disease (14%), Type 2 diabetes (12%) and substance use disorders (6%) were 
the main non-communicable diseases that contributed to the health gap. Infectious diseases 
and neonatal conditions explained almost the entire gap from Group I causes. Suicide (4%), 
road traffic accidents (3%) and homicide and violence (3%) were the major injuries 
contributing to the gap (Table 21). 
The largest contribution to the Indigenous health gap occurred in the 35- to 54-year-old age 
group (35%) followed by the 15- to 34-year-old age group (25%), the 55-year and older age 
group (23%) and then children under 15 years (17%). Cardiovascular disease, particularly 
ischaemic heart disease and diabetes, were the main contributors to the health gap at ages 35 
years and over. Injuries and mental disorders were the main contributors to the health gap in 
young adults aged 15–34 years; even at these young ages, cardiovascular disease and diabetes 
were responsible for one-fifth of the health gap. Suicide explained almost half of the health 
                                                
163  ABS, National Aboriginal and Torres Strait Islander Health Survey 2004-05, (ABS cat. no. 4715.0), Australian 
Bureau of Statistics, Canberra, 2006; AIHW, Child Protection Australia 2002-03, Australian Institute of Health 
and Welfare, Canberra, 2004; AIHW, Female SAAP Clients and Children Escaping Domestic and Family Violence 
2003-04, Australian Institute of Health and Welfare, Canberra, 2005; Department of Human Services and 
Health, National Drug Strategy Household Survey: Urban Aboriginal and Torres Strait Islander Supplement, 1994, 
Department of Human Services and Health, Canberra, 1995. 
164  Cunningham, J, O'Dea, K, Dunbar, T, Weeramanthri, T, Zimmet, P and Shaw, J, “Study protocol--diabetes 
and related conditions in urban indigenous people in the Darwin, Australia region: aims, methods and 
participation in the DRUID Study”, BMC Public Health, 2006, vol. 6, pp. 8; Wang, Z and Hoy, WE, 
“Hypertension, dyslipidemia, body mass index, diabetes and smoking status in Aboriginal Australians in a 
remote community”, Ethn Dis, 2003, vol. 13(3), pp. 324-30. 
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gap from injuries in young males. In young females, injuries contributed a lesser proportion 
to the gap but there was still considerable excess health loss from road traffic accidents, 
suicide and violence. Substance use disorders explained most of the gap from mental 
disorders in young adults (Table 21).  
Table 21: Indigenous health gap (DALYs) due to selected causes, expressed as a proportion of total 
Indigenous health gap by sex and as a proportion of total Indigenous burden, 2003 
  Total (%) 
Cause 0–14 15–34 35–54 55+ Total 
Health gap  
(DALYs) 
% of total  
Indigenous  
burden 
All causes 17 25 35 23 100 56,455 59 
Group I(a) 8 3 3 1 15 8,633 9 
Infectious and parasitic diseases 3 2 3 1 9 3,074 5 
Neonatal causes 4 0 0 0 4 2,354 2 
Non-communicable diseases 8 13 28 21 70 39,491 41 
Cancers 0 0 2 3 6 3,151 3 
Diabetes 0 2 6 4 12 6,833 7 
Cardiovascular disease 0 3 11 9 23 13,208 14 
Ischaemic heart disease 0 2 7 6 14 8,169 9 
Stroke 0 0 1 2 3 1,734 2 
Mental disorders 3 4 2 1 10 5,542 6 
Substance use disorders 1 2 2 1 6 3,239 3 
Other mental disorders 2 2 0 0 4 2,303 2 
Chronic respiratory disease 1 1 4 3 9 5,213 5 
Injuries 2 9 3 1 15 8,331 9 
Road traffic accidents 0 2 1 0 3 1,969 2 
Suicide 0 3 1 0 4 2,393 2 
Homicide & violence 0 2 1 0 3 1,716 2 
Notes: (a) Communicable diseases, maternal and neonatal conditions. 
 
Figure 16: Indigenous health gap (DALYs), proportional contribution by broad cause groups, 2003 
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The Indigenous health gap was equally distributed within males and females (Table 22). 
Two-thirds was due to premature mortality compared with 54% of the total Indigenous 
burden of disease, reflecting higher case fatality rates: i.e. when sick, Indigenous Australians 
are more likely to die. 
Table 22: Indigenous health gap (DALYs) due to selected causes by sex and remoteness, expressed as a 
proportion of total Indigenous health gap, 2003 
Cause 
Males 
(%) 
Females 
(%) 
Non-remote 
(%) 
Remote 
(%) 
All causes 100 100 100 100 
Group I(a) 14 16 12 20 
Infectious and parasitic diseases 9 10 7 14 
Neonatal causes 5 4 4 4 
Non-communicable diseases 67 73 76 62 
Cancers 4 7 6 5 
Diabetes 10 14 12 12 
Cardiovascular disease 24 23 24 23 
Ischaemic heart disease 16 13 16 13 
Stroke 3 3 3 3 
Mental disorders 10 9 14 4 
Substance use disorders 7 5 7 4 
Other mental disorders 4 5 7 0 
Chronic respiratory disease 9 10 10 8 
Injuries 18 11 12 18 
Road traffic accidents 4 3 2 5 
Suicide 6 2 4 5 
Homicide & violence 3 3 2 4 
Notes:	  (a)	  Communicable	  diseases,	  maternal	  and	  neonatal	  conditions. 
 
Tobacco (17%), high body mass (16%), physical inactivity (12%), high blood cholesterol 
(7%) and alcohol (4%) were the main risk factors contributing to the health gap (Table 23). 
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Table 23: Indigenous burden of disease and health gap (DALYs) due to 11 risk factors, 2003 
   Disease burden    Health gap 
  DALYs % of total  DALYs % of total  
Total Indigenous burden of disease 95,976 100 56,455 100 
Attributable to:         
Tobacco 11,633 12 9,816 17 
High body mass 10,919 11 8,953 16 
Physical inactivity 8,032 8 6,554 12 
High blood cholesterol 5,262 5 3,994 7 
Alcohol 5,171 5 2,362 4 
High blood pressure 4,417 5 3,215 6 
Low fruit and vegetable intake 3,344 3 2,873 5 
Illicit drugs 3,264 3 2,150 4 
Intimate partner violence 2,469 3 1,836 3 
Child sexual abuse 1,390 1 869 2 
Unsafe sex 1,174 1 926 2 
11 risk factors combined 35,908 37 27,383 49 
 
The majority of the health gap occurred in the non-remote Indigenous Australian population 
(60%). However, the 26% of Indigenous Australians residing in remote areas experienced a 
disproportionate amount of the health gap (40%) compared with those living in non-remote 
areas. This was true across all major disease groups (Table 22 and Figure 17). 
Figure 17: Indigenous health gap (DALYs) by broad cause groups expressed as proportions by 
remoteness, 2003 
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Discussion 
This analysis is the first comprehensive assessment of the health of Indigenous Australians 
and indeed, of Indigenous populations anywhere. It confirms previous findings of substantial 
excess mortality and greater disease occurrence in Indigenous Australians. The particular 
value of this analysis is that it provides a quantification and comparative assessment of those 
diseases and risk factors that contribute most to the overall Indigenous burden of disease and, 
even more of interest, that contribute most to the Indigenous health gap. The latter is most 
indicative of the potential for health gain. 
Precision	  of	  estimates	  	  
Because of inaccurate or incomplete identification of Indigenous status in health and 
population data, ascertainment of the true death rate requires adjustments by demographic 
methods, which inherently introduce an additional degree of uncertainty. We have shown 
elsewhere that our corrected estimates of Indigenous mortality rates are relatively insensitive 
to the assumption of a constant age pattern of mortality and the assumption of a constant age 
pattern of the unexplained population growth in the 1996–2001 intercensal period.165 
In this analysis, we assumed that the level of mortality estimated for the 1996–2001 period 
applied to our baseline year of 2003. However, recent information has indicated an 
improvement in life expectancy in Aboriginal people in the Northern Territory.166 If we apply 
the Northern Territory trend to adjust our mortality estimate downwards, the total amount of 
DALYs in Indigenous Australians would have been lower by 4%. 
Estimates of disability for the more than 170 disease and injury categories included in this 
study depended on a combination of methods. When available, we included data on directly 
observed Indigenous health events in routine health statistics databases, health surveys or 
epidemiological studies.167 For many diseases, such information did not exist. Instead, ratios 
of the differences between Indigenous and total population rates for hospital admissions or 
mortality were sought as proxy measures of disease occurrence. The consequence is that there 
are varying degrees of confidence about the accuracy of these estimates. Only six of the top 
                                                
165  Hill, K, Barker, B and Vos, T, “Excess Indigenous mortality: are Indigenous Australians more severely 
disadvantaged than other Indigenous populations?”. 
166  Wilson, T, Condon, JR and Barnes, T, “Northern Territory indigenous life expectancy improvements, 1967-
2004”, Aust N Z J Public Health, 2007, vol. 31(2), pp. 184-8. 
167  See supplementary Webtable 1 at http://ije.oxfordjournals.org/content/38/2/470/suppl/DC2 
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20 disabling conditions—ischaemic heart disease, stroke, homicide and violence, low birth 
weight, birth trauma and asphyxia and caries—were deemed to have good-quality sources of 
incidence data.168 We judged the accuracy of estimates for alcohol dependence, migraine and 
personality disorders as particularly poor. The accuracy of estimates for the remaining top 20 
conditions was judged as fair. This indicates that there is a large gap in knowledge to 
accurately estimate the disease occurrence of many major diseases contributing to the 
disability component of the burden of disease; including mental disorders, Type 2 diabetes, 
asthma and COPD. We resorted to finding differentials between Indigenous Australians and 
the total Australian population in proxy data sources, or were limited to a few isolated 
epidemiological studies to generalize to the whole population. 
A key gap in available data to estimate the burden attributable to major risk factors was the 
lack of representative health measurement data on risk factors, such as blood pressure, 
cholesterol and body mass.169 We recommend that a representative Indigenous health 
measurement survey be undertaken to measure the population distribution of exposure to 
these risk factors. 
Policy	  implications	  
A detailed description of the burden of disease and injury in a population is alone not 
sufficient for setting priorities in public health. It is, however, an important foundation on 
which to base debates and economic evaluations that underpin health policies. This study 
contributes most obviously by identifying the excess amount of disease burden—the 
Indigenous health gap—and by quantifying the contribution of major modifiable risks to this 
gap, indicating where the greatest potential for health gain lies. The fact that much lower 
rates of disease burden are experienced by the majority of Australians means that with 
existing knowledge and technologies, a reduction of most of the Indigenous health gap is 
theoretically achievable. However, reducing this health gap will require comprehensive 
actions given that the health disadvantage of Indigenous Australians is apparent for almost all 
diseases and risk factors, at all ages, in men and women, and in remote and less remote areas. 
Collectively, cardiovascular disease, diabetes and other tobacco-related conditions, such as 
lung cancer and chronic respiratory disease accounted for half the Indigenous health gap. 
                                                
168  See supplementary Webtable 2 at http://ije.oxfordjournals.org/content/38/2/470/suppl/DC2 
169  See supplementary Webtable 3 at http://ije.oxfordjournals.org/content/38/2/470/suppl/DC2 
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These diseases share additional lifestyle risk factors, including high body mass, physical 
inactivity, raised blood pressure and cholesterol. These health problems largely affect middle-
aged and older Indigenous Australians; however, they start at young ages, and there already is 
a sizeable burden in the 15- to 34-year-old age group. Prevention efforts should therefore 
target Indigenous adolescents and young adults. 
However, efforts to reduce the health gap should not focus on prevention alone. For example, 
two-thirds of the health gap was due to mortality, which in part reflects the much higher case 
fatality for most diseases in Indigenous Australians than in their non-Indigenous counterparts. 
This is most likely due to a combination of factors such as late presentation for treatment, 
shortcomings in acute surgical and medical management, and inadequate follow-up during 
the course of disease, all of which have important implications for the way in which health 
services are delivered to Indigenous Australians. 
It is also important to note that while the rate of disease burden may be higher in remote 
areas, the bulk of the health gap for Indigenous people arises in non-remote areas since the 
vast majority of Indigenous Australians reside in non-remote areas. The implication is that 
the focus of health service action to reduce inequalities in Indigenous health needs to include 
culturally appropriate and uniquely targeted approaches for non-remote and remote areas. 
Our findings will guide policy makers as to the emphasis to be given to health problems by 
broad remoteness area. 
Addressing the multitude of health problems facing Indigenous Australians is complex and 
will require a wide range of initiatives to increase preventive and curative efforts and 
particularly to strengthen Indigenous health services. However, responses from within the 
health sector alone are not sufficient. There is an urgent need to address the social and 
economic disadvantages that contribute to the poor health status of Indigenous Australians. 
This is in keeping with the broader Indigenous concept of health which acknowledges that 
improving Indigenous health is about improving the physical wellbeing of an individual 
within a context of improving the social, emotional and cultural well-being of the whole 
community.170 
                                                
170  NACCHO, Submission to the Commonwealth Parliamentary inquiry into the needs of urban dwelling Aboriginal and 
Torres Strait Islander peoples, National Aboriginal Community Controlled Health Organisation, Canberra, 
2001 viewed 14 August 2011, http://www.naccho.org.au/Files/Documents/Urbaninquirysubmission.pdf  
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While this may be so, these requirements should not lead to inaction by the health sector 
arguing that the social and economic problems should be tackled first. Much can be done by 
appropriately resourced health services to reduce a sizeable proportion of the Indigenous 
health gap. 
The results of this analysis are of immediate policy relevance to Australia yet also 
demonstrated how disparities in health experienced by Indigenous people in other countries, 
or indeed any other disadvantaged population group, can be comprehensively documented. 
Detailed information on the diseases and risk factors that contribute most to a disadvantage in 
health is a vital element of the evidence base for prioritizing interventions that can reduce 
such gaps. 
Afterword 
The above analysis was structured in response to the Council of Australian Governments 
(COAG) policy framework for Indigenous health matters, which features as a headline 
indicator the gap between Indigenous and non-Indigenous life expectancy. Its relevance in 
this respect, however, is debatable.  
A key issue is whether a gap analysis based on the DALY—an incidence-based measure, 
which incorporates a normative assumption about time preference—is numerically related to 
the causal drivers of a gap in life expectancy. In their original discussion on time preferences 
Murray and Lopez note that a discount rate of 3%—the rate applied to the DALY 
calculations above—has an important effect on not only the proportion of total DALYs in a 
population that is due to non-fatal causes, but also the age-distribution of DALYs and the 
distribution of DALYs by broad cause groups.171 Life expectancy, on the other hand, is 
unaffected by these considerations, although such technical distinctions are not mentioned in 
the published version of the above analysis. 
The potential for this omission to mislead is demonstrated by the National Health and 
Hospitals Reform Commission’s (NHHRC) use of the paper as evidence for the claim that 
                                                
171  Murray, CJL and Lopez, AD, eds, The Global Burden of Disease: a comprehensive assessment of mortality and 
disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Vol I. 
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70% of the Indigenous life expectancy gap is due to chronic illness.172 Presumably, the 
Commission derived this figure from Table 21. 
Arguably a more relevant metric for the Commission’s purposes because of its technical 
relatedness to life expectancy would have been HALE. However, this metric has traditionally 
not been regarded as a useful alternative to the DALY when information on causal drivers is 
required, mainly because of the perception that it cannot be decomposed by cause. Thanks to 
Nusselder and Looman such a perception no longer has any basis, as demonstrated not only 
by the results presented in Chapter 4 but also by those presented in a recent Queensland 
Government publication titled Making Tracks towards closing the gap in health outcomes for 
Indigenous Queenslanders by 2033 – policy and accountability framework.173  
Making Tracks represents Queensland’s response to the COAG target relating to closing the 
life expectancy gap and draws on a decomposition analysis of the difference HALE between 
Indigenous and non-Indigenous Queenslanders, the methods for which are described in 
Chapter 8. The focus here, however, is on how the results compare with the gap analysis 
based on the DALY, as presented in the preceding pages.  
Figure 18 is a reproduction of a chart presented in Making Tracks and shows, in order of 
importance, the major drivers of the health expectancy gap between Indigenous and non-
Indigenous Queenslanders, expressed as numbers of years. Cardiovascular conditions account 
for more than 4 years of this gap, followed by diabetes (3 years), injuries (more than two 
years), chronic respiratory conditions (1.5 years), cancers (more than 1 year) and infectious 
and parasitic conditions (about a year). The analysis has an intuitive interpretation by 
showing for any particular cause by how many years the health expectancy gap would be 
reduced if rates of mortality and disability in Indigenous Queenslanders were reduced to 
levels experienced by the rest of the population.   
                                                
172  NHHRC, A healthier future for all Australians : Interim report : December 2008, National Health and Hospitals 
Reform Commission, Canberra, 2008. 
173  Queensland Health: Serghi, M, Begg, S and others, Making tracks : toward closing the gap in health outcomes for 
Indigenous Queenslanders by 2033 : policy and accountability framework, Queensland Health, Brisbane, Qld., 
2010. 
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Figure 18: What causes the Indigenous health gap in remote areas of Queensland?174 
 
To illustrate the magnitude of the Commission’s error in equating DALYs with health 
expectancies it is useful to compare the results presented in Table 21 with a HALE 
decomposition analysis based on the same underlying data set (Table 24). This comparison 
indicates that a gap analysis based on DALYs underestimates the contribution of chronic 
illness (called non-communicable diseases in Table 24) to the health expectancy gap by more 
than 10 percentage points (70% and 81%, respectively). This is because the DALY as 
typically calculated attributes the non-fatal impact of a cause back to the age at which it 
becomes incident whereas for HALE it is more commonly attributed on the basis of 
prevalence (i.e. the age at which it is experienced).175 Life expectancy is less useful in this 
context since, while it can be decomposed by cause, it is calculated exclusively from 
mortality rates and thus ignores the impact of predominantly non-fatal but nevertheless 
chronic conditions such as diabetes and many mental disorders. 
                                                
174  ibid. 
175  At one state there were indications that the main results from the latest Global Burden of Disease Study may 
be presented using a new version of the DALY calculated on the basis of prevalence. 
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Table 24: Comparison between alternative measures of the Indigenous health gap 
Cause 
DALY gap(a) 
(%) 
HALE gap(b) 
(%) 
Difference  
(%) 
All causes 100 100 0 
Group I 15 10 -34 
Infectious and parasitic diseases 9 4 -59 
Neonatal causes 4 3 -29 
Non-communicable diseases 70 81 16 
Cancers 6 8 29 
Diabetes 12 15 25 
Cardiovascular disease 23 31 35 
Ischaemic heart disease 14 19 35 
Stroke 3 6 115 
Mental disorders 10 7 -29 
Substance use disorders 6 4 -27 
Other mental disorders 4 3 -32 
Chronic respiratory disease 9 12 30 
Injuries 15 7 -53 
Road traffic accidents 3 2 -31 
Suicide 4 3 -37 
Homicide & violence 3 2 -36 
Notes: (a) Reproduced from Table 21; (b) Calculated using hale_decomp from the same data set used to estimate the DALY gap.  
Calculated in these ways, the DALY gives greater weight than HALE to causes experienced 
earlier in life, such as infectious and parasitic diseases (9% compared to 4%), mental 
disorders (10% compared to 7%) and injuries (15% compared to 7%), notwithstanding the 
attenuating effect of discounting. The opposite is true for causes experienced later in life, 
such as cancers (6% compared to 8%), diabetes (12% compared to 15%) cardiovascular 
diseases (23% compared to 31%) and chronic respiratory disease (9% compared to 12%).  
This concludes Part III of this thesis. In Part IV, the final part, I consider the success or 
otherwise of the methods proposed in Chapter 2 with respect to facilitating the uptake of the 
Murray and Lopez framework by Australian governments.   
 Part IV: Implementation and 
conclusions 
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Chapter 8: Health outcomes in Queensland 
In this chapter I explore the practical dimensions of implementing the model represented by 
the set of workflows presented in Chapter 2 from outside the context of the case study. I use 
as an example a work program at Queensland Health, which relied on the process subpop-
IPM to derive a complete set of framework parameters for Queensland in 2003, stratified by 
cause, sex, age, socioeconomic quintile and remoteness category. This data set generated 
state-level totals consistent with the results for Queensland presented in Chapter 6 and 
provided the starting point for a number of analyses summarised here under three high-level 
objectives.  
Original baseline 
My initial objective was to integrate estimates from the Indigenous component of the case 
study, which, as described in chapter 2, had been derived using subpop-IPM mainly from 
the initial database of parameters but reported separately due to timing considerations. Given 
the much lower overall health status of Indigenous people compared to the rest of the 
Australian population, Indigeneity is a critical dimension when describing the health status of 
geographically defined populations that have a large Indigenous proportion, which is the case 
in some administrative areas of Queensland. These are currently referred to as Health Service 
Districts but will become Hospital and Health Services as a result of recent health reforms 
agreed to by the Council of Australian Governments. 
To integrate the Indigenous and non-Indigenous dimensions of the case study, I derived a set 
of selected parameters (incidence, prevalence, deaths, PYLD, YLD and YLL) for Indigenous 
people by combining the Indigenous proportion of the population in each statistical local area 
(SLA)—the smallest geographical unit of analysis in health data for practical purposes —
with population rates of the selected parameters for Indigenous Australians, stratified by 
cause, sex, age and remoteness category. Estimates for non-Indigenous people were derived 
by combining the non-Indigenous proportion of the population in each SLA with population 
rates of the selected parameters for Queensland, stratified by cause, sex, age, socioeconomic 
status and remoteness. I assigned a socioeconomic and remoteness classification to each SLA 
to allocate the correct population rate in each case. An unavoidable consequence of these 
methods was that for some causes, state-level totals were marginally different from the results 
presented in Chapter 6 relating to Queensland. 
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I then derived a set of outputs for each Health Service District by aggregating the selected 
parameters from the SLA level while preserving certain within-district stratifications (i.e. 
cause, sex, age, Indigeneity, socio-economic status and remoteness). I assumed these 
parameters were consistent with the SLA-level estimates so did not reprocess them using 
subpop-IPM. However, I did use the hale_decomp process described in Chapter 4 to 
decompose the drivers of differences in HALE for each Health Service District from the state 
average. In addition, a colleague undertook a state-level comparative risk assessment by 
combining risk models from the case study with estimates of risk prevalence for Queensland 
in 2003. As mentioned already, a discussion of these models is provided in the report that 
accompanies this thesis, although the details are not relevant to the present discussion. 
The results from these analyses provided the basis for the various information products listed 
in Table 25 with the identifier 2003 as the baseline year. The exception to this general flow of 
information was the 2006 edition of Queensland Health’s flagship series The Health of 
Queenslanders, which went to press prior to commencing the above work program and was 
therefore based on a set of estimates that excluded an explicit Indigenous dimension. 
Dynamic baseline 
My second objective was to update the set of framework parameters for Queensland with 
more contemporary data. The first step involved creating a new dataset with two 
supplementary parameters, stratified by year, cause, sex and age. The first of these recorded 
for Queensland the annual percentage change in incidence between 2003 and a new baseline 
year, which my colleagues derived from various proxy sources such as hospitalisation data, 
surveys, registry data and mortality data. The second recorded mortality data for Queensland 
between 2003 and the new baseline year. We combined both with state-level input parameters 
for 2003 and trend assumptions for the period before 2003 to derive a complete time-series of 
input parameters for the period 1979 to the new baseline, stratified by cause age, sex and 
year.  
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Table 25: Inventory of publications that incorporate information from the Queensland work program 
Publication 
Baseline 
year 
Chief Health Officer Reports(c)  
The Health of Queenslanders 2006: First report of the Chief Health Officer Queensland 2003(a) 
The Health of Queenslanders 2008: Second report of the Chief Health Officer Queensland 2006 
The Health of Queenslanders 2010: Third report of the Chief Health Officer Queensland 2007 
The Health of Queenslanders 2012: Fourth report of the Chief Health Officer Queensland(b) 2007 
Health Service Districts Reports(d)  
Burden of disease and health adjusted life expectancy in Health Service Districts of Queensland 
Health, 2003 
2003 
Burden of disease and health adjusted life expectancy in Health Service Districts of Queensland 
Health, 2006 
2006 
Queensland Burden of Disease and Injury Circulars(d)  
First Series  
Circular 1 - Overview of the burden of disease and injury in Queensland, 2003 2003 
Circular 2 - Leading causes of burden of disease and injury in Queensland, 2003 2003 
Circular 3 - Age group differences in burden of disease and injury in Queensland, 2003 2003 
Circular 4 - Risk factor impact on the burden of disease and injury in Queensland, 2003 2003 
Circular 5 - Differentials in the burden of disease and injury in Queensland, 2003 2003 
Circular 6 - Burden of disease and injury, life expectancy and health adjusted life expectancy in 
Queensland Health Service Districts, 2003 
2003 
Second Series  
Circular 1 - Overview of the burden of disease and injury in Queensland, 2006 2006 
Circular 2 - Leading causes of burden of disease and injury in Queensland, 2006 2006 
Circular 3 - Age group differences in burden of disease and injury in Queensland, 2006 2006 
Circular 4 - Differentials in the burden of disease and injury in Queensland, 2006 2006 
Circular 5 - Burden of disease and injury, life expectancy and health adjusted life expectancy in 
Queensland Health Service Districts, 2006 
2006 
Circular 6 - Risk factor impact on the burden of disease and injury in Queensland, 2007 2007 
Circular 7 - Projected burden of disease and injury in Queensland, 2007 to 2016 2007 
Notes:  (a) These estimates do not include a specific Indigenous dimension; (b) In preparation at the time of writing; (c) These publications can be 
accessed online at http://www.health.qld.gov.au/cho_report/default.asp; (d) These publications can be accessed online at 
http://www.health.qld.gov.au/epidemiology/publications/burden-of-disease.asp 
This new data set was then processed with cohort-IPM in a number of ways. In the first 
instance, I derived a complete set of framework parameters for 2006, this being the latest year 
for which mortality data was available at the time. In the second, a colleague derived a set for 
the period 2007 to 2016.176 For the projection component of the latter analysis, we processed 
state-level mortality using the regression methods described in chapter 2, except we used 
national multinomial models in place of those based on Queensland data because the 
                                                
176  We had hoped that 2008 might be the new baseline in this instance but the required mortality data from the 
ABS was unavailable (at the time of writing, this data was still unavailable due to a change in dissemination 
policies being implemented by the ABS). 
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observed trends for some causes were unstable in the latter. In the third, I combined elements 
of the set of parameters for 2007 with new inputs for key diseases to derive a complete set of 
parameters for Indigenous Queenslanders, stratified by three remoteness categories in the 
year 2007. 
In each case, we processed parameters for the new baselines using Equation 7 of Chapter 2 to 
account for the comorbidity considerations discussed in that chapter. In addition, we used the 
processes described above but modified to incorporate a new set of boundaries to 
disaggregate the parameters for 2006 to Health Service Districts. My colleagues also updated 
the state-level comparative risk assessments for both Indigenous and non-Indigenous 
Queenslanders to the year 2007. 
On the basis of these analyses we released a second series of information circulars, as listed 
in Table 25 with the baseline identifier 2006 or 2007, respectively, and, at the time of writing, 
we were in the process of preparing a second report in response to the Making Tracks 
document discussed in the afterword to Chapter 7. In addition, the South Australian and 
Western Australian health departments approached me to update the original set of 
parameters for these jurisdictions to 2006, and then disaggregate the new sets of parameters 
to relevant subpopulation groupings. Results from those consultancies are listed elsewhere.177  
A common feature in each of these analyses is the incorporation of new data on mortality, 
incidence and case-fatality. As such, they provide evidence for the successful implementation 
of the model illustrated in Figure 8 of Chapter 2. However, several points regarding this 
general observation are worth noting. First, not all jurisdictions had the resources to adopt the 
proposed model, hence there was no way to aggregate the individual analyses into a 
nationally cohesive picture such as the one presented in Parts II and III of this thesis. Second, 
no jurisdiction was in a position to create a more up-to-date national picture since access to a 
number of key national datasets was restricted. Finally, there was only limited capacity to 
review and update the parameter assumptions underlying the model, hence the need for 
additional resources to undertake such a body of work over the medium to longer term.  
                                                
177  See http://www.sahealth.sa.gov.au/wps/wcm/connect/public+content/sa+health+internet/about+us/ 
our+performance/health+statistics/other+statistics/burden+of+disease+in+sa and 
http://www.health.wa.gov.au/publications/BOD_Technical.cfm 
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In the remainder of this chapter I illustrate the potential scope of these work programs by 
describing an analysis that sought to quantify the projected health and expenditure outcomes 
of obesity reduction targets of the former Queensland Government. 
Scenario modelling 
Introduction	  
Obesity is most commonly assessed using the body mass index (BMI), which is calculated as 
weight in kilograms over the square of height in metres. Typically, a healthy body weight is 
defined as a BMI of 18.5 to less than 25, overweight as a BMI of 25 to less than 30 and obese 
as a BMI of 30 or above. As indicated in Chapter 6, high body mass accounted for more than 
one half of the total health loss from diabetes in Australia in 2003. Moreover, this risk is 
increasing, with a growth of almost 12% in recorded prevalence of overweight and obese 
Australian adults between 2001 and 2007–08. These attributes alone would appear to justify 
the setting of rigorous targets by government as a policy framework for mitigating further 
growth in levels of obesity.  
In this analysis my Queensland Health colleagues and I attempt to quantify the potential 
health and financial benefits of one target in particular as it relates to diabetes in the 
Queensland population.  
Methods	  
Our methods are identical to those established for diabetes in Chapter 2, but are described 
here in greater detail. In this approach the established relationship between BMI and the most 
common form of diabetes —Type 2 diabetes mellitus (or T2DM)—is modelled via the 
population impact fraction (PIF) 178, which can be used to assess the proportional change in 
incidence of disease after a change in exposure to a related risk. The incidence after this 
change is, 
€ 
ʹ′ I = I 1− PIF( ),  
Equation 19 
                                                
178  Morgenstern, H and Bursic, ES, “A method for using epidemiologic data to estimate the potential impact of 
an intervention on the health status of a target population”, J Community Health, 1982, vol. 7(4), pp. 292-309. 
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where I is the original incidence. We treat BMI as a log-normally distributed continuous risk 
because this is the distribution that most closely resembles the population-level data. The PIF 
for a continuous risk is given by, 
€ 
PIF =
RR x( )P x( ) −
x =1
h
∫ RR x( ) ʹ′ P x( )
x =1
h
∫
RR x( )P x( )
x =1
h
∫
, 
Equation 20 
where RR(x) is the relative risk at exposure level x, P(x) the population distribution of 
exposure, P′(x) the counterfactual distribution of exposure, and l and h are the integration 
boundaries.179 Unlike dichotomous or categorical risk attribution models, Equation 20 
assumes the risk conferred on T2DM increases exponentially with every unit increase in 
BMI, and quantifies this risk at all points in the population distribution minus a 
counterfactual. The counterfactual in this case is a theoretical minimum risk distribution for 
BMI, which—following Ezzati and colleagues—we assume has a mean of 21 and a standard 
deviation of 1.  
Together with some additional data and assumptions, these equations allow us to model via 
the cohort-IPM function both the likely prevalence of T2DM if current trends in obesity 
were to continue, and what this prevalence might be under alternative obesity trajectories. 
Prevalence of T2DM is a key parameter of interest in this analysis since, while obesity is a 
risk for becoming an incident case of T2DM, healthcare costs accrue from treating and 
managing prevalent cases of this disease. This general framework operationalises a set of 
ideas described by Murray and others in terms of the generic model illustrated in Figure 19. 
However, it differs from the model used by Goss to assess the impact of health reform 
proposals for the NHHRC180, which incorrectly assumed changes in obesity operate directly 
on prevalence rather than via incidence.181  
                                                
179  Ezzati, M, Lopez, AD, Rodgers, A and Murray, CJL, eds, Comparative quantification of health risks: Global and 
regional burden of disease attributable to selected major risk factors - Volume 1. 
180  See Afterword to Chapter 5. 
181  AIHW, Estimating the impact of selected National Health and Hospitals Reform Commission (NHHRC) reforms on 
health care expenditure, 2003 to 2033. 
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Figure 19: A generic model for health risk assessment182 
 
We derived the input parameters for the analysis from various sources, but primarily from the 
set of parameters for Queensland in 2003 described at the beginning of this chapter. This in 
turn was derived from the underlying epidemiological models referred to above but hitherto 
not described in any detail except in the accompanying case study report. As set out in 
Appendix 1 of that report, we derived the incidence of type 1 diabetes mellitus (or T1DM) in 
2000 from the National Diabetes Register,183 from which we estimated prevalence in Dismod 
II, assuming no remission and age-specific relative risk of dying for all diabetes from the 
Asia Pacific Cohort Studies Collaboration.184 For under 25-year-olds, we derived the 
                                                
182  Ezzati, M, Lopez, AD, Rodgers, A and Murray, CJL, eds, Comparative quantification of health risks: Global and 
regional burden of disease attributable to selected major risk factors - Volume 1. 
183  AIHW, National diabetes register: statistical profile, December 2001, Australian Institute of Health and Welfare, 
Canberra, 2003. 
184  Woodward, M, Zhang, X, Barzi, F, Pan, W, Ueshima, H, Rodgers, A and MacMahon, S, “The effects of 
diabetes on the risks of major cardiovascular diseases and death in the Asia-Pacific region”, Diabetes Care, 
2003, vol. 26(2), pp. 360-6. 
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incidence of T2DM also from the National Diabetes Register. For older ages, we subtracted 
the prevalence of T1DM from the total prevalence of measured diabetes in 2000 from the 
Ausdiab study—still the most reliable estimates available at the time of writing—before 
deriving incidence in Dismod II assuming an annual growth in incidence of 2.5% for males 
and 1.5% for females over the period 1980–1999.185  
In the absence of a direct measure of trends in incidence or prevalence of T2DM, we assumed 
the historically flat trend in mortality from this disease reflects the net effect of an increase in 
incidence and a decrease in case-fatality. The latter was assumed to be equivalent to half the 
trend in cardiovascular disease case-fatality since the main causes of death in people with 
diabetes have a vascular origin. On this basis we incorporated an annual decline in case-
fatality of 2% for males and 1% for females over the same period for which we modelled 
increasing trends in incidence. We extrapolated incidence and case-fatality by continuing the 
above trends and then used Dismod II, again with the same trend assumptions, to derive a 
complete epidemiological model for T2DM in Australia for the year 2003. 
As briefly outlined in Chapter 2, we disaggregated the incidence parameter in this model to 
states and territories using jurisdictional proportions of hospitalisation data. On the basis that 
case-fatality and remission are likely to be relatively uniform across jurisdictions, this 
provided a set of incidence, case-fatality and remission parameters for Queensland up until 
the year 2003, which we projected to 2007 to coincide with the most recent reliable source of 
BMI in Queenslanders, measured height and weight from the National Health Survey 2007-
2008. We modelled trends in incidence between 2003 and 2007 to follow trends in the PIF 
for BMI, which we calculated from various inputs: a regression model of observed mean 
BMI on age, birth cohort and sex186; the relationship between changes in the mean of BMI 
and its standard deviation based on measured distributions from Ausdiab, National Heart 
Foundation and Busselton studies; and the Asia Pacific Cohort relative risk of mortality 
estimates mentioned above.  
                                                
185  Dunstan, DW, Zimmet, PZ, Welborn, TA, De Courten, MP, Cameron, AJ, Sicree, RA, Dwyer, T, Colagiuri, S, 
Jolley, D, Knuiman, M, Atkins, R and Shaw, JE, “The rising prevalence of diabetes and impaired glucose 
tolerance: the Australian Diabetes, Obesity and Lifestyle Study”, Diabetes Care, 2002, vol. 25(5), pp. 829-34. 
186  Haby, MM, Vos, T, Carter, R, Moodie, M, Markwick, A, Magnus, A, Tay-Teo, KS and Swinburn, B, “A new 
approach to assessing the health benefit from obesity interventions in children and adolescents: the 
assessing cost-effectiveness in obesity project”, Int J Obes (Lond), 2006, vol. 30(10), pp. 1463-75. 
 109 
As stated already, we assumed half the trends in case-fatality for cardiovascular disease 
would also apply to diabetes. Following Unal, we modelled trends in cardiovascular disease 
case-fatality as being 48% of the overall trends in observed cardiovascular disease mortality, 
the remainder being accounted for by trends in incidence.187 Projections of cardiovascular 
disease mortality to 2033 were achieved by applying the combination of Poisson and 
multinomial regression techniques set out in Chapter 2. 
For 2007 and beyond we modelled four incidence trajectories for T2DM via the PIF. The first 
was a continuation of past trends in changes to the distribution of BMI, which we call the 
business as usual scenario. To achieve this we used the regression models discussed above, 
which we recalibrated to fit observed means and standard deviations for Queensland from the 
National Health Survey 2007-2008. The remaining scenarios were attenuations of the above 
as follows: 
1. One-third reduction scenario—based on the former Queensland Government’s target to 
cut the proportion of overweight or obese Queenslanders by one-third188, which we 
interpreted as a shift in the distribution of BMI such that the proportion of overweight or 
obese people in 2020 is approximately two-thirds the proportion observed in 2007; 
2. Immediate elimination scenario—based on the assumption that the proportion of 
overweight or obese people in 2007 is reduced to zero in 2008 and thereafter; and 
3. No change scenario—based on the assumption that the age-specific proportions of 
overweight or obese people in 2007 remain unchanged for the foreseeable future. 
Figure 20 illustrates the implications for the distribution of BMI in adults with respect to the 
first three of these scenarios (by definition, the fourth has no such implications). It also 
presents historic trends in measured BMI from various sources. Indicated in light grey is the 
proportion of overweight or obese people for 2007 with the historic distributions, and for 
2020 with the three scenarios. 
                                                
187  Unal, B, Critchley, JA and Capewell, S, “Explaining the decline in coronary heart disease mortality in 
England and Wales between 1981 and 2000”. 
188  The State of Queensland (Department of the Premier and Cabinet), Toward Q2: Tomorrow’s Queensland, 
Queensland Government, Brisbane, 2008, viewed 19 August 2011, 
http://www.towardq2.qld.gov.au/tomorrow/library/pdf/Towards_Q2_Tomorrows_Queensland.pdf. 
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Figure 20:  Distribution of BMI in adults, historic trends from 1978 to 2007, under three scenarios, 2007 
and 2020 
 
To quantify the potential change in treatment-related expenditure under each scenario we 
applied an annual cost per prevalent case assumption, which we estimated on the basis of the 
calculations by Goss as presented in the afterword to Chapter 5. This was equivalent to 
$1,211 in 2003 (in 2006–07 constant dollars), and growing in real terms by 2.2% per year 
thereafter.189 As discussed already, both sources use the same methodology but differ with 
respect to certain parameter assumptions. This led to a slower annual cost growth of 1.5% in 
the earlier calculations. However, in both cases the cost parameter should be regarded as 
conservative because it only relates to direct expenditure on type 2 diabetes and its 
complications, thus it ignores expenditure on conditions for which diabetes confers an 
elevated risk, such as cardiovascular disease. 
                                                
189  AIHW, Estimating the impact of selected National Health and Hospitals Reform Commission (NHHRC) reforms on 
health care expenditure, 2003 to 2033; Goss, J, Projection of Australian health care expenditure by disease, 2003 to 
2033. 
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Results	  
Table 26 summarises the key results of this analysis and shows that under the business as 
usual scenario, we expect 63.2% of the Queensland population to be overweight or obese by 
2020—an annual average growth of 0.9% from 2007 levels—and 7.5% to have T2DM. At 
these levels we expect direct expenditure on T2DM to be around $714 million (in 2006-07 
dollars), representing an average growth in real terms of 6.8% per year. 
Should the former Queensland Government’s target be reached instead, the proportion of 
overweight or obese Queenslanders in 2020 will be 37.8% (by definition), which represents 
an annual decline in risk of 3% over the projection period. Such a trajectory would most 
likely result in a stabilisation of T2DM at around 6.4% of the population by 2020 but a 18.4% 
increase from 2007, reflecting the lag between risk reduction and accumulated disease in the 
population. At this level of T2DM, direct annual expenditure would be around $617 million 
in 2020 (in 2006-07 dollars), which is equivalent to a potential saving of around $100 million 
compared to the business as usual scenario in that year, or $436 million in cumulative savings 
since 2007. However, growth would be only 1.2 percentage points lower than the business as 
usual scenario at 5.6% per year. 
Table 26: Overweight/obese, type 2 diabetes and direct expenditure on type 2 diabetes under various 
obesity scenarios, all ages, Queensland, 2007 and 2020 
 2007    2020   
 Total 
Un-
related 
 Business 
as usual 
No 
change 
One-third 
reduction 
Elimin-
ation 
Un-
related 
Overweight/obese         
Crude prevalence (%)  56.5  n.a.  63.2 57.5 37.8 0.0 n.a. 
Change pa. (%) n.a. n.a.  0.9 0.1 -3.0 n.a. n.a. 
Type 2 diabetes         
Crude prevalence (%)  5.4  2.1  7.5 7.3 6.4 4.2 2.3 
Change pa. (%) n.a. n.a.  2.4 2.3 1.3 -1.9 0.5 
Direct expenditure          
Annual ($ millions)  304  97  714 700 617 407 219 
Change pa. (%) n.a. n.a.  6.8 6.6 5.6 2.3 4.9 
Since 2007 ($ millions) n.a. n.a.  6,838 6,783 6,402 4,985 2,270 
 
In the event that age-specific levels of overweight or obese Queenslanders were to remain 
constant over the period 2007–2020 (the no change scenario), we would still expect a one 
percentage point increase in overweight and obesity across all ages because of the combined 
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effect of population ageing and the fact that older people tend to be fatter. At this level of risk 
we would expect real growth in direct expenditure on T2DM to be 6.6% per year. On the 
other hand, the immediate removal of obesity as a risk (if this were possible), would result in 
growth of 2.3% per year, until some point well beyond the projection period when the higher 
growth associated with non-obesity T2DM takes over as the dominant driver of expenditure 
for this disease. These trends are depicted graphically in Figure 21 and Figure 22. 
Figure 21: Prevalence (%) of type 2 diabetes under various obesity scenarios, all ages, Queensland, 2000 
to 2020 
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Figure 22: Direct health expenditure in 2006-07 constant dollars (millions) on type 2 diabetes under 
various obesity scenarios, all ages, Queensland, 2000 to 2020 
 
Discussion	  
This analysis demonstrates that an attenuation of recent trajectories in the distribution of body 
mass is likely to reduce the prevalence of T2DM, at least from what it would have otherwise 
been had these trends continued. However, it also shows that even if we were successful in 
achieving a one-third reduction in overweight and obesity by 2020, the prevalence of T2DM 
would continue to rise, albeit at a decreasing rate of growth, and would only start to stabilise 
towards the end of this period. Of the four scenarios examined, prevalence would only reduce 
from 2007 levels under the elimination scenario, illustrating the long lead-time between risk 
mitigation and absolute reduction in the prevalence of this disease.  
Whether these findings have economic implications is less clear. While the analysis shows 
there are likely to be direct expenditure savings under each scenario compared to business as 
usual, a more complete analysis would consider other health outcomes in addition to T2DM 
as well as the level of investment required to achieve the implied reductions in obesity. 
Changes in levels of health, productivity and utility might also be considered, depending on 
both the available evidence and the particular perspective of the analysis.  
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For example, a recent analysis by Vos and colleagues—which incorporated the 
epidemiological models developed as part of the case study—indicates that it may be cost-
effective from the perspective of the health system to focus on a limited set of interventions 
such as a 10% tax on unhealthy food, laparoscopic gastric banding for those who are severely 
obese, and diet and exercise interventions targeting overweight and obese people in primary 
care settings.190 However, this analysis does not account for the potential loss of individual 
utility resulting from, for example, increasing the cost of unhealthy food even for people of 
healthy weight.191 More importantly, its scope is severely restricted by the paucity of credible 
evidence on effective obesity control, suggesting that more evaluation research is needed 
before such analyses become more widely accepted as useful inputs into policy development 
in this area.  
Perhaps the most important finding from the analysis therefore is that direct expenditure on 
T2DM will continue to grow in real terms irrespective of our efforts to curb obesity. This 
conclusion is consistent with the findings presented in Chapter 5, which illustrate that factors 
other than underlying population risk are important drivers of growth in health expenditure. 
That this is likely to be the case even if there were unlimited resources for tackling obesity 
suggests that a balanced policy response to T2DM as an emergent risk to health system 
sustainability would focus on both the epidemiological and technological drivers of growth in 
expenditure on this disease. 
Afterword 
While undertaking this analysis I discovered an error in the original PIF calculation that 
underpinned the diabetes trends in the case study, which arose from my misinterpretation of 
advice from Barendregt regarding the use of a spreadsheet-based integration function he had 
developed.192 This error had a marginal downward effect on all results relating to diabetes 
projections from that work, including those discussed in Parts II and III of this thesis and the 
case study report. It also has implications for a paper titled ‘Projecting the burden of diabetes 
                                                
190  Vos, T, Carter, R, Barendregt, J, Mihalopoulos, C, Veerman, J, Magnus, A, Cobiac, L, Bertram, M, Wallace, A 
and ACE–Prevention Team, Assessing Cost-Effectiveness in Prevention (ACE–Prevention): Final Report. , 
University of Queensland and Deakin University, Brisbane & Melbourne, 2010. 
191  I am indebted to Mr Paul McGuire for highlighting this particular limitation. 
192  Risk factor Integral, Version 2.0, Epigear, Brisbane, 2011, viewed 12 August 2011, 
http://www.epigear.com/index_files/risk_factor.html.  
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in Australia - what is the size of the matter?’193 in which we discuss the importance of 
transparency in epidemiological modelling, particularly in relation to projecting the 
prevalence of diabetes given the policy significance of this disease. Table 27 reproduces the 
original Table 1 of that paper but with updated prevalence estimates based on a correct 
implementation of Equation 20.  
Table 27: Summary of the different published projections of diabetes prevalence in Australia 
 Year 
Age-group 
(years) 
Number of 
people with 
diabetes 
(millions) 
Predicted 
prevalence of 
diabetes (%) 
Sicree et al.194 2025 20–79 1.3 7.7 
Magliano et al.195     
Static incidence and 
mortality rates(a) 
2025 ≥25 2.0 11.4 
Dynamic incidence and 
mortality rates(b) 
2025 ≥25 3.0 17.0(c) 
Begg et al.196(d) 2023 All ages 2.5 10.4 
Corrected Begg et al. 2023 All ages 2.5 10.1 
Notes: (a) Static diabetes incidence and mortality rates for 2005 applied until 2025; (b) Incidence of diabetes rises by 4% every year and mortality 
(for those with and without diabetes) falls by 2.2% each year; (c) The prevalence of diabetes across all ages would be approximately 12.%; (d) 
Increasing but incorrectly calculated incidence trends are applied until the year 2023. The miscalculation was based on my erroneous assumption 
that the change in the first integral in the numerator of Equation 20 would be equivalent to the entire equation because Barendregt’s integral 
function included the ability to specify a reference point on the exposure scale. 
                                                
193  Magliano, D, Peeters, A, Vos, T, Sicree, R, Shaw, J, Sindall, C, Haby, M, Begg, S and Zimmet, P, “Projecting 
the burden of diabetes in Australia - what is the size of the matter?”, Australian and New Zealand Journal of 
Public Health, 2009, vol. 33(6 ), pp. 540-3. 
194  Sicree, R, Shaw, J and Zimmet, P, “Diabetes and impaired glucose tolerance”, in Gan, D, ed., Diabetes Atlas, 
3rd ed, International Diabetes Federation, Brussels, 2006. 
195  Magliano, DJ, Shaw, JE, Shortreed, SM, Nusselder, WJ, Liew, D, Barr, EL, Zimmet, PZ and Peeters, A, 
“Lifetime risk and projected population prevalence of diabetes”, Diabetologia, 2008, vol. 51(12), pp. 2179-86. 
196  Begg, S, Vos, T, Barker, B, Stevenson, C, Stanley, L and Lopez, A, The burden of disease and injury in Australia, 
2003. 
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Chapter 9: Conclusions 
I began this thesis with the proposition that the ‘burden of disease’ methodology introduced 
by Murray and Lopez in the early 1990s represents a useful platform from which to develop 
insights into several broad trends in Australia, unprecedented growth in health over the last 
century and even faster growth in the cost of accommodating this social phenomenon. This 
argument was positioned in the context of growing concerns about the sustainability of 
publicly funded healthcare, both here and overseas. Strictly speaking, it is government 
spending on health where these concerns are most acute since there is little evidence that total 
spending on health (i.e. both public and private) is close to exceeding the opportunity cost of 
using these resources elsewhere. Such a distinction is important when considering 
sustainability from the perspective of health system reform, for example, but for the present 
purposes can be put to one side. 
I then asserted that the corollary of this proposition—the generally held perception that 
Murray and Lopez’s contributions have little to offer such debates—is unfounded. The 
portrayal of their contributions in the literature was offered as one explanation for such a 
perception, although the point was not developed except to note that these discussions tend to 
be dominated by theoretical rather than policy considerations. Of course other explanations 
also exist, such as the language of ‘burden of disease’, a term commonly attached to the word 
‘study’ to imply its application is a discrete exercise, and the tendency to conflate the 
framework with one particular metric, the disability adjusted life year (DALY). Uncritical 
acceptance of these and other characterisations are unlikely to have broadened the appeal of 
the underlying concepts, although for the present purposes this point too can be put to one 
side. 
More central to my overall argument was the view that in order for propositions one and two 
to achieve more general acceptance a thorough overhaul of ‘burden of disease’ practice might 
be in order. Underlying this idea was the proposition that the main elements of the framework 
are best understood as a series of transformative processes that ultimately depends on only a 
handful of parameters, all but one of which is epidemiological; from these few parameters all 
other parameters of interest can be derived. Another way of expressing this is to regard the 
framework as a collection of principles about the practice of comprehensive and internally 
consistent descriptive epidemiology, and the transformation of information so derived into a 
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DALY or a comparative risk assessment as a second order process. I illustrated the 
consequences of not implementing the framework in this way by drawing attention to 
practical considerations that have constrained the usefulness of a key process to the range of 
applications typically associated with ‘burden of disease’ studies.  
The most obvious and arguably most important application beyond this range is monitoring 
trends in population health on a routine and comprehensive basis. Given health accounts for 
over one-fifth of total public expenditure in Australia each year (or $84.8 billion in 2009-10), 
the argument for this being an accepted function of government on financial accountability 
grounds alone seems strong. Nevertheless, Australia’s current framework for monitoring 
population health (the National Health Performance Framework197) reflects an overwhelming 
preference for partial indicators of success and, more revealingly, lacks an accepted process 
for synthesising the large volumes of information routinely collected each year into answers 
to simple questions such as how healthy are Australians, is it the same for everyone, or where 
is the most opportunity for improvement?  
I then introduced a setting in which I could test these propositions, which presented itself in 
the form of a project undertaken by the University and Queensland in collaboration with the 
Australian Institute of Health and Welfare (AIHW). This project was commissioned by the 
Australian Government Department of Health and Ageing (DOHA) in early 2003 and had as 
one of its objectives facilitating the uptake of the framework on a routine basis by 
government agencies, such as AIHW and state and territory health departments. As such, I 
adopted simple program logic principles to assess an alternative implementation model with 
respect to both its range of outputs compared to what might be expected and its intended 
outcomes more broadly with respect to facilitating the use of the framework on a routine 
basis.  
The key conclusion to draw from the material presented in the preceding chapters is that, with 
respect to outputs, the implementation model developed for the case study, which owed its 
                                                
197  AIHW, National Health Performance Framework 2009, Canberra, 2009, viewed 12 August 2011, 
http://meteor.aihw.gov.au/content/index.phtml/itemId/392569. The Australian Health Ministers’ 
Conference (AHMC) noted a revised version of this framework in September 2009 and COAG agreed to 
around 100 indicators in response, the majority of which (72) relate to the health system performance 
domain; the remainder are split between the determinants of health and the health status domains (18 and 
10, respectively). The intent of the latter is guided by several high-level questions such as how healthy are 
Australians and is it the same for everyone, although the indicators agreed to by COAG in this group have a 
much more narrow focus and comprise of several very basic measures of mortality and the prevalence of 
specific health conditions. 
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origins to a model developed at WHO for the GBD 2000 project, allowed for a much greater 
range of analyses than was attempted in a previous implementation by AIHW. The specific 
areas where these benefits were observed included the ability disaggregate the primary results 
to potentially any geographic boundary of interest in Australia, the ability to fore- and back-
cast these results while preserving internal consistency between parameters, the ability to 
generate a complete set of alternative results for various groupings of Australia’s Indigenous 
population, and the ability to account for dependent and independent comorbidity in 
disability calculations.  
In addition, the analysis demonstrated that the approach expanded the range of secondary 
analyses regarded as feasible to areas not previously associated with ‘burden of disease’, such 
as health expenditure projections and causal decomposition analyses of health-adjusted life 
expectancy. The former analysis was subsequently used by the National Health and Hospital 
Reform Commission in its consideration of reform options for Australia's health system, 
demonstrating that the framework has practical applications beyond those first articulated by 
Murray and Lopez. 
When it comes to outcomes, however, the conclusions are more circumspect. Certainly, the 
material presented in the preceding chapter demonstrates that several state governments 
successfully implemented the model on at least one occasion each to update the original case 
study outputs relating to these jurisdictions to the year 2006. It also demonstrates that, at the 
time of writing, the model was still being used on a semi-routine basis by one state 
government to update outputs relating to this jurisdiction for the year 2007, and to generate 
new outputs for three groupings of Indigenous populations. Its use beyond these applications 
was only really limited by the absence of dedicated resources to undertake additional 
analyses and by the lack of a critical input, coded mortality data for years later than 2007.  
Yet even this more restricted outcome suggests the model has potential as the basis of a 
country-level population health monitoring system, both Australia and elsewhere. The cost of 
such a system has not been worked out in any detail here but is likely to be marginal 
compared to the amount already spent on a routine basis on collecting many of the primary 
data inputs. Moreover, the return on this type of investment in terms of more informed policy 
discourse is likely to be substantial considering there is no other comparable system for 
synthesising the range of existing partial indicators of health across its various domains. Parts 
II and III of this thesis illustrate just a few of the contemporary policy debates that could 
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potentially benefit from such a system, particularly if a range of outputs were to be made 
available on a regular basis. It is worth exploring in these final pages, therefore, the extent to 
which there exists an appetite within government for the type of monitoring system embodied 
by the objective outlined in the opening chapter. 
To answer this question I present in the discussion that follows a brief analysis of relevant 
events, based mainly on documentary evidence. While a much wider range of methods—such 
as structured key informant interviews, thematic analysis and discourse analysis—could also 
have been employed, a more rigorous qualitative approach was considered beyond the scope 
of these concluding remarks. 
With respect to overarching policy direction, there appears to be strong alignment between 
the strategic priorities of the Australian Health Ministers’ Advisory Council (AHMAC)—the 
peak forum for governments to discuss health matters in Australia—and comprehensive 
monitoring of the population health becoming a routine function of government. This is 
evident in an AHMAC document titled the National Health Information Management 
Principal Committee Strategic Work Plan 2007–08 to 2012–13 (hereafter, the NHIMPC 
Plan), which, as its name implies, is the current strategic blueprint for NHIMPC, one of a 
number of principal committees of AHMAC.198  
The NHIMPC Plan outlines four priorities areas for better health outcomes in Australia, one 
of which is to increase the visibility of emerging risks through targeted investment in health 
information.199 In broad terms, the intent appears to have been to identify strategies for 
enhancing the scope and coverage of our health information infrastructure through (amongst 
other things) better health outcomes monitoring. To this end, Objective 4.5 is to improve the 
coverage, quality, utilisation and coordination of public health information. Two pre-existing 
AHMAC documents are referred to as evidence of ongoing progress in this respect, one of 
which is titled the National Public Health Information Plan 2005.  
                                                
198  Formerly called the National Health Information Management Principal Committee, the National E-Health 
and Information Principal Committee (NEHIPC) is one of several principal committees that report to 
AHMAC, which in turn provides support to the Standing Council on Health (SCoH), the peak decision-
making body on health matters in this country. 
199  National E-Health and Information Principal Committee, National Health Information Management Principal 
Committee Strategic Work Plan 2007-08 to 2012-13, Australian Health Ministers’ Advisory Council, Canberra, 
2007, viewed 12 August 2011, http://www.ahmac.gov.au/NHIMPC_Strategic_Work_Plan.pdf. 
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The National Public Health Information Plan 2005 is noteworthy in the context of the present 
discussion because it lists as a key strategy for using public health information in Australia to 
its fullest the case study.200 However, this is not as clear a statement of support for the 
objective stated in the opening chapter as it first appears. The plan itself, for instance, is 
presented as a joint effort of the Australian Institute of Health and Welfare (AIHW) and the 
National Public Health Information Working Group (NPHIWG), and is referred to hereafter 
as the AIHW/NPHIWG Plan in recognition of the stakeholders responsible for its 
development. The previously mentioned NHIMPC Plan attributes responsibility for its 
implementation to the Public Health Information Development Group (PHIDG) not 
NPHIWG, presumably to accommodate a restructuring of AHMAC in the period between the 
two documents.  
PHIDG is made up of essentially the same group of stakeholders that constituted NPHIWG 
(that is, representatives of the Commonwealth, state and territory governments, and of 
AIHW). However, it has no formal reporting relationship to NEHIPC (unlike NPHIWG had) 
nor does its website acknowledge responsibility for the AIHW/NPHIWG Plan.201 Instead, 
PHIDG reports to the Australian Population Health Development Principal Committee 
(APHDPC)—a separate principal committee of AHMAC—and aligns itself with the 
principles and practices of the National Health Information Agreement (hereafter, the NHIA). 
The NHIA, in turn, refers (confusingly) to NPHIWG not PHIDG, but makes no reference to 
the AIHW/NPHIWG Plan.202 More confusingly, of the five terms of reference listed on 
APHDPC’s website, only one relates to information and this is in the context of strengthening 
health development infrastructure rather than health information infrastructure.203  
Thus it seems that NPHIWG’s vision with respect to the case study was overtaken by events 
following the introduction of new lines of reporting within AHMAC. This conclusion is 
consistent with there being no more recent plan than NPHIWG's for strengthening Australia's 
health information infrastructure, just as it is with PHIDG's confirmation that it has no 
                                                
200  See p. 22 of AIHW and NPHIWG, National Public Health Information Plan 2005 Australian Institute of Health 
and Welfare, Canberra, 2005, viewed 12 August 2011, http://www.aihw.gov.au/publication-
detail/?id=6442467796. 
201  Population Health Information Development Group (PHIDG), AIHW, Canberra, 2011, viewed 11 August 
2011, http://www.aihw.gov.au/phidg/. 
202  COAG, National Health Information Agreement 2004-10, AIHW, Canberra, 2004, viewed 12 August 2011, 
http://meteor.aihw.gov.au/content/index.phtml/itemId/182135. 
203  Australian Population Health Development Principal Committee, AHMAC, Canberra, 2011, viewed 12 
August 2011, http://www.ahmac.gov.au/site/membership.aspx. 
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intention of building on the roadmap established by its predecessor, despite NPHIWG’s 
expectation that the AIHW/NPHIWG Plan would be reviewed after three years.204 
In addition to legitimate questions about the relevance of these two documents in the context 
of current AHMAC structures, it is also doubtful whether they should be called strategic 
since even the first post-dated negotiations leading to the case study by several years. 
Similarly, there is nothing in the project documentation to suggest that the provision of 
funding by DOHA to the University was in any way related to an AHMAC decision. As such, 
it is reasonable to characterise the objective discussed in the opening chapter as the product 
of a bilateral agreement between the respective agencies to undertake work on behalf of other 
agencies, rather than as the outcome of a clear policy intent to develop a national health 
monitoring capacity, as determined through established intergovernmental governance 
arrnagements.  
Notwithstanding the obvious success of this less formal approach at attracting funding for the 
case study, it does not appear to have been sufficient to affect lasting change at the national 
level. While it is inappropriate to go into the details here, there are grounds for believing that 
the effect of not having a clearly articulate benefits realisation strategy was compounded, at 
least initially, by a public dispute between the University and the Australian Bureau of 
Statistics.205 Certainly, soon after this dispute DOHA rejected a University proposal to 
develop a dissemination platform for more disaggregated results than were available in the 
case study report. Similarly, AIHW was subsequently unsuccessful in securing ongoing 
funding from DOHA's base appropriation for related purposes.  
Less clear, however, is the role of either of these factors over the longer term. For example, in 
a paper to PHIDG dated 7 April 2008 South Australia expressed the need for more 
disaggregated and regular information from the case study than was available publicly at the 
time, and revealed a preference for nationalising this function on efficiency grounds. While 
the letter AHIW wrote to state and territory health department CEOs in response was 
ultimately successful in securing resources to address both the short-term information needs 
of this level of government, and those of AIHW in relation to its flagship publication 
                                                
204  Queensland’s representative to PHIDG (personal communication July 2011). 
205  See, for example, Hare, J, “Whistleblower stonewalled as uni ignores orders to respond”, The Australian, 30 
May 2012, p. 5; O'Keefe, B, “Hackers pick up UQ cash prize”, The Australian, 21 March 2007, p. 33; O'Keefe, 
B, “Stats all, folks, for hackers”, The Australian, 7 Feb 2007, p. 30. 
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Australia’s Health,206 it also created the opportunity for AIHW to observe to jurisdictional 
health CEOs, ‘the question of ongoing funding for burden of disease work remains’.  
A more strategic response to the problems articulated by South Australia presented itself in 
the form of a paper to PHIDG on 7 October 2009 by AHIW titled ‘Proposal for a National 
Monitoring Centre for Burden of Disease’. Based broadly on the views expressed at a public 
forum of state, territory and AIHW officials on 2 October 2009, this paper set out the 
business case and funding options for establishing a comprehensive national health 
monitoring capacity such as the one embodied in the objective discussed in the opening 
chapter. The minutes of PHIDG’s consideration of this agenda item indicate in-principle 
support for the idea and note its recommendation that AIHW redraft the proposal for 
consideration by PHIDG's parent committee, APHDPC.  
The available information indicates that the final submission was for $2.25 million over four 
years funded on an established cost sharing arrangement involving a 50% contribution from 
the Commonwealth (around $280,000 per year) and a contribution to the remainder from 
each state and territory on the basis of population share (from around $2,900 per year for NT 
to $95,000 per year for NSW). The proposal notes: 
This bid is unlikely to be agreed from the AHMAC cost-shared budget as it requires an on-going 
funding source. [However,] it would be feasible for all jurisdictions to agree to contribute their share 
outside the cost-shared budget… PHIDG jurisdictional members have expressed strong support for 
coordinated, ongoing work in BoD measures.  
It is surprising given this level of support for the establishment of a comprehensive national 
health monitoring capacity that not only was APHDPC unable to provide in-principle support 
for the idea, even subject to further discussions around funding, but between rejecting it in 
late 2009 and PHIDG’s next meeting in mid 2010 APHDPC asserted its own view of the role 
of ‘burden of disease’ in Australia by providing PHIDG with the following advice:  
APHDPC would like PHIDG to continue and meet as and when required, noting the main body of 
work being Burden of Disease (BoD). The APHDPC advised this will remain the case until the 
                                                
206  See Section 2.7 of AIHW, Australia's health 2010 : the twelfth biennial health report of the Australian Institute of 
Health and Welfare, Australian Institute of Health and Welfare, Canberra, 2010. 
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outcome of the National Preventive Health Agency (NPHA) is known, at which time it would be 
reviewed.207 
These views reveal much about the balance of power within AHMAC and attribute to PHIDG 
a more active involvement in the implementation aspects of the framework in Australia than, 
with the exception of comparative risk assessment—a secondary process with clear links to 
prevention—the evidence allows. For example, some state and territory PHIDG 
representatives had experience with comparative risk assessment or were involved in 
calculating population attributable fractions at the time. However, none was considering a 
review of the parameters underlying the model described in Chapter 2 or, more importantly, 
had the resources to do so even if they wanted to. 
At its next meeting PHIDG considered another paper by AIHW titled ‘Burden of disease 
business case development’, which reiterated the various funding options for the proposed 
national monitoring centre. However, the minutes of this meeting simply note that funding 
was no longer available from either the Commonwealth or AHMAC for such purposes. 
Furthermore, PHIDG’s Queensland representative is able to confirm that no alterative 
options—such as contributions from interested parties outside of AHMAC arrangements—
were discussed. 
In a further example of its longer-term aspirations, AIHW’s next move was to offer to 
PHIDG the services of one of its senior officers for a limited period to: 
1. Form a network of State/Territory/Commonwealth BoD personnel 
2. Develop a workplan for further development of the national core work, including classification of 
the way BoD can respond to key policy issues requiring measurement under the National 
Healthcare Agreement 
3. Prepare a bid for National Health and Medical Research Council (NHMRC) funding for the future 
work. 208 
This three-part strategy approach resulted in PHIDG establishing a working group 
comprising representatives from each state and territory health department, as well as from 
                                                
207  Minutes from 21-22 July 2010 meeting of PHIDG. 
208  Ibid. 
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DOHA and AIHW.209 Referred to as the National Burden of Disease Collaborative Network 
(NBoDCN), this group—of which I was a member as one of Queensland’s self-appointed 
representatives—was chaired by AIHW and met several times during the course of 2010 
primarily to assist AIHW in developing a plan for implementing the Murray and Lopez 
framework at a national level.  
The work plan that emerged from this process set out desirable outputs from the perspective 
of NBoDCN should further national work occur, and how these might inform contemporary 
policy debate. More importantly, it attempted to address a key issue for network members, 
how to obtain these outputs on a regular and sustainable basis. Given this outcome, the plan 
shared many characteristics with the implementation model outlined in Chapter 2. AIHW 
provided a final draft of the plan for consideration by the chair of PHIDG in early 2011.  
At the time of writing these conclusions in May 2012, PHIDG’s chair had not yet distributed 
to the rest of PHIDG the AIHW plan. Several reasons have been provided in response to my 
queries about this situation, illness soon after the work was completed being the most likely. 
It seems equally plausible, however, that, on executing its obligations to PHIDG, AHIW 
judged it unproductive to further pursue the matter through AHMAC forums on the basis of 
existing advice from DOHA that, while representing a useful statement of aspirations, the 
plan could nevertheless be construed as an attempt to re-prosecute APHDPC’s decision not to 
support ongoing, nationally coordinated work.210  
In any event, a retreat from trying to engage DOHA on these issues appears ultimately 
vindicated by advice from PHIDG in March 2012 that, as foreshadowed by APHDPC, a 
newly established Commonwealth body, the Australian National Preventive Health Agency 
(ANPHA), had begun discussing ‘the future of burden of disease’ in national forums. This 
was followed by advice from AIHW in April 2012 that the Commonwealth had 
commissioned two papers on ‘possible national burden of disease work’. AIHW intends 
preparing these papers—which are to focus on technical issues associated with secondary 
aspects of the framework such as population attributable fractions and disability weights—
with input from researchers involved in Murray and Lopez’s most recent global analysis. In 
                                                
209  In accordance with its undertaking to PHIDG AIHW also approached NHMRC. However, on the basis of 
advice that NHMRC submissions have, on average, around a 20% chance of success AIHW decided not to 
pursue this route.  
210  DOHA’s representative to NBoDCN (personal communication, January 2011) 
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separate advice, it appears that APHDPC has all but dissolved as a principal committee of 
AHMAC. 
It is too early at this stage to predict what priorities might emerge from these latest 
developments. Nevertheless, after two publicly funded national ‘burden of disease studies’ in 
Australia since Murray and Lopez coined the term in the early 1990s it is useful to reflect on 
how far we have come with respect to such activities in this country. Equally, it is important 
to be aware of the choices now available to us. If, as seems likely, we ultimately embark on a 
third ‘study’, we will be guilty of no worse than confirming the wisdom of past practices. If, 
on the other hand, we were to start using the Murray and Lopez framework as the basis for a 
comprehensive program of population health monitoring nationally, there is no reason why 
we could not realise practical opportunities from beyond this paradigm. As this thesis has 
attempted to illustrate, such an alternative is not only feasible but is also likely to have 
tangible benefits for health policy analysis and debate more broadly.  
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Appendix A: Summary of practical experience with the 
Murray and Lopez framework 
Population Baseline Project sponsor Terms of engagement 
Australia    
All states  1996 Australian Institute of Health & Welfare Epidemiologist, Victorian Department of 
Human Services 
All states 2003 Commonwealth Department of Health 
& Ageing 
Lecturer, University of Queensland 
All states  2003 Commonwealth Treasury Consultant 
All states  2003 UN Consultant 
All states 
(Indigenous) 
2003 National Health & Hospital Reform 
Commission 
In kind contribution 
All states  
(risk factors) 
2003 National Heart Foundation Consultant 
Victoria 1996 Victorian Department of Human 
Services 
Epidemiologist, Victorian Department of 
Human Services 
Victoria 2001 Victorian Department of Human 
Services 
In kind contribution 
WA 2006 WA Department of Health Consultant 
SA 2006 SA Department of Health Consultant 
NT 2003 NT Department of Health Consultant 
Queensland 2003  Queensland Health Lecturer, University of Queensland 
Queensland 2006 Queensland Health Consultant 
Queensland 
(Indigenous) 
2006 Queensland Aboriginal & Islander 
Health Council 
In kind contribution 
Queensland 2008 Queensland Health Director, Queensland Health 
NSW 2003  NSW Department of Health In kind contribution 
Thailand 1999 Ministry of Health Consultant 
USA 1996 Centers for Disease Control & 
Prevention 
Research Fellow, Harvard University 
Turkey 2000 Baskent University Consultant 
Malaysia 2005 Ministry of Health Consultant 
Singapore 2004 Ministry of Health Consultant 
World (injuries) 2000 World Health Organization Consultant 
World (stroke) 2000 World Health Organization Scientist, World Health Organization 
World n.a. World Health Organization Consultant 
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Appendix B: IPM subroutines 
The code below consists of the following Mata subroutines: mata_IPM_calc, which 
performs most of the calculations set out by Barendregt and colleagues,211 except duration; 
and mata_dur_calc, which performs the duration calculations. These routines are used by 
the Stata ado programs cohort-IPM, subpop-IPM and Indig-IPM, as indicated 
in Appendices C, D and E, respectively. 
real matrix mata_IPM_calc(real matrix i, real matrix r, real matrix f) 
{ 
 S=J(101,1,.) 
 C=J(101,1,.) 
 D=J(101,1,.) 
 PY=J(101,1,.) 
 c=J(101,1,.) 
 b=J(101,1,.) 
 l = i :+ f :+ r 
 q = sqrt(i :^2 :+ 2 :* i :* r :- 2 :* i :* f :+ r :^2 :+ 2 :* f :* r :+ f 
:^2) 
 w = exp(-1 :* (l :+ q) :/ 2) 
 v = exp(-1 :* (l :- q) :/ 2) 
 for (a=1;a<=101;a++) { 
  subS=(a==1 ? 1000 : S[a-1]) 
  subC=(a==1 ? 0 : C[a-1]) 
  subD=(a==1 ? 0 : D[a-1]) 
  S[a] =max((0,(q[a]==0 ? subS : (2 * (v[a] - w[a]) * (subS * (f[a] + 
r[a]) + subC * r[a]) + subS * (v[a] * (q[a] - l[a]) + w[a] * (q[a] + l[a]))) / (2 * 
q[a])))) 
  C[a] =max((0,(q[a]==0 ? subC : -1 * ((v[a] - w[a]) * (2 * ((f[a] + 
r[a]) * (subS + subC) - l[a] * subS) - subC * l[a]) - subC * q[a] * (v[a] + w[a])) 
/ (2 * q[a])))) 
      D[a] =max((0,(q[a]==0 ? subD : ((v[a] - w[a]) * (2 * f[a] * subC - 
l[a] * (subS + subC)) - q[a] * (subS + subC) * (v[a] + w[a]) + 2 * q[a] * (subS + 
subC + subD)) / (2 * q[a])))) 
      PY[a] = 0.5 * (subS + subC + S[a] + C[a]) 
      c[a] = 0.5 * ((subC + C[a]) / PY[a]) 
      b[a] = (D[a] - subD) / PY[a] 
 } 
 return(c,b) 
} 
 
real matrix mata_dur_calc(real matrix B, real matrix i) 
{ 
 Dur=J(101,1,0) 
 y=J(101,1,.) 
 x=J(101,1,.) 
 for (a=1;a <=101;a++) { 
  if (i[a]>0) { 
   if (exp(-i[a])~=1) { 
    if (B[a]==0) { 
     y[a]=1 
     x[a]=.5 
    } 
    else if (B[a]==i[a]) { 
     y[a]=i[a]*(exp(-i[a])/(1-exp(-i[a]))) 
                                                
211  Barendregt, JJ, Van Oortmarssen, GJ, Vos, T and Murray, CJ, “A generic model for the assessment of disease 
epidemiology: the computational basis of DisMod II”. 
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     x[a]=1/B[a]-1/(exp(B[a])-1) 
    } 
    else { 
     temp=(exp(-B[a])-exp(-i[a]))/(1-exp(-i[a])) 
     y[a]=(i[a]/(i[a]-B[a]))*temp 
     x[a]=1/B[a]-(i[a]/((i[a]-B[a])*B[a]))*temp 
    } 
    for (k=a+1;k <=100;k++) { 
     if (B[k]==0) { 
      y[k]=y[k-1] 
      x[k]=x[k-1] 
     } 
     else { 
      y[k]=y[k-1]*exp(-B[k]) 
      x[k]=(y[k-1]/B[k])*(1-exp(-B[k])) 
     } 
    } 
    if (B[a]==0) { 
     if (a==101) x[101]=1000 
     else x[101]=y[100]*1000 
    } 
    else { 
     if (a==101) x[101]=1/B[101] 
     else x[101]=y[100]/B[101] 
    } 
    for (k=a;k <=101;k++) { 
     Dur[a]=Dur[a]+x[k] 
    } 
   } 
  } 
 } 
 return(Dur) 
}  
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Appendix C: Cohort-IPM routine 
The Stata ado program cohort-IPM is a ‘wrapping’ routine that calls the Mata subroutine 
mata_cohort-IPM, which, in turn, executes mata_IPM_calc and mata_dur_calc 
for each age cohort as it ages over time. Instructions on how to use cohort-IPM are 
provided in Chapter 2. The code for mata_IPM_calc and mata_dur_calc is included 
at Appendix B. 
program define cohort-IPM, byable(recall)  
 version 9.1 
 syntax  varname(numeric) using/ [if],  Sex(varname numeric ) Inc(varname 
numeric) Cf(varname numeric) Rem(varname numeric) [Lag(varname numeric)] 
[Year(varname numeric)] 
 marksample touse 
 local index=_byindex() 
 quietly if `index'==1 { 
  local allvars "`_byvars'  `sex' `varlist' `year'" 
  global allvars : list uniq allvars 
  global reshapevars : list allvars - year 
  global hazvars "`inc' `cf' `rem'" 
  cap confirm var `varlist'  
  cap bysort `_byvars' `varlist' `sex' `year': assert _N==1 
  if _rc~=0 { 
   di in red "the variables $allvars do not uniquely identify the 
data" 
   error 1 
  } 
  assert inlist(sex,1,2) 
  cap gen _prev=. 
  cap gen _dur=. 
  mata: mata matuse "`using'", replace 
  mata: st_matrix("pop_m",pop_m) 
  mata: st_matrix("pop_f",pop_f) 
  mata: st_matrix("mort_m",mort_m) 
  mata: st_matrix("mort_f",mort_f) 
 } 
 quietly sum `sex' if `touse' 
 local sexval=r(max) 
 if `sexval'==1{ 
  local mort "mort_m" 
  local pop "pop_m" 
 } 
 else { 
  local mort "mort_f" 
  local pop "pop_f" 
 } 
 if "`lag'"~="" { 
  quietly sum `lag' if `touse' 
  local lagflag=r(max)>0 
 } 
 else local lagflag=0 
 mata: mata_cohort-IPM("`1'","`inc'","`rem'","`cf'","`lag'", 
`lagflag',"`year'") 
end  
 
version 9.1 
mata: 
mata clear 
void mata_cohort-IPM(string scalar agecat,string scalar inc,string scalar rem, 
string scalar cf,string scalar lag,numeric scalar lagflag, string scalar year) 
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{ 
 tM=st_matrix(st_local("mort")) 
 pop=st_matrix(st_local("pop")) 
 st_view(data_in,.,(agecat,year,inc,cf,rem),st_local("touse")) 
 agecat=uniqrows(data_in[.,1]) 
 agerows=rows(agecat) 
 i=rowshape(data_in[.,3],agerows) 
 f=rowshape(data_in[.,4],agerows) 
 r=rowshape(data_in[.,5],agerows) 
 years=cols(i) 
 for (k=1;k<=agerows;k++) { 
  thisage=agecat[k] 
  nextage=(k==agerows ? 101 : agecat[k+1]) 
  mult=J(nextage-thisage,years,1) 
  trend_i=(k==1 ? mult :* i[k,.] : trend_i\mult :* i[k,.]) 
  trend_f=(k==1 ? mult :* f[k,.] : trend_f\mult :* f[k,.]) 
  trend_r=(k==1 ? mult :* r[k,.] : trend_r\mult :* r[k,.]) 
 } 
 for (k=1;k<=years+100;k++) { 
  row1=max((102-k,1)) 
  col1=max((1,k-100)) 
  col2=min((k,years)) 
  row2=row1+(col2-col1) 
  i=diagonal(trend_i[|row1,col1\row2,col2|]) 
  f=diagonal(trend_f[|row1,col1\row2,col2|]) 
  r=diagonal(trend_r[|row1,col1\row2,col2|]) 
  if (row1-1>=1) { 
   i=trend_i[|1,1\(row1-1),1|]\i 
   f=trend_f[|1,1\(row1-1),1|]\f 
   r=trend_r[|1,1\(row1-1),1|]\r 
  } 
  if (row2+1<=101) { 
   i=i\trend_i[|(row2+1),years\.,years|] 
   f=f\trend_f[|(row2+1),years\.,years|] 
   r=r\trend_r[|(row2+1),years\.,years|] 
  } 
 
  IPM_calc=mata_IPM_calc(i,r,f) 
 
  trend_c=(k==1 ? IPM_calc[.,1] : trend_c,IPM_calc[.,1]) 
  trend_b=(k==1 ? IPM_calc[.,2] : trend_b,IPM_calc[.,2]) 
  trend_f1=(k==1 ? f : trend_f1,f) 
  trend_r1=(k==1 ? r : trend_r1,r) 
  trend_i1=(k==1 ? i : trend_i1,i) 
 } 
 trend_c=trend_c[(101::1),.] 
 trend_b=trend_b[(101::1),.] 
 trend_f1=trend_f1[(101::1),.] 
 trend_r1=trend_r1[(101::1),.] 
 trend_i1=trend_i1[(101::1),.] 
 for (k=1;k<=years;k++) { 
  c1=diagonal(trend_c[|1,k\.,.|])[(101::1),.] 
  b1=diagonal(trend_b[|1,k\.,.|])[(101::1),.] 
  f1=diagonal(trend_f1[|1,k\.,.|])[(101::1),.] 
  r1=diagonal(trend_r1[|1,k\.,.|])[(101::1),.] 
  i1=diagonal(trend_i1[|1,k\.,.|])[(101::1),.] 
 
  B = r1 :+ f1 :+ (tM[.,k] :- b1) 
  d1=mata_dur_calc(B,i1) 
  i_num=i1:*pop[.,k] 
  for (a=1;a<=agerows;a++) { 
   thisage=agecat[a] 
   nextage=(a==agerows ? 101 : agecat[a+1]) 
   temp=sum(c1[|thisage+1\nextage|] :* 
pop[|thisage+1,k\nextage,k|]) / sum(pop[|thisage+1,k\nextage,k|] ) 
   c2=(a==1 ? (a,k,temp) : c2\(a,k,temp)) 
   temp=(sum(i_num[|thisage+1\nextage|] )==0 ? 0 : 
sum(d1[|thisage+1\nextage|] :* i_num[|thisage+1\nextage|]) / 
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sum(i_num[|thisage+1\nextage|] )) 
   d2=(a==1 ? (a,k,temp) : d2\(a,k,temp)) 
  } 
  c3=(k==1 ? c2: c3\c2) 
  d3=(k==1 ? d2: d3\d2) 
 } 
 _sort(c3,(1,2)) 
 _sort(d3,(1,2)) 
 st_store(.,"_prev",st_local("touse"),c3[.,3]) 
 st_store(.,"_dur",st_local("touse"),d3[.,3]) 
}  
end  
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Appendix D: Subpop-IPM routine 
The Stata ado program subpop-IPM is a ‘wrapping’ routine that calls the Mata subroutine 
mata_subpop-IPM, which, in turn, executes mata_IPM_calc and mata_dur_calc 
for 15 subpopulations stratified by three remoteness categories (major cities, regional areas 
and remote areas) and five socioeconomic quintiles. Instructions on how to use subpop-
IPM are provided in Chapter 2. The code for mata_IPM_calc and mata_dur_calc is 
included at Appendix B. 
program define subpop-IPM, byable(recall, noheader)  
 version 9.1 
 syntax  varname(numeric) using/ [if],  Sex(varname) Inc(varname numeric) 
Cf(varname numeric) Rem(varname numeric) Subpopulation(varlist numeric) 
 tokenize `varlist' 
 local age `1' 
 marksample touse 
 local index=_byindex() 
 local firstcase=_byn1() 
 quietly if `index'==1 { 
  cap gen _prev=. 
  cap gen _dur=. 
  mata: mata matuse "`using'", replace 
  mata: st_matrix("pop_m_1_1",pop_m_1_1) 
  mata: st_matrix("pop_m_2_1",pop_m_2_1) 
  mata: st_matrix("pop_m_3_1",pop_m_3_1) 
  mata: st_matrix("pop_m_4_1",pop_m_4_1) 
  mata: st_matrix("pop_m_5_1",pop_m_5_1) 
  mata: st_matrix("pop_m_1_2",pop_m_1_2) 
  mata: st_matrix("pop_m_2_2",pop_m_2_2) 
  mata: st_matrix("pop_m_3_2",pop_m_3_2) 
  mata: st_matrix("pop_m_4_2",pop_m_4_2) 
  mata: st_matrix("pop_m_5_2",pop_m_5_2) 
  mata: st_matrix("pop_m_1_3",pop_m_1_3) 
  mata: st_matrix("pop_m_2_3",pop_m_2_3) 
  mata: st_matrix("pop_m_3_3",pop_m_3_3) 
  mata: st_matrix("pop_m_4_3",pop_m_4_3) 
  mata: st_matrix("pop_m_5_3",pop_m_5_3) 
  mata: st_matrix("pop_f_1_1",pop_f_1_1) 
  mata: st_matrix("pop_f_2_1",pop_f_2_1) 
  mata: st_matrix("pop_f_3_1",pop_f_3_1) 
  mata: st_matrix("pop_f_4_1",pop_f_4_1) 
  mata: st_matrix("pop_f_5_1",pop_f_5_1) 
  mata: st_matrix("pop_f_1_2",pop_f_1_2) 
  mata: st_matrix("pop_f_2_2",pop_f_2_2) 
  mata: st_matrix("pop_f_3_2",pop_f_3_2) 
  mata: st_matrix("pop_f_4_2",pop_f_4_2) 
  mata: st_matrix("pop_f_5_2",pop_f_5_2) 
  mata: st_matrix("pop_f_1_3",pop_f_1_3) 
  mata: st_matrix("pop_f_2_3",pop_f_2_3) 
  mata: st_matrix("pop_f_3_3",pop_f_3_3) 
  mata: st_matrix("pop_f_4_3",pop_f_4_3) 
  mata: st_matrix("pop_f_5_3",pop_f_5_3) 
  mata: st_matrix("mort_m_1_1",mort_m_1_1) 
  mata: st_matrix("mort_m_2_1",mort_m_2_1) 
  mata: st_matrix("mort_m_3_1",mort_m_3_1) 
  mata: st_matrix("mort_m_4_1",mort_m_4_1) 
  mata: st_matrix("mort_m_5_1",mort_m_5_1) 
  mata: st_matrix("mort_m_1_2",mort_m_1_2) 
  mata: st_matrix("mort_m_2_2",mort_m_2_2) 
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  mata: st_matrix("mort_m_3_2",mort_m_3_2) 
  mata: st_matrix("mort_m_4_2",mort_m_4_2) 
  mata: st_matrix("mort_m_5_2",mort_m_5_2) 
  mata: st_matrix("mort_m_1_3",mort_m_1_3) 
  mata: st_matrix("mort_m_2_3",mort_m_2_3) 
  mata: st_matrix("mort_m_3_3",mort_m_3_3) 
  mata: st_matrix("mort_m_4_3",mort_m_4_3) 
  mata: st_matrix("mort_m_5_3",mort_m_5_3) 
  mata: st_matrix("mort_f_1_1",mort_f_1_1) 
  mata: st_matrix("mort_f_2_1",mort_f_2_1) 
  mata: st_matrix("mort_f_3_1",mort_f_3_1) 
  mata: st_matrix("mort_f_4_1",mort_f_4_1) 
  mata: st_matrix("mort_f_5_1",mort_f_5_1) 
  mata: st_matrix("mort_f_1_2",mort_f_1_2) 
  mata: st_matrix("mort_f_2_2",mort_f_2_2) 
  mata: st_matrix("mort_f_3_2",mort_f_3_2) 
  mata: st_matrix("mort_f_4_2",mort_f_4_2) 
  mata: st_matrix("mort_f_5_2",mort_f_5_2) 
  mata: st_matrix("mort_f_1_3",mort_f_1_3) 
  mata: st_matrix("mort_f_2_3",mort_f_2_3) 
  mata: st_matrix("mort_f_3_3",mort_f_3_3) 
  mata: st_matrix("mort_f_4_3",mort_f_4_3) 
  mata: st_matrix("mort_f_5_3",mort_f_5_3) 
 } 
 tokenize `subpopulation' 
 local seifaval=`1'[`firstcase'] 
 local remoteval=`2'[`firstcase'] 
 local sexval=`sex'[`firstcase'] 
 if `sexval'==1{ 
  local mort "mort_m_`seifaval'_`remoteval'" 
  local pop "pop_m_`seifaval'_`remoteval'" 
 } 
 else { 
  local mort "mort_f_`seifaval'_`remoteval'" 
  local pop "pop_f_`seifaval'_`remoteval'" 
 } 
 mata: mata_subpop-IPM("`age'","`inc'","`rem'","`cf'") 
end  
 
version 9.1 
mata: 
mata clear 
void mata_subpop-IPM(string scalar agecat,string scalar inc,string scalar rem, 
string scalar cf) 
{ 
 tM=st_matrix(st_local("mort")) 
 pop=st_matrix(st_local("pop")) 
 st_view(age_in,.,agecat,st_local("touse")) 
 st_view(i_in,.,inc,st_local("touse")) 
 st_view(f_in,.,cf,st_local("touse")) 
 st_view(r_in,.,rem,st_local("touse")) 
 agerows=rows(age_in) 
 age=(0::100) 
 i=J(101,1,0) 
 f=J(101,1,0) 
 r=J(101,1,0) 
 for (a=age_in[agerows]+1;a<=101;a++) { 
   i[a]=i_in[agerows] 
   f[a]=f_in[agerows] 
   r[a]=r_in[agerows] 
 } 
 for (k=1;k<=agerows-1;k++) { 
  for (a=age_in[k]+1;a<=age_in[k+1];a++) { 
   i[a]=i_in[k] 
   f[a]=f_in[k] 
   r[a]=r_in[k] 
  } 
 } 
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 IPM_calc=mata_IPM_calc(i,r,f) 
 c= IPM_calc[.,1] 
 B = r :+ f :+ (tM :- IPM_calc[.,2]) 
 Dur=mata_dur_calc(B,i) 
 i_num=i:*pop 
 for (a=1;a<=agerows;a++) { 
  temp=sum(c[|age_in[a]+1\(a==agerows ? 101 : age_in[a+1])|] :* 
pop[|age_in[a]+1\(a==agerows ? 101 : age_in[a+1])|]) / 
sum(pop[|age_in[a]+1\(a==agerows ? 101 : age_in[a+1])|] ) 
  c_out=(a==1 ? temp : c_out\temp) 
  temp=(sum(i_num[|age_in[a]+1\(a==agerows ? 101 : age_in[a+1])|] )==0 ? 
0 : sum(Dur[|age_in[a]+1\(a==agerows ? 101 : age_in[a+1])|] :* 
i_num[|age_in[a]+1\(a==agerows ? 101 : age_in[a+1])|]) / 
sum(i_num[|age_in[a]+1\(a==agerows ? 101 : age_in[a+1])|] )) 
  Dur_out=(a==1 ? temp : Dur_out\temp) 
 } 
 st_store(.,"_prev",st_local("touse"),c_out) 
 st_store(.,"_dur",st_local("touse"),Dur_out) 
} 
end  
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Appendix E: Indig-IPM routine 
The Stata ado program Indig-IPM is a ‘wrapping’ routine that calls the Mata subroutine 
mata_Indig-IPM, which, in turn, executes mata_IPM_calc and mata_dur_calc 
for each of two Indigenous populations (major cities and regional areas combined, and 
remote areas). Instructions on how to use Indig-IPM are provided in Chapter 2. The code 
for mata_IPM_calc and mata_dur_calc is included at Appendix B. 
program define Indig-IPM, byable(recall, noheader)  
 version 9.1 
 syntax  varname(numeric) using/ [if],  Sex(varname) Inc(varname numeric) 
Cf(varname numeric) Rem(varname numeric) Remote(varlist numeric) 
 tokenize `varlist' 
 local age `1' 
 marksample touse 
 local index=_byindex() 
 local firstcase=_byn1() 
 quietly if `index'==1 { 
  cap gen _prev=. 
  cap gen _dur=. 
  mata: mata matuse "`using'", replace 
  mata: st_matrix("pop_m_1",pop_m_1) 
  mata: st_matrix("pop_m_2",pop_m_2) 
  mata: st_matrix("pop_f_1",pop_f_1) 
  mata: st_matrix("pop_f_2",pop_f_2) 
  mata: st_matrix("mort_m_1",mort_m_1) 
  mata: st_matrix("mort_m_2",mort_m_2) 
  mata: st_matrix("mort_f_1",mort_f_1) 
  mata: st_matrix("mort_f_2",mort_f_2) 
 } 
 local remoteval=`remote'[`firstcase'] 
 local sexval=`sex'[`firstcase'] 
 if `sexval'==1{ 
  local mort "mort_m_`remoteval'" 
  local pop "pop_m_`remoteval'" 
 } 
 else { 
  local mort "mort_f_`remoteval'" 
  local pop "pop_f_`remoteval'" 
 } 
 mata: mata_Indig-IPM("`age'","`inc'","`rem'","`cf'") 
end  
 
version 9.1 
mata: 
mata clear 
void mata_Indig-IPM(string scalar agecat,string scalar inc,string scalar rem, 
string scalar cf) 
{ 
 tM=st_matrix(st_local("mort")) 
 pop=st_matrix(st_local("pop")) 
 st_view(age_in,.,agecat,st_local("touse")) 
 st_view(i_in,.,inc,st_local("touse")) 
 st_view(f_in,.,cf,st_local("touse")) 
 st_view(r_in,.,rem,st_local("touse")) 
 agerows=rows(age_in) 
 age=(0::85) 
 i=J(86,1,0) 
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 f=J(86,1,0) 
 r=J(86,1,0) 
 for (a=age_in[agerows]+1;a<=86;a++) { 
   i[a]=i_in[agerows] 
   f[a]=f_in[agerows] 
   r[a]=r_in[agerows] 
 } 
 for (k=1;k<=agerows-1;k++) { 
  for (a=age_in[k]+1;a<=age_in[k+1];a++) { 
   i[a]=i_in[k] 
   f[a]=f_in[k] 
   r[a]=r_in[k] 
  } 
 } 
 dismod_calc=mata_dismod_calc(i,r,f) 
 c= dismod_calc[.,1] 
 B = r :+ f :+ (tM :- dismod_calc[.,2]) 
 Dur=mata_dur_calc(B,i) 
 i_num=i:*pop 
 for (a=1;a<=agerows;a++) { 
  temp=sum(c[|age_in[a]+1\(a==agerows ? 86 : age_in[a+1])|] :* 
pop[|age_in[a]+1\(a==agerows ? 86 : age_in[a+1])|]) / 
sum(pop[|age_in[a]+1\(a==agerows ? 86 : age_in[a+1])|] ) 
  c_out=(a==1 ? temp : c_out\temp) 
  temp=(sum(i_num[|age_in[a]+1\(a==agerows ? 86 : age_in[a+1])|] )==0 ? 
0 : sum(Dur[|age_in[a]+1\(a==agerows ? 86 : age_in[a+1])|] :* 
i_num[|age_in[a]+1\(a==agerows ? 86 : age_in[a+1])|]) / 
sum(i_num[|age_in[a]+1\(a==agerows ? 86 : age_in[a+1])|] )) 
  Dur_out=(a==1 ? temp : Dur_out\temp) 
 } 
 st_store(.,"_prev",st_local("touse"),c_out) 
 st_store(.,"_dur",st_local("touse"),Dur_out) 
} 
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Appendix F: Comorbidity routines 
The set of routines below implement the comorbidity correction principles outlined in 
Chapter 2. 
Prepare data 
local group1="A B C D E" 
local group2="F G H I J K L M N O P Q R S Z" 
local group3="T U" 
local files=`""NHS2001 Comorbidity" "SDAC2003 COMORBIDITY" "MHS1997 Comorbidity" 
"AusDiab Comorbidity""' 
quietly foreach file of local files  { 
 odbc load, table("`file'") clear 
 if "`file'"=="NHS2001 Comorbidity" drop J* H?? 
 if "`file'"=="SDAC2003 COMORBIDITY" drop J02-J04 ZILL INJURIES-XN33_DIS 
 rename AGE agecat 
 rename SEX sex 
 foreach var of varlist * { 
  if inlist("`var'","sex","agecat","TOTAL") continue 
  local firstchar=substr("`var'",1,1) 
  forvalues x=1/3{ 
   local groupflag : list firstchar in group`x' 
   if `groupflag'==1 local group=`x' 
  } 
  gen v`var'=`var'==1 
 } 
 recode agecat 75/100=75 
 tokenize "`file'" 
 aorder 
 collapse (sum) total`1'=TOTAL if inrange(agecat,25,75), by(sex agecat v*) 
 save "`1'", replace 
 noisily des 
} 
tempfile data 
local files="NHS2001 SDAC2003 MHS1997 AusDiab" 
quietly foreach file of local files  { 
 use `file', clear 
 gen source="`file'" 
 cap append using `data' 
 save `data', replace 
} 
egen total=rsum(total*) 
save "Combined comorbidity data", replace 
Run simulations 
tempfile sexage sourcedata sequence combined  
use "Combined comorbidity data", clear 
save `combined' 
collapse (sum) total, by(sex age) 
egen double prob=pc(total), prop 
replace prob=prob+prob[_n-1] if _n~=1 
gen count=_n 
save `sexage' 
mkmat  sex agecat prob, matrix(sexage) 
 
use "Combined comorbidity data", clear 
collapse (count) v*, by(age sex source) 
save `sourcedata' 
collapse (count) v*, by(source) 
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reshape long v, i(source) j(cause) string 
levelsof cause, local(allvars) clean 
 
file open hndl using c:\temp\simulations.txt, write text replace 
file write hndl "sex" _tab "age" _tab 
foreach var of local allvars { 
 file write hndl "`var'"  
 if "`ferest()'"~="" file write hndl _tab 
} 
local starttime= c(current_time) 
file write hndl _newline 
quietly forvalues z=1/1000000 { 
 noisily di `z' 
 use `sexage', clear 
 local rnd=uniform() 
 sum count if prob>`rnd' 
 local row=r(min) 
 local sex=sex[`row'] 
 local age=age[`row'] 
 file write hndl "`sex'" _tab "`age'" _tab 
 use `sourcedata' if sex==`sex' & age==`age', clear 
 gen sourceorder=uniform() 
 sort sourceorder 
 replace sourceorder=_n 
 reshape long v, i(age sex source) j(cause) string 
 reshape wide v sourceorder, i(age sex cause) j(source) string 
 gen order=uniform() 
 sort order 
 replace order=_n 
 local maxorder=_N 
 reshape long 
 keep if v~=0  
 sort age sex source order 
 by age sex source: gen count=_n 
 sort age sex order count sourceorder 
 by age sex order : gen max= _n==_N 
 save `sequence', replace 
 macro drop outcome* 
 forvalues x=1/`maxorder'  {  
  use `sequence', clear 
  levelsof source if order==`x' & max==1, local(source) clean 
  levelsof order if order==`x' & max==1, local(order) clean 
  levelsof cause if order==`x' & max==1, local(targetvar) clean 
  local conditionalvars="" 
  cap levelsof cause if source=="`source'" & order<=`order' & 
cause~="`targetvar'", local(conditionalvars) clean 
  use `combined' if sex==`sex' & age==`age' & source=="`source'", clear 
  renpfix v  
  foreach conditionalvar of local conditionalvars { 
   count if `conditionalvar'==`outcome`conditionalvar'' 
   if r(N)~=0 { 
    keep if `conditionalvar'==`outcome`conditionalvar'' 
   } 
  } 
  collapse (sum) total,by(`targetvar') 
  egen prob=pc(total), prop 
  replace prob=prob+prob[_n-1] if _n~=1 
  local rnd=uniform() 
  sum `targetvar' if prob>`rnd' 
  local outcome`targetvar'= r(min) 
 } 
 foreach var of local allvars { 
  file write hndl "`outcome`var''"  
  if "`ferest()'"~="" file write hndl _tab 
 } 
 file write hndl _newline 
} 
local endtime= c(current_time) 
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file close hndl  
noisily di "Start time: `starttime' End time: `endtime'" 
} 
insheet using "simulations.txt", clear 
foreach var of varlist a-z02 { 
 local varname=upper("`var'") 
 rename `var' flag`varname' 
} 
rename age agecat 
contract sex age flag*, freq(num) 
egen prev=pc(num), by(sex age) prop 
save "simulations", replace 
Create adjustment factors 
 
use "s:\bod\aus trends\Epi by bodicode, seq, sex, age 1979 to 2033" if year==2003, 
clear 
keep bodicode seq sex agecat dw _prev3 pop comorbid_code inc  
tempfile dw 
save `dw' 
replace _prev3=_prev3*pop 
drop if comorb=="XXXX" 
rename bodicode code 
bysort code seq sex (agecat): replace dw=dw[_n-1] if _n>1 & dw[_n]==0 & dw[_n-1]>0 
& dw[_n-1]<=1 
gsort code seq sex -agecat 
by code seq sex : replace dw=dw[_n-1] if _n>1 & dw[_n]==0 & dw[_n-1]>0 & dw[_n-
1]<=1 
assert dw>0 if inc>0  
collapse (mean) dw [iw=_prev3] if ~missing(comorbid), by(comorbid_code sex agecat) 
reshape wide dw , i(sex age) j(comorbid_code ) string  
tempfile data 
save `data' 
 
use "simulations", clear 
merge sex age using `data', nokeep 
drop _* 
foreach var of varlist flag* { 
 local cause=subinstr("`var'","flag","",1) 
 cap sum dw`cause' 
 if _rc~=0 { 
  di in red "`cause'" 
  drop `var'  
 } 
} 
 
gen total_unadj_dw=0 
gen combined_dw=1 
foreach var of varlist flag* { 
 local cause=subinstr("`var'","flag","",1) 
 replace dw`cause'=cond(`var'==0,.,dw`cause') 
 replace combined_dw=combined_dw*(1-cond(missing(dw`cause'),0,dw`cause')) 
 replace total_unadj_dw=total_unadj_dw+cond(missing(dw`cause'),0,dw`cause') 
} 
replace combined_dw=1-combined_dw 
 
foreach var of varlist flag* { 
 local cause=subinstr("`var'","flag","dw",1) 
 gen orig_`cause'=`cause' 
 replace `cause'=(`cause'/total_unadj_dw)*combined_dw 
} 
collapse (mean) dw* (max) orig* [iw=prev], by(sex age) fast 
reshape long dw orig_dw, i(sex age) j(cause) string 
gen AdjFact=dw/orig 
sort cause sex age 
tempfile factors 
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save `factors' 
 
contract cause 
levelsof cause, local(causes) 
local N=_N+1 
set obs `N' 
replace cause="XXXX" if missing(cause) 
drop _f 
tempfile data1 data2 
save `data1' 
foreach sex of numlist 1 2 { 
 foreach age of numlist 0 1 5(5)100{ 
  use `data1', clear 
  gen sex=`sex' 
  gen agecat=`age' 
  cap append using `data2' 
  save `data2', replace 
 } 
} 
gen nage=age   
replace age=75 if age>75 
sort cause sex age 
merge cause sex age using `factors' 
replace age=nage 
tab _m 
drop _m 
 
xi i.sex 
gen PredAdjFact=1 
gen lnAdj=logit(Adj) if ~(cause=="K01" & agecat<50) 
bysort cause sex (agecat): gen 
age_at_onset=cond(_n==_N,102.5,(agecat[_n]+agecat[_n+1])/2) 
 
quietly foreach cause of local causes { 
noisily di in green "`cause'"  
 cap reg lnAdj age_at _Isex_2 if cause=="`cause'" 
 if _rc==0{ 
  tempvar temp 
  predict `temp' 
  replace PredAdjFact=invlogit(`temp') if cause=="`cause'" 
 } 
 else di in red "`cause'"  
} 
replace AdjFact =. if agecat>75 
rename cause comorbid_code 
keep comorbid_code sex agecat PredAdjFact  
joinby comorbid_code sex agecat using `dw' 
gen adjdw= PredAdjFact*dw 
keep  bodicode seq sex agecat adjdw 
reshape wide adjdw, i(bodicode seq sex) j(agecat) 
save "Comorbidity adjustment factors", replace 
Apply adjustment factors to epidemiological data 
quietly { 
use year bodicode seq sex agecat _inc _prev3 _dur3 _dur1 seqlagflag pop lag 
time_symptomatic duration dw comorbid_code /* 
 */ using "Epi by bodicode, seq, sex, age 1979 to 2033" if 
inlist(year,1993,2003,2013,2023), clear 
sort bodicode seq sex 
merge bodicode seq sex using "Comorbidity adjustment factors", nokeep 
assert _m==3 
drop _m 
rename bodicode code 
 
rename lag _lag 
rename duration _duration 
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rename dw _dw 
 
gen lag=cond(seqlagflag==1,_dur1,0) 
rename _prev3 prev 
rename _dur3 duration 
rename _inc inc 
bysort year code seq sex (agecat): gen 
age_at_onset=cond(_n==_N,102.5,(agecat[_n]+agecat[_n+1])/2) 
local DisRate=.03 
cap drop low hi dis_dur_* check* yld* 
gen low=age_at_onset+lag 
gen hi=age_at_onset+duration+lag 
gen yld=0 
gen lagcur_age=0 
 
foreach cur_agecat of numlist 0 1 5(5)100 135{ 
 if "`ferest()'"~=""{ 
  tokenize "`ferest()'" 
  gen dur_`cur_agecat'=cond(`cur_agecat'<=hi & `1'>=low,min(`1',hi)-
max(`cur_agecat',low),0) 
  replace lagcur_age=cond(`cur_agecat'<=hi & 
`1'>=low,max(`cur_agecat',low)-age_at_onset,0) 
  replace yld=yld+adjdw`cur_agecat'*time_symptomatic* /* 
   */ (1/`DisRate'*(exp(-`DisRate'*lagcur_age)-exp(-
`DisRate'*(lagcur_age+ dur_`cur_agecat')))) 
 } 
} 
drop dur_*  
foreach cur_agecat of numlist 0 1 5(5)100{ 
 gen pyld_`cur_agecat'=adjdw`cur_agecat'*time_symptomatic*prev*pop if 
agecat==`cur_agecat' 
 gen prev_`cur_agecat'=pop*prev if agecat==`cur_agecat' 
 gen yld_`cur_agecat'=inc*pop*yld if agecat==`cur_agecat' 
 gen inc_`cur_agecat'=inc*pop if agecat==`cur_agecat' 
 gen pop_`cur_agecat'=pop if agecat==`cur_agecat' 
 gen dur_`cur_agecat'=duration if agecat==`cur_agecat' 
 gen _dur_`cur_agecat'=_duration if agecat==`cur_agecat' 
 gen _yld_`cur_agecat'=inc*pop*_dw*time_sym*(1/`DisRate'*(exp(-
`DisRate'*_lag)-exp(-`DisRate'*(_lag+_duration)))) if agecat==`cur_agecat' 
} 
collapse (sum) pop_* inc_*  yld_* _yld_* prev_* pyld_* dur_* _dur_*, by(year code 
seq sex) fast 
reshape long pop_ inc_ yld_ _yld_ prev_ pyld_ dur_ _dur_, i(year code seq sex) 
j(agecat) 
} 
save "Corrected results", replace 
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Appendix G: hale_decomp routine 
The Stata ado program hale_decomp is a ‘wrapping’ routine that calls a number of Mata 
subroutines which, in turn, implement the equations set out by Nusselder and Looman.212 
Instructions on how to use cohort-IPM are provided in Chapter 4.  
program define hale_decomp 
 version 9.1 
 syntax  varlist(min=3 max=3),  Deaths(varname numeric) PYLD(varname numeric) 
POP(varname numeric) Strata(varname) base(string) 
  confirm new var _Mx _PIx _ex _lx _Lx _PIex _iRyk _iPIxk _iTOTxk _iLWD_MORxk 
_iLWD_DISxk _iLWD_TOTxk _iDFLE_TOTxk _iDFLE_DISxk _iDFLE_MORxk 
 tokenize `varlist' 
 local cause `1' 
 local age `2' 
 local ax `3' 
quietly { 
 sort `strata'  `age' `cause' 
 local allvars "`strata'  `age' `cause'" 
 global allvars : list uniq allvars 
 cap by $allvars : assert _N==1  
 if _rc~=0 { 
  noisily di in red "the variables $allvars do not uniquely identify the 
data" 
  error 1 
 } 
 levelsof `strata', local(stratum) 
 local baseok : list base in stratum 
 if `baseok'~=1 { 
  noisily di in red "the strata variable `strata' does not contain the 
base value `base'" 
  error 1 
 } 
 tempvar stratavar causevar flag_n0 flag_n1 
 cap egen `stratavar'=group(`strata') if `strata'~=`base' 
 cap egen `stratavar'=group(`strata') if `strata'~="`base'" 
 replace `stratavar'=0 if missing(`stratavar') 
 gen `flag_n0'=`stratavar'==0 
 gen `flag_n1' = 0 
 egen `causevar'=group(`cause') 
 preserve 
 collapse (sum) `deaths' `pyld' (max) `pop' `ax', by( `strata' `age' 
`stratavar' `flag_n0' `flag_n1' ) fast 
 gen _Mx=`deaths'/`pop' 
 gen _PIx=`pyld'/`pop' 
 by `strata' : _lifetable `age' `ax', rate(_Mx) pyld(_PIx) 
 quietly sum `stratavar' 
 local stratavarmax=r(max) 
 forvalues t=1/`stratavarmax'{ 
  replace `flag_n1' = `stratavar' == `t'  
  mata: mata_decomp("iTOTxy_`t'") 
 }  
 tempfile data 
 save `data' 
 restore 
 merge `strata' `age' using `data' 
 egen _iRyk=pc(`deaths'), prop by( `strata' `age') 
 gen _iPIxk=`pyld'/`pop' 
                                                
212  Nusselder, WJ and Looman, CW, “Decomposition of differences in health expectancy by cause”. 
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 drop _m  
 sort `strata'  `cause' `age' 
 gen _iTOTxk=. 
 gen _iLWD_MORxk=. 
 gen _iLWD_DISxk=. 
 quietly sum `causevar' 
 local causevarmax=r(max) 
 forvalues t=1/`stratavarmax'{ 
  forvalues k=1/`causevarmax'{ 
   replace `flag_n1' = `stratavar' == `t' & `causevar'==`k' 
   replace `flag_n0' = `stratavar' == 0 & `causevar'==`k' 
   mata: mata_cause_decomp("iTOTxy_`t'") 
 
  } 
 } 
 gen _iLWD_TOTxk=_iLWD_MORxk+_iLWD_DISxk 
 gen _iDFLE_TOTxk=_iTOTxk-_iLWD_TOTxk 
 gen _iDFLE_DISxk=-_iLWD_DISxk 
 gen _iDFLE_MORxk=_iDFLE_TOTxk-_iDFLE_DISxk 
 } 
end 
program define _lifetable, byable(recall, noheader) sortpreserve 
 version 9.1 
 syntax  varlist(min=1 max=2 numeric) [if],  [Rate(varname numeric)] 
[PYLD(varname numeric)] 
 tokenize `varlist' 
 local age `1' 
 local ax `2' 
 marksample touse 
 cap gen _ex=. 
 cap gen _lx=. 
 cap gen _Lx=. 
 cap gen _PIex=. 
 mata: mata_lt_rate() 
end  
version 9.1 
mata: 
mata clear 
void mata_cause_decomp(string scalar matname) 
{ 
 st_view(_iRyk_n0,.,"_iRyk",st_local("flag_n0")) 
 st_view(_iRyk_n1,.,"_iRyk",st_local("flag_n1")) 
 st_view(_Mx_n0,.,"_Mx",st_local("flag_n0")) 
 st_view(_Mx_n1,.,"_Mx",st_local("flag_n1")) 
 st_view(_PIx_n0,.,"_PIx",st_local("flag_n0")) 
 st_view(_PIx_n1,.,"_PIx",st_local("flag_n1")) 
 st_view(_iPIxk_n0,.,"_iPIxk",st_local("flag_n0")) 
 st_view(_iPIxk_n1,.,"_iPIxk",st_local("flag_n1")) 
 st_view(_Lx_n0,.,"_Lx",st_local("flag_n0")) 
 st_view(_Lx_n1,.,"_Lx",st_local("flag_n1")) 
 iCyk=((_iRyk_n1 :* _Mx_n1) :- (_iRyk_n0 :* _Mx_n0)) :/ (_Mx_n1 :- _Mx_n0) 
 iTOTxk=colsum(iCyk :* st_matrix(matname))' 
 iMORxk=((_PIx_n1 :+ _PIx_n0) :/ 2) :* iTOTxk 
 del_iPIxk=_iPIxk_n1 :- _iPIxk_n0 
 iDISxk=((_Lx_n1 :+ _Lx_n0) :/ 2) :* del_iPIxk 
 st_store(.,"_iTOTxk",st_local("flag_n1"),iTOTxk) 
 st_store(.,"_iLWD_MORxk",st_local("flag_n1"),iMORxk) 
 st_store(.,"_iLWD_DISxk",st_local("flag_n1"),iDISxk) 
} 
 
void mata_decomp(string scalar matname) 
{ 
 st_view(_Lx_n0,.,"_Lx",st_local("flag_n0")) 
 st_view(_Lx_n1,.,"_Lx",st_local("flag_n1")) 
 st_view(_lx_n0,.,"_lx",st_local("flag_n0")) 
 st_view(_lx_n1,.,"_lx",st_local("flag_n1")) 
 st_view(_PIx_n0,.,"_PIx",st_local("flag_n0")) 
 st_view(_PIx_n1,.,"_PIx",st_local("flag_n1")) 
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 rownum=rows(_Lx_n0) 
  
 _del_iLx=_Lx_n1 :- _Lx_n0 
 _del_iPIx=_PIx_n1 :- _PIx_n0 
 _iMORx=((_PIx_n0 :+ _PIx_n1) :/ 2) :* _del_iLx 
 _iDISx=((_Lx_n0 :+ _Lx_n1) :/ 2) :* _del_iPIx 
  
 iIExy=J(rownum,rownum,0) 
 iOExy=J(rownum,rownum,0) 
 iDExy=diag((_lx_n0 :/ _lx_n0[1]) :* ((_Lx_n1 :/_lx_n1) :- (_Lx_n0 
:/_lx_n0))) 
 for (y=1;y<rownum;y++) { 
  for (x=y+1;x<=rownum;x++) { 
   iIExy[y,x]=(_Lx_n0[x] :/_lx_n0[1]) :*((_lx_n0[y] :* 
_lx_n1[y+1]) :/(_lx_n0[y+1] :* _lx_n1[y]) :-1) 
   iOExy[y,x]=(_Lx_n1[x] :/_lx_n0[1]) :*((_lx_n0[y] :/ _lx_n1[y]) 
:- (_lx_n0[y+1] :/ _lx_n1[y+1])) 
  } 
 } 
 iIxy=iOExy :- iIExy 
 iTOTxy=iDExy :+ iIExy :+ iIxy 
 st_matrix(matname,iTOTxy) 
} 
 
void mata_lt_rate() 
{ 
 st_view(age,.,st_local("age"),st_local("touse")) 
 st_view(M,.,st_local("rate"),st_local("touse")) 
 st_view(ax,.,st_local("ax"),st_local("touse")) 
 st_view(pyld,.,st_local("pyld"),st_local("touse")) 
 n=J(rows(age),1,.) 
 T=J(rows(age),1,.) 
 l=J(rows(age),1,1) 
 for (i=1;i<=rows(age)-1;i++) { 
  n[i]=(age[i+1]-age[i]) 
 } 
 q=(n :* M):/(1 :+ (n :* M :*(1 :- ax))) ; q[rows(q)]=1 
 d=l :* q 
 for (i=2;i<=rows(age);i++) { 
  l[i]=l[i-1]-d[i-1] 
  d[i]=l[i]*q[i] 
 } 
 L=((l :- d) :* n) :+ (d :* ax :* n) 
 L[rows(L)]=d[rows(d)]/M[rows(M)] 
 for (i=1;i<=rows(age);i++) { 
  T[i]=sum(L[|i,1\.,1|]) 
 } 
 ex=T :/ l  
 st_store(.,"_ex",st_local("touse"),ex) 
 st_store(.,"_lx",st_local("touse"),l) 
 st_store(.,"_Lx",st_local("touse"),L) 
 L=(1 :- pyld) :* L 
 for (i=1;i<=rows(age);i++) { 
  T[i]=sum(L[|i,1\.,1|]) 
 } 
 ex=T :/ l  
 st_store(.,"_PIex",st_local("touse"),ex) 
} 
end 
 
 
